UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2020.

 

or

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to __________.

 

Commission File Number: 001-33899

 

Digital Ally, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   20-0064269

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

15612 College Blvd, Lenexa, KS 66219

(Address of principal executive offices) (Zip Code)

 

(913) 814-7774

(Registrant’s telephone number, including area code)

 

9705 Loiret Blvd., Lenexa, KS 66219

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common stock, $0.001 par value   DGLY   the Nasdaq Capital Market, LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of Exchange Act.

 

Large accelerated filer [  ]   Accelerated filer [  ]
Non-accelerated filer [  ] (Do not check if a smaller reporting company)   Smaller reporting company [X]
Emerging growth company [  ]    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes [  ] No [X]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

 

Class   Outstanding at August 12, 2020
Common Stock, $0.001 par value per share   26,581,600

 

 

 

 
 

 

FORM 10-Q

DIGITAL ALLY, INC.

JUNE 30, 2020

 

TABLE OF CONTENTS   Page(s)
PART I – FINANCIAL INFORMATION    
     
Item 1. Financial Statements.   3
     
Condensed Consolidated Balance Sheets – June 30, 2020 (Unaudited) and December 31, 2019   3
     
Condensed Consolidated Statements of Operations for the Three and Six months ended June 30, 2020 and 2019 (Unaudited)   4
     
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Three and Six months ended June 30, 2020 and 2019 (Unaudited)   5
     
Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2020 and 2019 (Unaudited)   6
     
Notes to the Condensed Consolidated Financial Statements (Unaudited)   7-29
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.   30-53
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk.   53
     
Item 4. Controls and Procedures.   53
     
PART II - OTHER INFORMATION    
     
Item 1. Legal Proceedings.   54
     

Item 1A. Risk Factors

  54
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.   54
     
Item 3. Defaults Upon Senior Securities   54
     
Item 4. Mine Safety Disclosures   54
     
Item 5. Other Information.   54
     
Item 6. Exhibits.   55
     
SIGNATURES   56

 

 2 
 

 

PART I – FINANCIAL INFORMATION

 

Item 1 – Financial Statements.

 

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

JUNE 30, 2020 AND DECEMBER 31, 2019

 

   June 30, 2020 (Unaudited)   December 31, 2019 
Assets          
Current assets:          
Cash and cash equivalents  $16,165,550   $359,685 
Accounts receivable-trade, less allowance for doubtful accounts
of $123,224 – 2020 and 2019
   1,080,884    1,071,018 
Accounts receivable-other   538,350    514,730 
Inventories, net   4,752,285    5,280,412 
Income tax refund receivable, current   44,650    44,650 
Prepaid expenses   574,456    381,090 
           
Total current assets   23,156,175    7,651,585 
           
Furniture, fixtures and equipment, net   208,291    197,063 
Intangible assets, net   431,006    413,268 
Operating lease right of use assets   769,635    122,459 
Other assets   452,519    532,500 
           
Total assets  $25,017,626   $8,916,875 
           
Liabilities and Stockholders’ Equity (Deficit)          
Current liabilities:          
Accounts payable  $1,535,865   $2,339,985 
Accrued expenses   838,747    845,881 
Operating lease obligations – Current   44,308    159,160 
Contract liabilities – Current   1,756,402    1,707,943 
Proceeds investment agreement obligation, at fair value – Current   3,615,000     
Debt obligations – Current   552,258    1,827,748 
Income taxes payable   1,158    5,934 
           
Total current liabilities   8,343,738    6,886,651 
           
Long-term liabilities:          
Proceeds investment agreement obligation, at fair value – Long-term       6,500,000 
Operating lease obligation – Long-term   731,334    44,460 
Debt obligations – Long-term   1,016,642     
Contract liabilities – Long-term   1,580,085    1,803,143 
           
Total liabilities   11,671,799    15,234,254 
           
Commitments and contingencies          
           
Stockholders’ Equity (Deficit):          
Common stock, $0.001 par value per share; 50,000,000 shares authorized; shares issued: 26,645,118 – June 30, 2020 and 12,079,095 – December 31, 2019   26,645    12,079 
Additional paid in capital   105,697,031    83,216,387 
Treasury stock, at cost (63,518 shares)   (2,157,226)   (2,157,226)
Accumulated deficit   (90,220,623)   (87,388,619)
           
Total stockholders’ equity (deficit)   13,345,827    (6,317,379)
           
Total liabilities and stockholders’ equity (deficit)  $25,017,626   $8,916,875 

 

See Notes to the Unaudited Condensed Consolidated Financial Statements.

 

 3 
 

 

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED

JUNE 30, 2020 AND 2019

(Unaudited)

 

   Three months ended June 30,   Six months ended June 30, 
   2020   2019   2020   2019 
                 
Revenue:                    
Product  $1,053,581   $1,945,724   $2,820,116   $3,866,188 
Service and other   678,611    601,259    1,337,820    1,231,591 
                     
Total revenue   1,732,192    2,546,983    4,157,936    5,097,779 
                     
Cost of revenue:                    
Product   1,165,528    1,468,828    2,154,774    2,731,899 
Service and other   173,906    127,343    345,374    233,328 
                     
Total cost of revenue   1,339,434    1,596,171    2,500,148    2,965,227 
                     
Gross profit   392,758    950,812    1,657,788    2,132,552 
Selling, general and administrative expenses:                    
Research and development expense   359,697    582,905    845,445    1,045,076 
Selling, advertising and promotional expense   486,649    1,237,947    1,169,030    1,993,936 
Stock-based compensation expense   376,738    585,195    688,415    1,310,393 
General and administrative expense   1,312,828    1,977,123    3,025,417    4,301,663 
Patent litigation settlement       (6,000,000)       (6,000,000)
                     
Total selling, general and administrative expenses   2,535,912    (1,616,830)   5,728,307    2,651,068 
                     
Operating (loss) income   (2,143,154)   2,567,642    (4,070,519)   (518,516)
                     
Other income (expense)                    
Interest income   15,609    5,628    21,869    23,612 
Interest expense   (25,636)       (333,196)    
Secured convertible notes issuance expense   (34,906)       (34,906)    
Change in fair value of proceeds investment agreement   2,578,000    (2,961,000)   2,885,000    (3,098,000)
Change in fair value of secured convertible notes   (887,807)       (1,300,252)    
Total other income (expense)   1,645,260    (2,955,372)   1,238,515    (3,074,388)
                     
Loss before income tax benefit   (497,894)   (387,730)   (2,832,004)   (3,592,904)
Income tax benefit                
                     
Net loss  $(497,894)  $(387,730)  $(2,832,004)  $(3,592,904)
                     
Net loss per share information:                    
Basic  $(0.03)  $(0.03)  $(0.17)  $(0.32)
Diluted  $(0.03)  $(0.03)  $(0.17)  $(0.32)
                     
Weighted average shares outstanding:                    
Basic   18,976,724    11,305,248    16,430,214    11,124,222 
Diluted   18,976,724    11,305,248    16,430,214    11,124,222 

 

See Notes to the Unaudited Condensed Consolidated Financial Statements.

 

 4 
 

 

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2020 AND 2019

(Unaudited)

 

           Additional             
   Common Stock   Paid In   Treasury   Accumulated     
   Shares   Amount   Capital   stock   deficit   Total 
Balance, December 31, 2018   10,445,445   $10,445   $78,117,507   $(2,157,226)  $(77,382,906)  $(1,412,180)
Stock-based compensation           725,198            725,198 
Restricted common stock grant   522,110    522    (522)            
Restricted common stock forfeitures   (2,500)   (2)   2             
Issuance of common stock upon exercise of common stock purchase warrants   161,000    161    515,839            516,000 
Net loss                   (3,205,174)   (3,205,174)
                               
Balance, March 31, 2019   11,126,055    11,126    79,358,024    (2,157,226)   (80,588,080)   (3,376,156)
                               
Stock-based compensation           585,195            585,195 
Issuance of common stock upon exercise of common stock purchase warrants   368,000    368    1,047,632            1,048,000 
Net loss                   (387,730)   (387,730)
                               
Balance, June 30, 2019   11,494,055   $11,494   $80,990,851   $(2,157,226)  $(80,975,810)  $(2,130,691)
                               
Balance, December 31, 2019   12,079,095   $12,079   $83,216,387   $(2,157,226)  $(87,388,619)  $(6,317,379)
Stock-based compensation           311,677            311,677 
Restricted common stock grant   530,050    530    (530)            
Restricted common stock forfeitures   (22,500)   (23)   23             
Issuance of common stock upon conversion of secured convertible notes and interest   959,543    960    1,342,400            1,343,360 
Issuance of common stock through underwritten public offering at $1.15 per share (net of offering expenses and underwriters’ discount)   2,521,740    2,522    2,499,614            2,502,136 
Issuance of common stock purchase warrants in connection with issuance of unsecured promissory note payable           20,806            20,806 
Net loss                   (2,334,110)   (2,334,110)
                               
Balance, March 31, 2020   16,067,928    16,068    87,390,377    (2,157,226)   (89,722,729)   (4,473,510)
                               
Stock-based compensation           376,738            376,738 
Restricted common stock grant   135,450    135    (135)            
Restricted common stock forfeitures   (12,750)   (13)   13             
Issuance of common stock upon conversion of secured convertible notes and interest   1,664,669    1,665    1,679,660            1,681,325 
Issuance of common stock through underwritten public offering at $1.65 per share (net of offering expenses and underwriters’ discount)   3,554,545    3,554    5,346,859            5,350,413 
Issuance of common stock through underwritten public offering at $2.15 per share (net of offering expenses and underwriters’ discount)   2,539,534    2,540    4,974,152            4,976,692 
Issuance of common stock upon exercise of common stock purchase warrants   2,693,867    2,694    5,200,428            5,203,122 
Issuance of common stock upon exercise of stock options   1,875    2    7,798              7,800 
Issuance of common stock purchase warrants in connection with issuance of secured convertible notes           721,141            721,141 
                               
Net loss                   (497,894)   (497,894)
                               
Balance, June 30, 2020   26,645,118   $26,645   $105,697,031   $(2,157,226)  $(90,220,623)  $13,345,827 

 

See Notes to the Unaudited Condensed Consolidated Financial Statements.

 

 5 
 

 

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2020 AND 2019

(Unaudited)

 

   2020   2019 
Cash Flows From Operating Activities:          
Net loss  $(2,832,004)  $(3,592,904)
Adjustments to reconcile net loss to net cash flows (used in) provided by operating activities:          
Depreciation and amortization   134,143    206,969 
Stock based compensation   688,415    1,310,393 
Provision for inventory obsolescence   238,957    371,494 
Amortization of discount on unsecured promissory notes   86,867     
Change in fair value of secured convertible notes   1,300,252     
Change in fair value of proceeds investment agreement   (2,885,000)   3,098,000 
Provision for doubtful accounts receivable       20,000 
Debt issuance costs   34,906     
           
Change in operating assets and liabilities:          
(Increase) decrease in:          
Accounts receivable – trade   (9,866)   215,840 
Accounts receivable – other   (23,620)   (118,556)
Inventories   289,170    (164,483)
Prepaid expenses   (193,366)   135 
Operating lease right of use assets   (647,176)   224,413 
Other assets   79,981    (133,000)
Increase (decrease) in:          
Accounts payable   (804,120)   1,073,021 
Accrued expenses   92,811    (1,018,433)
Income taxes payable   (4,776)   244 
Operating lease obligations   572,022    (143,252)
Contract liabilities   (174,599)   (80,434)
           
Net cash (used in) provided by operating activities   (4,057,003)   1,269,447 
           
Cash Flows from Investing Activities:          
Purchases of furniture, fixtures and equipment   (96,011)   (73,705)
Additions to intangible assets   (67,098)   (26,884)
           
Net cash used in investing activities   (163,109)   (100,589)
           
Cash Flows from Financing Activities:          
Proceeds from unsecured promissory note payable, related party   319,000     
Proceeds from unsecured promissory note payable   100,000     
Proceeds from promissory notes payable   1,568,900     
Proceeds from issuance of common stock upon exercise of warrants   5,203,122    1,564,000 
Proceeds from issuance of secured convertible notes payable   1,500,000      
Proceeds from sale of common stock in underwritten public offering   12,829,241     
Proceeds from exercise of stock options   7,800     
Principal payment on subordinated notes payable   (400,000)    
Principal payment on secured convertible notes   (748,180)    
Principal payments on unsecured promissory note payable, related party   (319,000)    
Debt issuance costs   (34,906)     
Principal payment on proceeds investment agreement       (6,000,000)
           
Net cash provided by (used in) financing activities   20,025,977    (4,436,000)
           
Net increase (decrease) in cash and cash equivalents   15,805,865    (3,267,142)
Cash, cash equivalents, beginning of period   359,685    3,598,807 
           
Cash, cash equivalents, end of period  $16,165,550   $331,655 
           
Supplemental disclosures of cash flow information:          
Cash payments for interest  $128,911   $ 
           
Cash payments for income taxes  $4,776   $5,756 
           
Supplemental disclosures of non-cash investing and financing activities:          
Restricted common stock grant  $664   $522 
           
Restricted common stock forfeitures  $36   $2 
           
Cashless exercise of common stock purchase warrants  $7   $ 
           
Impact of Adoption of ASC 842 - obtaining right of use asset for lease liability  $   $500,751 
           
Issuance of common stock upon conversion of secured convertible notes  $3,024,685   $ 
           
Amounts allocated to common stock purchase warrants in connection with issuance of unsecured promissory note payable  $741,947   $ 

 

See Notes to the Unaudited Condensed Consolidated Financial Statements.

 

 6 
 

 

DIGITAL ALLY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1. NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations:

 

Digital Ally, Inc. its wholly-owned subsidiaries, Digital Ally International, Inc. and Shield Products, LLC (collectively, “Digital Ally,” “Digital,” the “Company”) produces digital video imaging, storage products and disinfectant and related safety products for use in law enforcement, security and commercial applications. The Company’s products include in-car digital video/audio recorders contained in a rear-view mirror for use in law enforcement and commercial fleets; a system that provides its law enforcement customers with audio/video surveillance from multiple vantage points and hands-free automatic activation of body-worn cameras and in-car video systems; a miniature digital video system designed to be worn on an individual’s body; and cloud storage solutions. The Company has recently added two new lines of branded products: (1) the ThermoVu™ line, which is a line of self-contained temperature monitoring stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2) the Shield™ disinfectant and cleanser line, which is for use against viruses and bacteria and which we began offering to the Company’s law enforcement and commercials customers beginning late in the second quarter of 2020. Both product lines are manufactured by third parties. In addition, the Company has active research and development programs to adapt its technologies to other applications. It can integrate electronic, radio, computer, mechanical, and multi-media technologies to create unique solutions to address needs in a variety of other industries and markets, including mass transit, school bus, taxicab and the military. The Company sells its products to law enforcement agencies, private security customers and organizations and consumer and commercial fleet operators through direct sales domestically and third-party distributors internationally.

 

The Company was originally incorporated in Nevada on December 13, 2000 as Vegas Petra, Inc. and had no operations until 2004. On November 30, 2004, Vegas Petra, Inc. entered into a Plan of Merger with Digital Ally, Inc., at which time the merged entity was renamed Digital Ally, Inc.

 

Basis of Presentation:

 

The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month period ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

 

The balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements.

 

For further information, refer to the audited financial statements and footnotes included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 and the unaudited financial statements and footnotes included in the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2020.

 

COVID-19 pandemic:

 

The World Health Organization has declared the outbreak of COVID-19, or coronavirus, which began in December 2019, a pandemic and the U.S. federal government has declared it a national emergency. The COVID-19 pandemic had a negative impact on our revenues in the first and second quarters of 2020  and we expect it will adversely affect our business and operations during the remainder of 2020. While its full and continued impact cannot be determined at present, we do expect it will have a material adverse effect on our future business, financial condition, results of operations, and cash flows. The global spread of COVID-19 has already created significant volatility, uncertainty and economic disruption in the markets in which we operate. Governments, public institutions, and other organizations in countries and localities where cases of COVID-19 have been detected are taking certain emergency measures to mitigate its spread, including implementing travel restrictions and closing factories, schools, public buildings, and businesses. We are closely monitoring the spread of COVID-19 and continually assessing its potential effects on our business. In response to the impact that the COVID-19 pandemic and other future pandemics may have on the Company’s customers and legacy products, the Company has recently added two new lines of branded products: (1) the ThermoVu™ which is a line of self-contained temperature monitoring stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2) the Shield™ disinfectant and cleanser line which is for use against viruses and bacteria and which we began offering to the Company’s law enforcement and commercials customers beginning late in the second quarter of 2020.

 

 7 
 

 

The extent to which our future results are affected by COVID-19 will largely depend on future developments that cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy, our customers’ demand for our products and services, and our ability to provide our products and services, particularly as result of our employees working remotely and/or the closure of certain offices and facilities.

 

Management’s Liquidity Plan and Going Concern:

 

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred operating losses for the six months ended June 30, 2020 and for the year ended December 31, 2019 primarily due to reduced revenues and gross margins caused by a variety of factors, including the COVID-19 pandemic and its related effects on our customers and our supply chain, and by competitors’ introduction of newer products with more advanced features together with significant price cutting of their products. The Company incurred net losses of approximately $2.8 million during the six months ended June 30, 2020 and $10.0 million for the year ended December 31, 2019 and it had an accumulated deficit of $90.2 million as of June 30, 2020. During 2019, the Company settled one of its patent infringement cases and received a lump sum payment of $6.0 million, which was used to pay its obligations under its Proceeds Investment Agreement, as more fully described in Note 4 — “Proceeds Investment Agreement Obligation.”. In recent years the Company has accessed the public and private capital markets to raise funding through the issuance of debt and equity. In that regard, the Company raised $12.8 million in underwritten public offerings of its common stock, raised $5.2 million through the exercise of common stock purchase warrants and options, raised $1.6 million through the issuance of promissory notes through the Small Business Administration’s (“SBA”) Paycheck Protection Program (“PPP”) and the Economic Injury Disaster Loan (“EIDL”) programs, raised $1.5 million through the issuance of secured convertible notes and raised $419,000 in unsecured promissory notes and detachable warrants during the six months ended June 30, 2020. In addition, the Company raised $1,564,000 in the year ended December 31, 2019 from the exercise of warrants, the Company borrowed $300,000 pursuant to a short-term promissory note payable on December 23, 2019 with detachable warrants to purchase 107,000 shares of common stock and on August 5, 2019, it raised funds from the issuance of $2.78 million principal balance of secured convertible notes with detachable warrants to purchase 571,248 shares of common stock with the net proceeds being used for working capital purposes as more fully described in Note 3 – “Debt Obligations”. These debt and equity raises were utilized to fund its operations and management expects to continue this pattern until it achieves positive cash flows from operations, although it can offer no assurance in this regard.

 

The Company will have to restore positive operating cash flows and profitability over the next year and/or raise additional capital to fund its operational plans, meet its customary payment obligations and otherwise execute its business plan. There can be no assurance that it will be successful in restoring positive cash flows and profitability, or that it can raise additional financing when needed, and obtain it on terms acceptable or favorable to the Company.

 

The Company has increased its addressable market to non-law enforcement customers and obtained new non-law enforcement contracts in 2020 and 2019, which contracts include recurring revenue during the period 2020 to 2023. Further, it added two new product lines in response to the Covid-19 pandemic. The Company believes that its quality control and cost cutting initiatives, expansion to non-law enforcement sales channels and new product introductions will eventually restore positive operating cash flows and profitability, although it can offer no assurances in this regard. The extent to which its future operating results are affected by COVID-19 will largely depend on future developments which cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy, our customers’ demand for our products and services, and our ability to provide our products and services, particularly as result of our employees working remotely and/or the closure of certain offices and facilities. While degree of impact of these factors is uncertain, we believe that the COVID-19 pandemic or the perception of its effects will have a material adverse effect on our business, financial condition, results of operations, and cash flows.

 

Based on the uncertainties described above, the Company believes its business plan does not alleviate the existence of substantial doubt about its ability to continue as a going concern within one year from the date of the issuance of these unaudited condensed consolidated financial statements. The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Basis of Consolidation:

 

The accompanying financial statements include the consolidated accounts of Digital Ally and its wholly-owned subsidiaries, Digital Ally International, Inc. and Shield Products, LLC. All intercompany balances and transactions have been eliminated during consolidation.

 

The Company formed Digital Ally International, Inc. during August 2009 to facilitate the export sales of its products. The Company formed Shield Products, LLC in May 2020 to facilitate the sales of its Shield™ line of disinfectant/cleanser products and ThermoVu™ line of temperature monitoring equipment.

 

 8 
 

 

Revenue Recognition:

 

The Company applies the provisions of Accounting Standards Codification (ASC) 606-10, Revenue from Contracts with Customers, and all related appropriate guidance. The Company recognizes revenue under the core principle to depict the transfer of control to its customers in an amount reflecting the consideration to which it expects to be entitled. In order to achieve that core principle, the Company applies the following five-step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.

 

The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with the customer. In situation where sales are to a distributor, the Company had concluded its contracts are with the distributor as the Company holds a contract bearing enforceable rights and obligations only with the distributor. As part of part of its consideration for the contract, the Company evaluates certain factors including the customers’ ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. As the Company’s standard payment terms are less than one year, it has elected the practical expedient under ASC 606-10-32-18 to not assess whether a contract has a significant financing component. The Company allocates the transaction price to each distinct product based on its relative standalone selling price. The product price as specified on the purchase order is considered the standalone selling price as it is an observable input which depicts the price as if sold to a similar customer in similar circumstances. Revenue is recognized when control of the product is transferred to the customer (i.e. when the Company’s performance obligations is satisfied), which typically occurs at shipment. Further in determining whether control has been transferred, the Company considers if there is a present right to payment and legal title, along with risks and rewards of ownership having transferred to the customer. Customers do not have a right to return the product other than for warranty reasons for which they would only receive repair services or replacement product. The Company has also elected the practical expedient under ASC 340-40-25-4 to expense commissions for product sales when incurred as the amortization period of the commission asset the Company would have otherwise recognized is less than one year.

 

The Company sells its products and services to law enforcement and commercial customers in the following manner:

 

  Sales to domestic customers are made direct to the end customer (typically a law enforcement agency or a commercial customer) through its sales force, which is composed of its employees. Revenue is recorded when the product is shipped to the end customer.
     
  Sales to international customers are made through independent distributors who purchase products from the Company at a wholesale price and sell to the end user (typically law enforcement agencies or a commercial customer) at a retail price. The distributor retains the margin as its compensation for its role in the transaction. The distributor generally maintains product inventory, customer receivables and all related risks and rewards of ownership. Accordingly, upon application of steps one through five above, revenue is recorded when the product is shipped to the distributor consistent with the terms of the distribution agreement.
     
  Repair parts and services for domestic and international customers are generally handled by its inside customer service employees. Revenue is recognized upon shipment of the repair parts and acceptance of the service or materials by the end customer.

 

Sales taxes collected on products sold are excluded from revenues and are reported as accrued expenses in the accompanying balance sheets until payments are remitted.

 

Service and other revenue is comprised of revenues from extended warranties, repair services, cloud revenue and software revenue. Revenue is recognized upon shipment of the product and acceptance of the service or materials by the end customer for repair services. Revenue for extended warranty, cloud service or other software-based products is over the term of the contract warranty or service period. A time-elapsed method is used to measure progress because the Company transfers control evenly over the contractual period. Accordingly, the fixed consideration related to these revenues is generally recognized on a straight-line basis over the contract term, as long as the other revenue recognition criteria have been met.

 

Contracts with some of the Company’s customers contain multiple performance obligations that are distinct and accounted for separately. The transaction price is allocated to the separate performance obligations on a relative standalone selling price (“SSP”). The Company determined SSP for all the performance obligations using observable inputs, such as standalone sales and historical pricing. SSP is consistent with the Company’s overall pricing objectives, taking into consideration the type of service being provided. SSP also reflects the amount the Company would charge for the performance obligation if it were sold separately in a standalone sale. Multiple performance obligations consist of product, software, cloud subscriptions and extended warranties.

 

The Company’s multiple performance obligations may include future in-car or body-worn camera devices to be delivered at defined points within a multi-year contract, and in those arrangements, the Company allocates total arrangement consideration over the life of the multi-year contract to future deliverables using management’s best estimate of selling price.

 

Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract and are reported separately as current liabilities and non-current liabilities in the Condensed Consolidated Balance Sheets. Such amounts consist of extended warranty contracts, prepaid cloud services and prepaid installation services and are generally recognized as the respective performance obligations are satisfied. Total contract liabilities consist of the following: Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract and are reported separately as current liabilities and non-current liabilities in the Condensed Consolidated Balance Sheets. Such amounts consist of extended warranty contracts, prepaid cloud services and prepaid installation services and are generally recognized as the respective performance obligations are satisfied.

 

 9 
 

 

Accounts Receivable:

 

Accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a weekly basis. The Company determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded when received.

 

A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than thirty (30) days beyond terms. No interest is charged on overdue trade receivables.

 

Segments of Business:

 

Management has determined that its operations comprise one reportable segment: the sale of digital audio and video recording and speed detection devices. For the three and six months ended June 30, 2020 and 2019, sales by geographic area were as follows:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2020   2019   2020   2019 
Sales by geographic area:                    
United States of America  $1,726,119   $2,477,717   $4,097,815   $4,992,059 
Foreign   6,073    69,266    60,121    105,720 
                     
Total  $1,732,192   $2,546,983   $4,157,936   $5,097,779 

 

Sales to customers outside of the United States are denominated in U.S. dollars. All Company assets are physically located within the United States.

 

Recent Accounting Pronouncements:

 

In February 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-02, Leases (“Topic 842”). The guidance requires lessees to put most leases on their balance sheets but recognize expenses on their income statements in a manner similar to today’s accounting. Lessees initially recognize a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The lease liability is measured at the present value of the lease payments over the lease term. The right-of-use asset is measured at the lease liability amount, adjusted for lease prepayments, lease incentives received and the lessee’s initial direct costs. The standard is effective for public business entities for annual reporting periods beginning after December 15, 2018, and interim periods within that reporting period, which was the first quarter of 2019 for the Company.

 

The Company adopted the new guidance on January 1, 2019 using the optional transitional method and elected to use the package of three practical expedients which allows the Company not to reassess whether contracts are or contain leases, lease classification and whether initial direct costs qualify for capitalization. The Company has completed its assessment of the impact of the standard and determined that the only lease that the Company held was an operating lease for its office and warehouse space. Upon adoption of the standard, the Company recorded Right of Use (ROU) assets of approximately $501,000 and lease liabilities of approximately $582,000 related to it office and warehouse space operating leases. The Company also removed deferred rent of approximately $81,000 when adopting the new guidance.

 

 10 
 

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission (the “SEC”) to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation will not be required until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

 

In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. Furthermore, an entity is permitted to early adopt any removed or modified disclosures upon issuance of the update and delay adoption of the additional disclosures until their effective date. The Company implemented the revised disclosure requirements upon adoption of ASU 2018-13.

 

In August 2018, the FASB issued ASU No. 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40), or ASU 2018-15. ASU 2018-15 updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes - simplifying the accounting for income taxes (Topic 740), which is meant to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, Income Taxes. The amendment also improves consistent application and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

 

NOTE 2. INVENTORIES

 

Inventories consisted of the following at June 30, 2020 and December 31, 2019:

 

  

June 30, 2020

   December 31, 2019 
Raw material and component parts  $2,575,710   $4,481,611 
Work-in-process   30,679    35,858 
Finished goods   4,146,308    4,906,956 
           
Subtotal   6,752,697    9,424,425 
Reserve for excess and obsolete inventory   (2,000,412)   (4,144,013)
           
Total  $4,752,285   $5,280,412 

 

Finished goods inventory includes units held by potential customers and sales agents for test and evaluation purposes. The cost of such units totaled $140,158 and $80,711 as of June 30, 2020 and December 31, 2019, respectively.

 

 11 
 

 

NOTE 3. DEBT OBLIGATIONS

 

Debt obligations is comprised of the following:

 

  

June 30, 2020

   December 31, 2019 
Payroll protection program loan (PPP)  $1,418,900   $ 
Economic injury disaster loan (EIDL)   150,000     
2019 Secured convertible notes, at fair value       1,593,809 
Unsecured promissory notes payable, less unamortized discount of $-0- and $66,061 at June 30, 2020 and December 31, 2019, respectively       233,939 
           
Debt obligations   1,568,900    1,827,748 
Less: current maturities of debt obligations   552,258    1,827,748 
Debt obligations, long-term  $1,016,642   $ 

 

Debt obligations mature as follows as of June 30, 2020:

 

  

June 30, 2020

 
2020 (July 1, 2020 to December 31, 2020)  $68,241 
2021   948,391 
2022   401,321 
2023   3,166 
2024   3,286 
2025 and thereafter   144,495 
      
Total  $1,568,900 

 

2020 Small Business Administration Notes.

 

On April 4, 2020, the Company issued a promissory note in connection with the receipt of the PPP Loan of $1,418,900 under the SBA’s PPP Program under the CARES Act. The PPP Loan has a two-year term and bears interest at a rate of 1.0% per annum. Monthly principal and interest payments are deferred for six months after the date of disbursement and total $79,850.57 per month thereafter. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. The promissory note contains events of default and other provisions customary for a loan of this type. The PPP provides that the PPP Loan may be partially or wholly forgiven if the funds are used for certain qualifying expenses as described in the CARES Act. The Company intends to use the majority of the PPP Loan amount for qualifying expenses and to apply for forgiveness of the PPP Loan in accordance with the terms of the CARES Act.

 

On May 12, 2020 the Company received $150,000 in loan funding from the SBA under the EIDL program administered by the SBA, which program was expanded pursuant to the recently enacted CARES Act. The EIDL is evidenced by a promissory note, dated May 8, 2020, in the original principal amount of $150,000 with the SBA, the lender.

 

Under the terms of the note issued under the EIDL program, interest accrues on the outstanding principal at the rate of 3.75% per annum. The term of such note is thirty years, though it may be payable sooner upon an event of default under such note. Monthly principal and interest payments are deferred for twelve months after the date of disbursement and total $731.00 per month thereafter. Such note may be prepaid in part or in full, at any time, without penalty.

 

 12 
 

 

2019 Secured Convertible Notes.

 

On August 5, 2019, the Company, entered into a securities purchase agreement with several accredited investors providing for the issuance of (i) the Company’s 8% secured convertible notes due August 4, 2020 with a principal face amount of $2,777,777.78, which convertible notes are, subject to certain conditions, convertible into 1,984,126 shares of the Company’s common stock, at a price per share of $1.40 (the “2019 Convertible Notes”); (ii) five-year warrants to purchase an aggregate of 571,428 shares of Common Stock at an exercise price of $1.8125, which warrants are immediately exercisable upon issuance and on a cashless basis if the Warrants have not been registered 180 days after the date of issuance; and (iii) the issuance of shares of common stock equal to 5% of the aggregate purchase price of the convertible notes, with an aggregate value of $125,000 (the “Commitment Shares”). The accredited investors purchased the foregoing securities for an aggregate cash purchase price of $2,500,000.

 

Under the purchase agreement, the convertible notes and warrants contain provisions whereby the accredited investors are prohibited from exercising their rights to convert the notes or exercise the warrants if, as a result of such conversion or exercise, such holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. However, the investors may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to the Company.

 

The Company elected to account for the secured convertible notes on the fair value basis. Therefore, the Company determined the fair value of the (1) secured convertible notes, (2) the Commitment Shares and (3) the common stock purchase warrants which yielded estimated fair values of the secured convertible notes including their embedded derivatives, the Commitment Shares and the detachable common stock purchase warrants. The following represents the resulting fair value as determined on August 5, 2019, the date of origination:

 

Secured convertible notes  $1,845,512 
Common stock issued as Commitment Shares   118,749 
Common stock purchase warrants   535,739 
      
Gross cash proceeds  $2,500,000 

 

During the six months ended June 30, 2020, the holders of the 2019 Convertible Notes exercised their right to convert principal balances aggregating $1,259,074 into equity. In addition, the Company paid regular monthly principal payments totaling $172,839 during the six months ended June 30, 2020 and on March 3, 2020, the Company exercised its right to prepay in cash the remaining outstanding principal balance aggregating $574,341. There remains no outstanding 2019 Convertible Notes as of June 30, 2020 as a result of these conversions and prepayments.

 

Under the fair value basis, the Company determines the fair value of the secured convertible notes and adjusts the carrying value of the secured convertible notes at each reporting date with the resulting charge or credit being reflected in the condensed consolidated statement of operations. Following is an analysis of the activity in the secured convertible notes during the six months ended June 30, 2020:

 

   Amount 
Balance at December 31, 2019  $1,593,809 
Principal repaid during the period by issuance of common stock   (1,259,074)
Principal repaid during the period by payment of cash   (747,180)
Change in fair value of secured convertible note during the period   412,445 
      
Balance at June 30, 2020  $ 

 

 13 
 

 

Following is a range of certain estimates and assumptions utilized as of December 31, 2019 to determine the fair value of secured convertible notes:

 

   December 31, 2019 
   Assumptions 
Volatility – range   115%
Risk-free rate   1.60%
Contractual term   0.6 years 
Calibrated stock price  $1.06 
Debt yield   123.6%

 

2020 Secured Convertible Notes.

 

On April 17, 2020, the Company entered into a securities purchase agreement with several accredited investors providing for the issuance of (i) the Company’s 8% secured convertible notes due April 16, 2021 with a principal face amount of $1,666,666, which convertible notes are, subject to certain conditions, convertible into 1,650,164 shares of the Company’s common stock, at a price per share of $1.01 (the “2020 Convertible Notes”), and (ii) five-year warrants to purchase an aggregate of 1,237,624 shares of Common Stock at an exercise price of $1.31, which warrants are immediately exercisable upon issuance and on a cashless basis if the Warrants have not been registered 180 days after the date of issuance. The accredited investors purchased the foregoing securities for an aggregate cash purchase price of $1,500,000.

 

Under the purchase agreement, the convertible notes and warrants contain provisions whereby the accredited investors are prohibited from exercising their rights to convert the notes or exercise the warrants if, as a result of such conversion or exercise, such holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. However, the investors may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to the Company.

 

The Company elected to account for the secured convertible notes on the fair value basis. Therefore, the Company determined the fair value of the secured convertible notes and the common stock purchase warrants which yielded estimated fair values of the secured convertible notes including their embedded derivatives and the detachable common stock purchase warrants. The following represents the resulting fair value as determined on April 17, 2020, the date of origination:

 

Secured convertible notes  $778,859 
Common stock purchase warrants   721,141 
      
Gross cash proceeds  $1,500,000 

 

During the six months ended June 30, 2020, the holders of the 2020 Convertible Notes exercised their right to convert principal balances aggregating $1,665,666 into equity. In addition, on June 12, 2020, the Company exercised its right to prepay in cash the remaining outstanding principal balance aggregating $1,000. There remains no outstanding 2020 Convertible notes as of June 30, 2020 as a result of these conversions and prepayments.

 

Under the fair value basis, the Company determines the fair value of the secured convertible notes and adjusts the carrying value of the secured convertible notes at each reporting date with the resulting charge or credit being reflected in the condensed consolidated statement of operations. Following is an analysis of the activity in the secured convertible notes during the six months ended June 30, 2020:

 

   Amount 
Balance at December 31, 2019  $ 
Issuance of 2020 convertible notes at fair value   778,859 
Principal repaid during the period by issuance of common stock   (1,665,666)
Principal repaid during the period by payment of cash   (1,000)
Change in fair value of secured convertible note during the period   887,807 
      
Balance at June 30, 2020  $ 

 

 14 
 

 

Following is a range of certain estimates and assumptions utilized as of the April 17, 2020 issuance date to determine the fair value of secured convertible notes:

 

   April 17, 2020 
   Assumptions 
Volatility – range   90%
Risk-free rate   0.36%
Contractual term   1.0 years 
Stock price  $0.92 
Debt yield   132.2%

 

Unsecured Promissory Notes Payable.

 

On December 23, 2019, the Company, borrowed $300,000 under an unsecured note payable to a private, third-party lender. The promissory note bore interest at the rate of 8% per annum with principal and accrued interest payable on or before its maturity date of March 31, 2020 (this note was repaid in full on May 6, 2020). The Company granted the lender warrants exercisable to purchase a total of 107,000 shares of its common stock at an exercise price of $1.40 per share until December 23, 2024. The Company allocated $71,869 of the proceeds of the promissory note to additional paid-in-capital, which represented the grant date relative fair value of the warrants issued to the lender. The discount was amortized to interest expense ratably over the term of the promissory note which approximates the effective interest method. The amortization of discount resulted in $66,061 of the discount amortized to interest expense during the six months ended June 30, 2020.

 

On January 17, 2020, the Company, borrowed $100,000 under an unsecured note payable to a private, third-party lender. The promissory note bore interest at the rate of 8% per annum with principal and accrued interest payable on or before its maturity date of April 17, 2020. The Company granted the lender warrants exercisable to purchase a total of 35,750 shares of its common stock at an exercise price of $1.40 per share until January 17, 2025. The Company allocated $20,806 of the proceeds of the promissory note to additional paid-in-capital, which represented the grant date relative fair value of the warrants issued to the lender. The note was repaid in full on March 12, 2020 and the discount was amortized to interest expense through the date of payment. The amortization of discount resulted in $20,806 of the discount amortized to interest expense during the six months ended June 30, 2020.

 

Unsecured Promissory Notes Payable – Related party

 

During February and April 2020, the Company borrowed a total of $319,000 from the Company’s Chairman, CEO & President under an unsecured promissory note bearing interest at 6% through its May 28, 2020 maturity date. The proceeds from the note were used for general corporate purposes. The principal balance and related accrued interest was paid in full during the six months ended June 30, 2020. Total interest accrued and paid on this note was $5,236.

 

NOTE 4. PROCEEDS INVESTMENT AGREEMENT OBLIGATION

 

The proceeds investment agreement obligations is comprised of the following:

 

  

June 30, 2020

   December 31, 2019 
Proceeds investment agreement, at fair value  $3,615,000   $6,500,000 
Less: Current portion   (3,615,000)    
           
Proceeds investment agreement, at fair value - Long-term  $   $6,500,000 

 

 15 
 

 

On July 31, 2018, the Company entered into a Proceeds Investment Agreement (the “PIA”) with Brickell Key Investments LP (“BKI”), pursuant to which BKI funded an aggregate of $500,000 (the “First Tranche”) to be used (i) to fund the Company’s litigation proceedings relating to the infringement of certain patent assets listed in the PIA and (ii) to repay the Company’s existing debt obligations and for certain working capital purposes set forth in the PIA. Pursuant to the PIA, BKI was granted an option to provide the Company with an additional $9.5 million, at BKI’s sole discretion (the “Second Tranche”). On August 21, 2018, BKI exercised its option on the Second Tranche for $9.5 million which completed the $10.0 million funding.

 

Pursuant to the PIA and in consideration for the $10.0 million in funding, the Company agreed to assign to BKI (i) 100% of all gross, pre-tax monetary recoveries paid by any defendant(s) to the Company or its affiliates agreed to in a settlement or awarded in judgment in connection with the patent assets, plus any interest paid in connection therewith by such defendant(s) (the “Patent Assets Proceeds”), up to the minimum return (as defined in the PIA) and (ii) if BKI has not received its minimum return by the earlier of a liquidity event (as defined in the PIA) and July 31, 2020, then the Company agreed to assign to BKI 100% of the Patent Asset Proceeds until BKI has received an amount equal to the minimum return on $4.0 million.

 

Pursuant to the PIA, the Company granted BKI (i) a senior security interest in the Patent Assets, the claims (as defined in the PIA) and the Patent Assets Proceeds until such time as the minimum return is paid, in which case, the security interest on the patent assets, the claims and the Patent Assets Proceeds will be released, and (ii) a senior security interest in all other assets of the Company until such time as the minimum return is paid on $4.0 million, in which case, the security interest on such other assets will be released.

 

The security interest is enforceable by BKI if the Company is in default under the PIA which would occur if (i) the Company fails, after five (5) days’ written notice, to pay any due amount payable to BKI under the PIA, (ii) the Company fails to comply with any provision of the PIA or any other agreement or document contemplated under the PIA Agreement, (iii) the Company becomes insolvent or insolvency proceedings are commenced (and not subsequently discharged) with respect to the Company, (iv) the Company’s creditors commence actions against the Company (which are not subsequently discharged) that affect material assets of the Company, (v) the Company, without BKI’s consent, incurs indebtedness other than immaterial ordinary course indebtedness up to $500,000, (vi) the Company fails, within five (5) business days following the closing of the second tranche, to fully satisfy its obligations to certain holders of the Company’s senior secured convertible promissory notes listed in the PIA and fails to obtain unconditional releases from such holders as to the Company’s obligations to such holders and the security interests in the Company held by such holders or (vii) there is an uncured non-compliance of the Company’s obligations or misrepresentations by the Company under the PIA.

 

Under the PIA, the Company issued BKI a warrant to purchase up to 465,712 shares of the Company’s common stock (the “PIA Warrant”), at an exercise price of $2.60 per share provided that the holder of the PIA Warrant will be prohibited from exercising the PIA Warrant if, as a result of such exercise, such holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. However, such holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to the Company. The PIA Warrant is exercisable for five years from the date of issuance and is exercisable on a cashless exercise basis if there is no effective registration statement. No contractual registration rights were given.

 

The Company elected to account for the PIA on the fair value basis. Therefore, the Company determined the fair value of the PIA and PIA Warrants which yielded estimated fair values of the PIA including their embedded derivatives and the detachable PIA Warrants as follows:

 

Proceeds investment agreement  $9,067,513 
Common stock purchase warrants   932,487 
      
Gross cash proceeds  $10,000,000 

 

 16 
 

 

The Company utilized a probability weighted present value of expected patent asset proceeds for the litigation involving both Axon Enterprises, Inc. (“Axon,” formerly known as Taser International, Inc.) and WatchGuard (see Note 9 – “Commitments and Contingencies”) which involved estimates of the amount and timing of the expected patent asset proceeds from the alleged patent infringement. The fair value of the PIA is updated for actual and estimated activity affecting the probability weighted present value of expected patent asset proceeds at each reporting date with the change charged/credited to operations. Following is a range of certain estimates and assumptions utilized as of June 30, 2020 and December 31, 2019 to probability weighted present value of expected patent asset proceeds for the litigation involving both Axon and WatchGuard:

 

   June 30, 2020   December 31, 2019 
Discount rate   15.13% -15.18%    3.0% -16.6% 
Expected term to patent asset proceeds payment   0.33 years – 3.75 .06 - .29 years    0.58 years - 4 years 
Probability of success   90.0%   5.9% -38.5% 
Estimated minimum return payable to BKI   $ 4 million    $ 21 million 
Negotiation discount   0.0%   43.3%

 

In May 2019, the Company settled its patent infringement litigation with WatchGuard whereby it received a lump-sum payment of $6.0 million as further described in Note 9 – “Commitments and Contingencies”. In accordance with the terms of the PIA, the Company remitted the $6.0 as a principal payment toward its minimum return payment obligations under the PIA.

 

The following represents activity in the PIA during the six months ended June 30, 2020:

 

Beginning balance as of December 31, 2019  $6,500,000 
Repayment of obligation    
Change in the fair value during the period   (2,885,000)
Ending balance as of June 30, 2020  $3,615,000 

 

Based on the recent unfavorable decisions by the United States Court of Appeals for the Tenth Circuit (see Note 9 – “Commitments and Contingencies”) the estimated future payments to BKI pursuant to the PIA has been reduced substantially resulting in the significant change in fair value (income) during the six months ended June 30, 2020. Subsequent to June 30, 2020 the Company also entered into a settlement agreement with BKI which may further reduce its obligations under the PIA. (See Note 14 – “Subsequent Events”).

 

NOTE 5. FAIR VALUE MEASUREMENT

 

In accordance with ASC Topic 820 — Fair Value Measurements and Disclosures (“ASC 820”), the Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets, liabilities or a group of assets or liabilities, such as a business.

 

ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1 — Quoted prices in active markets for identical assets and liabilities
   
Level 2 — Other significant observable inputs (including quoted prices in active markets for similar assets or liabilities)
   
Level 3 — Significant unobservable inputs (including the Company’s own assumptions in determining the fair value)

 

 17 
 

 

The following table represents the Company’s hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2020 and December 31, 2019:

 

   June 30, 2020 
   Level 1   Level 2   Level 3   Total 
Liabilities:                    
Secured convertible notes  $   $   $   $ 
Proceeds investment agreement obligation           3,615,000    3,615,000 
   $   $   $3,615,000   $3,615,000 

 

   December 31, 2019 
   Level 1   Level 2   Level 3   Total 
Liabilities:                    
Secured convertible notes  $   $   $1,593,809   $1,593,809 
Proceeds investment agreement obligation           6,500,000    6,500,000 
   $   $   $8,093,809   $8,093,809 

 

The following table represents the change in Level 3 tier value measurements:

 

   2019   2020         
   Secured   Secured   Proceeds     
   Convertible   Convertible   Investment     
   Notes   Notes   Agreement   Total 
                 
Balance, December 31, 2019  $1,593,809   $   $6,500,000   $8,093,809 
                     
Issuance of secured convertible debt       778,859        778,859 
                     
Conversion of secured convertible debentures   (1,259,074)   (1,665,666)       (2,924,740)
                     
Repayment of secured convertible notes   (747,180)   (1,000)       (748,180)
Change in fair value of secured convertible debentures and proceeds investment agreement   412,445    887,807    (2,885,000)   (1,548,748)
                     
Balance, June 30, 2020  $   $   $3,615,000   $3,615,000 

 

NOTE 6. ACCRUED EXPENSES

 

Accrued expenses comprised of the following at June 30, 2020 and December 31, 2019:

 

  

June 30, 2020

  

December 31, 2019

 
Accrued warranty expense  $30,711   $17,838 
Accrued litigation costs   250,000    295,000 
Accrued sales commissions   25,772    28,480 
Accrued payroll and related fringes   181,970    233,254 
Accrued insurance   60,894    78,579 
Accrued sales returns and allowances   10,267    18,258 
Accrued sales taxes   43,900    50,136 
Other   235,233    124,336 
           
   $838,747   $845,881 

 

Accrued warranty expense comprised of the following for the six months ended June 30, 2020:

 

Beginning balance  $17,838 
Provision for warranty expense   52,796 
Charges applied to warranty reserve   (39,923)
      
Ending balance  $30,711 

 

 18 
 

 

NOTE 7. INCOME TAXES

 

The effective tax rate for the six months ended June 30, 2020 and 2019 varied from the expected statutory rate due to the Company continuing to provide a 100% valuation allowance on net deferred tax assets. The Company determined that it was appropriate to continue the full valuation allowance on net deferred tax assets as of June 30, 2020 primarily because of the Company’s history of operating losses.

 

The Company has incurred operating losses in recent years and it continues to be in a three-year cumulative loss position at June 30, 2020. Accordingly, the Company determined there was not sufficient positive evidence regarding its potential for future profits to outweigh the negative evidence of our three-year cumulative loss position under the guidance provided in ASC 740. Therefore, it determined to continue to provide a 100% valuation allowance on its net deferred tax assets. The Company expects to continue to maintain a full valuation allowance until it determines that it can sustain a level of profitability that demonstrates its ability to realize these assets. To the extent the Company determines that the realization of some or all of these benefits is more likely than not based upon expected future taxable income, a portion or all of the valuation allowance will be reversed. As of June 30, 2020, it had approximately $66,925,000 of net operating loss carryforwards and $1,795,000 of research and development tax credit carryforwards as determined on December 31, 2019 available to offset future net taxable income.

 

NOTE 8. OPERATING LEASES

 

On May 13, 2020, the Company entered into an operating lease for new warehouse and office space which will serve as its new principal executive office and primary business location. The terms of the lease include no base rent for the first six months and monthly payments ranging from $12,398 to $13,693 thereafter, with a termination date of December 2026. The Company is responsible for property taxes, utilities, insurance and its proportionate share of common area costs related to its new location. The Company took possession of the leased facilities on June 15, 2020. The remaining lease term for the Company’s office and warehouse operating lease as of June 30, 2020 was seventy-eight months. The Company’s previous office and warehouse space lease expired in April 2020 and the Company paid holdover rent for the time period until it moved to and commenced occupying the new space on June 15, 2020.

 

The Company entered into an operating lease with a third party in October 2019 for copiers used for office and warehouse purposes. The terms of the lease include 48 monthly payments of $1,598 with a maturity date of October 2023. The Company has the option to purchase the equipment at maturity for its estimated fair market value at that point in time. The remaining lease term for the Company’s copier operating lease as of June 30, 2020 was 40 months.

 

Lease expense related to the office space and copier operating leases were recorded on a straight-line basis over their respective lease terms. Total lease expense was $252,290 for the six months ended June 30, 2020.

 

The discount rate implicit within the Company’s operating leases was not generally determinable and therefore it determined the discount rate based on its incremental borrowing rate on the information available at commencement date. As of commencement date, the operating lease liabilities reflect a weighted average discount rate of 8%.

 

The following sets forth the operating lease right of use assets and liabilities as of June 30, 2020:

 

Assets:     
Operating lease right of use assets  $769,635 
      
Liabilities:     
Operating lease obligations-Long-term portion  $731,334 
Operating lease obligations-Current portion  $44,308 
Total operating lease obligations  $775,642 

 

 19 
 

 

The components of lease expense were as follows for the six months ended June 30, 2020:

 

Selling, general and administrative expenses  $252,290 

 

Following are the minimum lease payments for each year and in total.

 

Year ending December 31:    
2020 (July 1, to December 31, 2020)  $21,986 
2021   169,691 
2022   172,666 
2023   172,542 
2024   159,703 
Thereafter   310,259 
Total undiscounted minimum future lease payments   1,006,847 
Imputed interest   (231,205)
Total operating lease liability  $775,642 

 

NOTE 9. COMMITMENTS AND CONTINGENCIES

 

COVID-19 pandemic

 

The World Health Organization has declared the outbreak of COVID-19, or coronavirus, which began in December 2019, a pandemic and the U.S. federal government has declared it a national emergency. Our business, financial condition, results of operations and cash flows could be materially and adversely affected by the effects of COVID-19. The global spread of COVID-19 has already created significant volatility, uncertainty and economic disruption in the markets in which we operate. Governments, public institutions, and other organizations in countries and localities where cases of COVID-19 have been detected are taking certain emergency measures to mitigate its spread, including implementing travel restrictions and closing factories, schools, public buildings, and businesses. While the full impact of this outbreak is not yet known, we are closely monitoring the spread of COVID-19 and continually assessing its potential effects on our business.

 

The extent to which our results are affected by COVID-19 will largely depend on future developments which cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy, our customers’ demand for our products and services, and our ability to provide our products and services, particularly as result of our employees working remotely and/or the closure of certain offices and facilities.

 

Litigation.

 

From time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. It is our policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of the amount of the loss or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We reevaluate and update accruals as matters progress over time.

 

While the ultimate resolution is unknown, based on the information currently available, we do not expect that these lawsuits will individually, or in the aggregate, have a material adverse effect to our results of operations, financial condition and cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows.

 

 20 
 

 

Axon

 

The Company owns U.S. Patent No. 9,253,452 (the “ ‘452 Patent”), which generally covers the automatic activation and coordination of multiple recording devices in response to a triggering event, such as a law enforcement officer activating the light bar on the vehicle.

 

The Company filed suit on January 15, 2016 in the U.S. District Court for the District of Kansas (the “U.S. District Court”) (Case No: 2:16-cv-02032) against Axon, alleging willful patent infringement against Axon’s body camera product line and Signal auto-activation product. The Company is seeking both monetary damages and a permanent injunction against Axon for infringement of the ‘452 Patent.

 

In December 2016 and January 2017, Axon filed two petitions for Inter Partes Review (“IPR”) against the ‘452 Patent. The United States Patent and Trademark Office (“USPTO”) rejected both of Axon’s petitions. Axon is now statutorily precluded from filing any more IPR petitions against the ‘452 Patent.

 

The U.S. District Court litigation was temporarily stayed following the filing of the petitions for IPR. However, on November 17, 2017, the U.S. District Court of Kansas rejected Axon’s request to maintain the stay. With this ruling, the parties proceeded towards trial, after which the parties filed motions for summary judgment on January 31, 2019.

 

On June 17, 2019, the U.S. District Court granted Axon’s motion for summary judgment that Axon did not infringe on the Company’s patent and dismissed the case. The U.S. District Court’s ruling did not find that the ‘452 Patent was invalid. It also did not address any other issue, such as whether the Company’s requested damages were appropriate, and it did not impact the Company’s ability to file additional lawsuits to hold other competitors accountable for patent infringement. This ruling solely related to an interpretation of the Company’s claims as they relate to Axon and was unrelated to the supplemental briefing the Company filed on its damages claim and the WatchGuard settlement. Those issues are separate and the U.S. District Court’s ruling on the motion for summary judgment had nothing to do with the Company’s damages request.

 

The Company filed an opening appeal brief on August 26, 2019 with the U.S. Court of Appeals for the Tenth Circuit (the “Court of Appeals”), appealing the U.S. District Court’s granting of Axon’s motion for summary judgment. Axon responded by filing a responsive brief on November 6, 2019 and we then filed a reply brief responding to Axon on November 27, 2019. The Court of Appeals scheduled oral arguments on our appeal of the U.S. District Court’s summary judgment ruling on April 6, 2020. This appeal was intended to address the Company’s position that the U.S. District Court incorrectly dismissed our claims against Axon. If the Court of Appeals overturns the ruling of the U.S. District Court, the case will be remanded to the U.S District Court before a new judge. On March 12, 2020, the panel of judges for the Court of Appeals issued an order cancelling the oral arguments previously set for April 6, 2020, having determined that the appeal will be decided solely based on the parties’ briefs. On April 22, 2020, a three-judge panel of the United States Court of Appeals denied our appeal and affirmed the District Court’s previous decision to grant Axon summary judgment. On May 22, 2020, we filed a petition for panel rehearing requesting that we be granted a rehearing of our appeal of the U.S. District Court’s summary judgment ruling. Furthermore, we requested that we be given an opportunity to make our case through oral argument in front of the three-judge panel of the Court of Appeals, which was also denied. The Company is reviewing its alternatives at this point.

 

WatchGuard

 

On May 27, 2016, the Company filed suit against WatchGuard (Case No. 2:16-cv-02349-JTM-JPO) alleging patent infringement based on WatchGuard’s VISTA Wifi and 4RE In-Car product lines.

 

On May 13, 2019, the parties resolved the dispute and executed a settlement agreement in the form of a Release and License Agreement. The litigation has been dismissed as a result of this settlement.

 

 21 
 

 

The Release and License Agreement contains the following key terms:

 

  WatchGuard paid Digital Ally a one-time, lump settlement payment of $6,000,000.
     
  Digital Ally granted WatchGuard a perpetual covenant not to sue if WatchGuard’s products incorporate agreed-upon modified recording functionality. Digital Ally also granted WatchGuard a license to the ‘292 Patent and the ‘452 Patent (and related patents, now existing and yet-to-issue) through December 31, 2023. The parties agreed to negotiate in good faith to attempt to resolve any alleged infringement that occurs after the license period expires.
     
  The parties further agreed to release each other from all claims or liabilities pre-existing the settlement.
     
  As part of the settlement, the parties agreed that WatchGuard made no admission that it infringed any of Digital Ally’s patents.

 

Upon receipt of the $6,000,000 the parties filed a joint motion to dismiss the lawsuit with the court, which was granted.

 

NASDAQ LISTING.

 

On July 11, 2019, we were officially notified by The Nasdaq Stock Market LLC that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (the “MVLS”) for our Common Stock was below the $35 million minimum MVLS requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we had 180 calendar days, or until January 7, 2020, to regain compliance with the MVLS Rule, or in the alternative, the minimum stockholders’ equity requirement of $2,500,000. To regain compliance with the MVLS Rule, the minimum MVLS for our Common Stock must have been at least $35 million for a minimum of 10 consecutive business days at any time during this 180-day period. If we failed to regain compliance with either the MVLS Rule or the minimum stockholders’ equity requirement by January 7, 2020, we could have been delisted from Nasdaq.

 

On January 8, 2020, we received a determination letter from the staff of The Nasdaq Stock Market LLC stating that we had not regained compliance with the MVLS Standard, since our Common Stock was below the $35 million minimum MVLS requirement for continued listing on Nasdaq under the MLVS Rule and had not been at least $35 million for a minimum of 10 consecutive business days at any time during the 180-day grace period granted to us. Pursuant to the Letter, unless we requested a hearing to appeal this determination by January 15, 2020, our Common Stock would have been delisted from Nasdaq, trading of our Common Stock would have been suspended at the opening of business on January 17, 2020, and a Form 25-NSE would have been filed with the SEC, which would have removed our Common Stock from listing and registration on Nasdaq.

 

 22 
 

 

On January 13, 2020, we requested a hearing before the Nasdaq Hearings Panel to appeal the Letter and a hearing was held on February 20, 2020, when we appeared before the Panel to discuss our plan to regain compliance, including, but not limited to, complying with Nasdaq Listing Rule 5550(b)(1), which is the minimum stockholdersequity standard for continued listing, which requires that companies listed on Nasdaq maintain a minimum of $2,500,000 in stockholders’ equity (“Rule 5550(b)(1)”). On March 6, 2020, we received written notice from the Panel indicating that, based on the plan of compliance that we had presented at such hearing, the Panel granted our request for the continued listing of our Common Stock on Nasdaq, subject to, among other things, us keeping the Staff updated on the progress of our compliance plan and ultimately being able to evidence shareholder equity in an amount greater than or equal to $2,500,000 in accordance with Rule 5550(b)(1) no later than June 30, 2020. During this time, our Common Stock remained listed and trading on Nasdaq.

 

On June 4, 2020 and June 10, 2020, we consummated underwritten public offerings, pursuant to underwriting agreements and raised aggregate gross proceeds of approximately $11.3 million, before underwriting discounts and commissions and other estimated expenses of such offerings. As a result of such offerings, we achieved compliance with Rule 5550(b)(1) and on June 18, 2020 we received written notice from the Staff stating that we had regained compliance with such rule and the matter is now closed.

 

On April 22, 2020, we received a written notification from the Nasdaq Stock Market LLC indicating that we were not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price for our Common Stock was below $1.00 per share for the last thirty (30) consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we were granted a 180-calendar day compliance period to regain compliance with the minimum bid price requirement. Subsequently, the 180-day grace period to regain compliance with such minimum bid price requirement under applicable Nasdaq Stock Market LLC rules was extended due to the global market impact caused by COVID-19. More specifically, the Nasdaq Stock Market LLC has stated that the compliance periods for any company previously notified about non-compliance will be suspended effective April 16, 2020, through June 30, 2020. On July 1, 2020, companies not in compliance would receive the balance of any pending compliance period exception to come back into compliance with such minimum bid price requirement. As a result of this extension, we had until December 28, 2020, to regain compliance with such minimum bid price requirement. During the compliance period, our Common Stock would still continue to be listed and traded on Nasdaq. To regain compliance, the closing bid price of the Common Stock had to have met or exceeded $1.00 per share for at least ten (10) consecutive business days by December 28, 2020. On June 11, 2020, our Common Stock met such minimum bid price requirement, as the closing sale price of our Common Stock had equaled or exceeded $1.00 per share on Nasdaq at the close of each trading day since May 29, 2020, and we received written notice from the Staff stating that the Company regained compliance with such requirement and the matter is now closed.

 

NOTE 10. STOCK-BASED COMPENSATION

 

The Company recorded pretax compensation expense related to the grant of stock options and restricted stock issued of $376,738 and $585,195 for the three months ended June 30, 2020 and 2019 and $688,415 and $1,310,393 for the six months ended June 30, 2020 and 2019, respectively.

 

As of June 30, 2020, the Company had adopted seven separate stock option and restricted stock plans: (i) the 2005 Stock Option and Restricted Stock Plan (the “2005 Plan”), (ii) the 2006 Stock Option and Restricted Stock Plan (the “2006 Plan”), (iii) the 2007 Stock Option and Restricted Stock Plan (the “2007 Plan”), (iv) the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), (v) the 2011 Stock Option and Restricted Stock Plan (the “2011 Plan”), (vi) the 2013 Stock Option and Restricted Stock Plan (the “2013 Plan”), (vii) the 2015 Stock Option and Restricted Stock Plan (the “2015 Plan”) and (vii) the 2018 Stock Option and Restricted Stock Plan (the “2018 Plan”). The 2005 Plan, 2006 Plan, 2007 Plan, 2008 Plan, 2011 Plan, 2013 Plan, 2015 Plan and 2018 Plan are referred to as the “Plans.”

 

These Plans permit the grant of stock options or restricted stock to its employees, non-employee directors and others for up to a total of 4,175,000 shares of common stock. The 2005 Plan terminated during 2015 with 19,678 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2005 Plan that remain unexercised and outstanding as of June 30, 2020 total 7,563. The 2006 Plan terminated during 2016 with 25,849 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2006 Plan that remain unexercised and outstanding as of June 30, 2020 total 39,750. The 2007 Plan terminated during 2017 with 89,651 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2007 Plan that remain unexercised and outstanding as of June 30, 2020 total 5,000. The 2008 Plan terminated during 2018 with 9,249 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2008 Plan that remain unexercised and outstanding as of June 30, 2020 total 31,250.

 

 23 
 

 

Our Board of Directors adopted the 2020 Stock Option and Restricted Stock Plan (the “2020 Plan”) on June 30, 2020. At the annual meeting of the Company’s stockholders to be held on September 9, 2020 (the “Annual Meeting”) the Company is asking its stockholders to approve the 2020 Plan and the reservation of 1,500,000 shares of common stock issuable under the 2020 Plan. The 2020 Plan would authorize us to issue 1,500,000 shares of Common Stock upon exercise of options and grant of restricted stock awards. No options have been granted under the 2020 Plan to date. The 2020 Plan would also authorize us to grant (i) to the key employees incentive stock options to purchase shares of Common Stock and non-qualified stock options to purchase shares of Common Stock and restricted stock awards and (ii) to non-employee directors and consultants non-qualified stock options and restricted stock. As of June 30, 2020, approximately 78 employees, two executive officers, and three non-employee directors were eligible to participate in the 2020 Plan.

 

The Company believes that such awards better align the interests of our employees with those of its stockholders. Option awards have been granted with an exercise price equal to the market price of its stock at the date of grant with such option awards generally vesting based on the completion of continuous service and having ten-year contractual terms. These option awards typically provide for accelerated vesting if there is a change in control (as defined in the Plans). The Company has registered all shares of common stock that are issuable under its Plans with the SEC, except for shares of Common Stock issuable under the 2020 Plan, which the Company expects to register after the Annual Meeting, if the 2020 Plan is approved by the Company’s stockholders. A total of 1,437 shares remained available for awards under the various Plans (other than the 2020 Plan) as of June 30, 2020, and a total of 1,500,000 shares of Common Stock remained available for awards under the 2020 Plan as of June 30, 2020, which awards are not available for grant until the 2020 Plan is approved by the Company’s stockholders at the Annual Meeting, or which awards are terminable if such approval is not obtained, depending on the type of award available under the 2020 Plan.

 

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model.

 

Activity in the various Plans during the six months ended June 30, 2020:

 

Options 

Number of

Shares

  

Weighted

Average

Exercise Price

 
Outstanding at December 31, 2019   589,125   $3.74 
Granted        
Exercised   (1,875)   4.16 
Forfeited   (3,937)   (12.14)
Outstanding at June 30, 2020   583,313   $3.69 
Exercisable at June 30, 2020   583,313   $3.69 

 

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model. The total estimated grant date fair value stock options issued during the six months ended June 30, 2020 was $-0- as there were no grants during that period.

 

The Plans allow for the cashless exercise of stock options. This provision allows the option holder to surrender/cancel options with an intrinsic value equivalent to the purchase/exercise price of other options exercised. There were no shares surrendered pursuant to cashless exercises during the six months ended June 30, 2020 and 2019.

 

At June 30, 2020, the aggregate intrinsic value of options outstanding was approximately $187,800 and the aggregate intrinsic value of options exercisable was approximately $187,800. No options were exercised in the six months ended June 30, 2019.

 

As of June 30, 2020, the unrecognized portion of stock compensation expense on all existing stock options was $-0-.

 

 24 
 

 

The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable options under the Company’s option plans as of June 30, 2020:

 

      Outstanding options   Exercisable options  

Exercise price

range

   

Number of

options

   

Weighted average

remaining

contractual life

 

Number of

options

   

Weighted average

remaining

contractual life

 
                         
$ 0.01 to $3.49       470,313     7.9 years     470,313       7.9 years  
$ 3.50 to $4.99       64,000     3.8 years     64,000       3.8 years  
$ 5.00 to $6.49           — years           — years  
$ 6.50 to $7.99       7,250     1.3 years     7,250       1.3 years  
$ 8.00 to $9.99       2,500     0.9 years     2,500       0.9 years  
$ 10.00 to $19.99       39,250     0.5 years     39,250       0.5 years  
                                 
          583,313     6.8 years     583,313       6.8 years  

 

Restricted stock grants. The Board of Directors has granted restricted stock awards under the Plans. Restricted stock awards are valued on the date of grant and have no purchase price for the recipient. Restricted stock awards typically vest over one to four years corresponding to anniversaries of the grant date. Under the Plans, unvested shares of restricted stock awards may be forfeited upon the termination of service to or employment with the Company, depending upon the circumstances of termination. Except for restrictions placed on the transferability of restricted stock, holders of unvested restricted stock have full stockholder’s rights, including voting rights and the right to receive cash dividends.

 

A summary of all restricted stock activity under the equity compensation plans for the six months ended June 30, 2020 is as follows:

 

  

Number of

Restricted

shares

  

Weighted

average

grant date

fair

value

 
Nonvested balance, January 1, 2020   514,875   $2.97 
Granted   665,500    1.05 
Vested   (410,375)   (2.14)
Forfeited   (35,250)   (1.84)
Nonvested balance, June 30, 2020   734,750   $1.75 

 

The Company estimated the fair market value of these restricted stock grants based on the closing market price on the date of grant. As of June 30, 2020, there were $505,271 of total unrecognized compensation costs related to all remaining non-vested restricted stock grants, which will be amortized over the next 18 months in accordance with their respective vesting scale.

 

The nonvested balance of restricted stock vests as follows:

 

Years ended 

Number of

shares

 
     
2020 (April 1, 2020 through December 31, 2020)   13,125 
2021   480,250 
2022   241,375 

 

 25 
 

 

NOTE 11. COMMON STOCK PURCHASE WARRANTS

 

The Company has issued common stock purchase warrants in conjunction with various debt and equity issuances. The warrants are either immediately exercisable, or have a delayed initial exercise date, no more than six months from their respective issue date and allow the holders to purchase up to 3,393,364 shares of common stock at $1.40 to $16.50 per share as of June 30, 2020. The warrants expire from July 15, 2020 through January 17, 2025 and allow for cashless exercise.

 

The following table summarizes information about shares issuable under warrants outstanding during the six months ended June 30, 2020:

 

   Warrants  

Weighted

average

exercise

price

 
Vested Balance, January 1, 2020   4,824,573   $5.15 
Granted   1,273,374    1.31 
Exercised   (2,704,583)   (1.95)
Cancelled        
Vested Balance, June 30, 2020   3,393,364   $6.26 

 

The total intrinsic value of all outstanding warrants aggregated $295,836 as of June 30, 2020 and the weighted average remaining term is 21.8 months.

 

During the six months ended June 30, 2020, warrants to purchase 2,686,582 common shares were exercised for cash proceeds of $5,203,122 and warrants to purchase 18,000 common shares were exercised on a cashless basis through the forfeiture of 10,715 common shares.

 

The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable warrants to purchase common shares as of June 30, 2020:

 

    Outstanding and exercisable warrants 
Exercise price   Number of warrants  

Weighted average

remaining

contractual life

 
$2.60    465,712    3.1 years 
$3.00    316,800    2.8 years 
$3.36    166,667    1.7 years 
$3.36    566,666    2.7 years 
$3.65    167,000    2.0 years 
$3.75    25,753    2.1 years 
$5.00    800,000    1.5 years 
$13.43    879,766    0.6 years 
$16.50    5,000    0.1 years 
             
      3,393,364    1.8 years 

 

NOTE 12. STOCKHOLDERS’ EQUITY (DEFICIT)

 

Underwritten Public Offerings

 

On March 3, 2020, the Company entered into an underwriting agreement with Aegis Capital Corp., as the representative of the underwriters and sole book-running manager, pursuant to which the Company agreed to sell to the underwriters in a firm commitment underwritten public offering (the “Offering”) an aggregate of 2,521,740 shares of the Company’s common stock at a public price of $1.15 per share. The Company also granted the underwriters a forty-five (45)-day option to purchase up to an additional 378,261 shares of common stock to cover over-allotments, if any. The Offering was registered and the common stock was issued pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-225227), which was initially filed with the SEC on May 25, 2018 and was declared effective on June 6, 2018.

 

 26 
 

 

The underwriting agreement contained customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters. The Underwriters received discounts and commissions of seven percent (7%) of the gross cash proceeds received by the Company from the sale of the common stock in the Offering. In addition, the Company agreed to pay the Underwriters (a) a non-accountable expense reimbursement of 1% of the gross proceeds received and (b) “road show” expenses, diligence fees and the fees and expenses of the Underwriters’ legal counsel not to exceed $50,000. The net proceeds to the Company from the Offering totaled approximately $2,502,136, after deducting underwriting discounts and commissions and estimated expenses payable by the Company.

 

On June 2, 2020, the Company entered into an underwriting agreement with Aegis Capital Corp., as the representative of the underwriters and sole book-running manager, pursuant to which the Company agreed to sell to the underwriters in a firm commitment underwritten public offering an aggregate of 3,090,909 shares of the Company’s common stock, at a public price of $1.65 per share (the “June 2nd Offering”). The Company also granted the underwriters a forty-five (45)-day option to purchase up to an additional 463,636 shares of common stock to cover over-allotments, if any (the “June 2nd Option Shares”). The June 2nd Offering was registered and the common stock was issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-225227), which was initially filed with the SEC on May 25, 2018 and was declared effective on June 6, 2018.

 

On June 8, 2020, the Underwriters fully exercised their over-allotment option to acquire the June 2nd Option Shares at $1.65 per share, and the offering of the June 2nd Option Shares closed on June 10, 2020. The exercise of such over-allotment option resulted in additional gross proceeds, before deducting underwriting discounts and commissions and other estimated offering expenses, of $765,000, which the Company intends to use for general corporate purposes, including for compliance with certain Nasdaq continued listing requirements and continued investments in the Company’s commercialization efforts.

 

The underwriting agreement contained customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters. The Underwriters received discounts and commissions of seven percent (7%) of the gross cash proceeds received by the Company from the sale of the common shares in the June 2nd Offering. In addition, the Company agreed to pay the Underwriters “road show” expenses, diligence fees and the fees and expenses of the Underwriters’ legal counsel not to exceed $30,000. The net proceeds to the Company from the June 2nd Offering totaled $5,350,413, including the exercise of the underwriter’s overallotment option and after deducting underwriting discounts and commissions and estimated expenses payable by the Company.

 

On June 8, 2020, the Company entered into an underwriting agreement with Aegis Capital Corp., as the representative of the underwriters and sole book-running manager, pursuant to which the Company agreed to sell to the underwriters in a firm commitment underwritten public offering an aggregate of 2,325,581 shares of common stock at a public price of $2.15 per share (the “June 8th Offering”). The Company also granted the underwriters a forty-five (45)-day option to purchase up to an additional 213,953 shares of common stock to cover over-allotments, if any (the “June 8th Option Shares”).The June 8th Offering was registered and the common stock was issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-225227), which was initially filed with the SEC on May 25, 2018 and was declared effective on June 6, 2018.

 

On June 10, 2020, the Underwriters fully exercised their over-allotment option to acquire the June 8th Option Shares at $2.15 per share, and the offering of the June 8th Option Shares closed on June 10, 2020. The exercise of such over-allotment option resulted in additional gross proceeds, before deducting underwriting discounts and commissions and other estimated Offering expenses, of $460,000, which the Company intends to use for general corporate purposes, including for compliance with certain Nasdaq continued listing requirements and continued investments in the Company’s commercialization efforts.

 

The underwriting agreement contained customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters. The Underwriters received discounts and commissions of seven percent (7%) of the gross cash proceeds received by the Company from the sale of the common shares in the June 8th Offering. In addition, the Company agreed to pay the Underwriters “road show” expenses, diligence fees and the fees and expenses of the Underwriters’ legal counsel not to exceed $30,000. The net proceeds to the Company from the June 8th Offering totaled $4,976,692, including the exercise of the underwriter’s overallotment option and after deducting underwriting discounts and commissions and estimated expenses payable by the Company.

 

 27 
 

 

2020 Issuances of Restricted Common Stock.

 

On January 3, 2020, the board of directors approved the grant of 530,050 shares of restricted common stock to officers and employees of the Company. Such shares will generally vest one-half on January 2, 2021 and one half on January 2, 2022, provided that each grantee remains an officer or employee on such dates.

 

In April 17, 2020 the Compensation Committee of the Board of Directors of the Company determined that the cash portion of the annual base salaries of the Company’s President and Chief Executive Officer, and the Company’s Chief Financial Officer, Treasurer and Secretary, would be reduced to annual rates of $150,000 each for the balance of 2020 commencing May 1, 2020.

 

The Committee also decided that the reduction of the base annual salaries of Company’s President and Chief Executive Officer, and the Company’s Chief Financial Officer, Treasurer and Secretary, for 2020, which totaled $69,231 and $55,384, respectively, as of May 1, 2020 was paid through the issuance of shares of restricted stock under the 2018 Stock Option and Restricted Stock Plan with the Company paying the applicable federal and state taxes on such amounts. Accordingly, the Company issued the Company’s President and Chief Executive Officer, and the Company’s Chief Financial Officer, Treasurer and Secretary 75,250 shares and 60,200 shares, respectively, effective April 17, 2020 based on a closing price of $0.92 per share on such date.

 

NOTE 13. NET LOSS PER SHARE

 

The calculation of the weighted average number of shares outstanding and loss per share outstanding for the three and six months ended June 30, 2020 and 2019 are as follows:

 

  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
   2020   2019   2020   2019 
Numerator for basic and diluted income per share – Net loss  $(497,894)  $(387,730)  $(2,832,004)  $(3,592,904)
                     
Denominator for basic loss per share – weighted average shares outstanding   18,976,724    11,305,248    16,430,214    11,124,222 
Dilutive effect of shares issuable under stock options and warrants outstanding                
                     
Denominator for diluted loss per share – adjusted weighted average shares outstanding   18,976,724    11,305,248    16,430,214    11,124,222 
                     
Net loss per share:                    
Basic  $(0.03)  $(0.03)  $(0.17)  $(0.32)
Diluted  $(0.03)  $(0.03)  $(0.17)  $(0.32)

 

Basic loss per share is based upon the weighted average number of common shares outstanding during the period. For the three and six months ended June 30, 2020 and 2019, all shares issuable upon conversion of convertible debt and the exercise of outstanding stock options and warrants were antidilutive, and, therefore, not included in the computation of diluted income (loss) per share.

 

 28 
 

 

NOTE 14. SUBSEQUENT EVENTS

 

Warehouse Building Acquisition. On July 13, 2020, the Company entered into a Commercial and Industrial Real Estate Sale Contract (the “Contract”) whereby it will purchase new warehouse space which will serve as the company’s warehouse and distribution location for its new branded temperature screening device ThermoVU™ and its Shield™ line of disinfectant/cleanser products. The terms of the Contract include a total purchase price of $420,000 with the closing expected to occur on or before August 21, 2020. The Company paid cash to close the purchase of the building on July 16, 2020.

 

Proceeds Investment Agreement Termination Agreement. - On July 20, 2020, the Company and BKI executed a Termination Agreement and Mutual Release (the “Termination Agreement”). Under the terms of the Termination Agreement the parties agreed to terminate the PIA and to release one another from any further liability under the PIA obligation. (See Note 4 — “Proceeds Investment Agreement Obligation”).

 

Under the terms of the Termination Agreement, upon payment of $1,250,000 by the Company to BKI both parties agreed to terminate the PIA and to release each other from any further liability thereunder. Such $1,250,000 payment was made on July 22, 2020. In addition to the $1,250,000 payment, the Company further agreed to pay BKI the following: (a) a contingent payment in the amount of $2,750,000 following the closing of an asset purchase, membership interest purchase, or similar transaction between the Company and a specified third-party (the “Purchase Transaction”) and (b) any and all future proceeds received from Watchguard and its successors and assigns by the Company for WatchGuard’s use of U.S. Patent Nos. 8,781,292 and 9,253,452. For clarity, the Company and BKI further agreed that the payment of the contingent payment would only be due and payable upon the closing of the specified Purchase Transaction and the relevant contingent payment portion of the Termination Agreement, and any obligations stemming therefrom, would automatically terminate if the specified Purchase Transaction is abandoned prior to its closing, including its failure to close within three years from the date of the Termination Agreement. The specified Purchase Transaction has not yet occurred and there is no binding agreement to complete such Purchase Transaction.

 

Shelf Registration Statement on Form S-3 On July 2, 2020 the SEC declared the Company’s shelf registration statement on Form S-3 (the “Shelf Registration Statement”) effective. The Shelf Registration Statement allows the Company to offer and sell, from time to time in one or more offerings, any combination of our common stock, debt securities, debt securities convertible into common stock or other securities in any combination thereof, rights to purchase shares of common stock or other securities in any combination thereof, warrants to purchase shares of common stock or other securities in any combination thereof or units consisting of common stock or other securities in any combination thereof having an aggregate initial offering price not exceeding $125,000,000.

 

*************************************

 

 29 
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation.

 

This quarterly report on Form 10-Q of Digital Ally, Inc. (the “Company”, “we”, “us”, or “our”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “may,” “should,” “could,” “will,” “plan,” “future,” “continue,” and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters identify forward-looking statements. These forward-looking statements are based largely on our expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond our control. Therefore, actual results could differ materially from the forward-looking statements contained in this document, and readers are cautioned not to place undue reliance on such forward-looking statements.

 

We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this document will, in fact, transpire or prove to be accurate.

 

Factors that could cause or contribute to our actual results differing materially from those discussed herein or for our stock price to be adversely affected include, but are not limited to: (1) our losses in recent years, including during the six months ended June 30, 2020 and the 2019 fiscal year; (2) economic and other risks for our business from the effects of the COVID-19 pandemic, including the impacts on our law-enforcement and commercial customers, suppliers and employees and on our ability to raise capital as required; (3) our ability to increase revenues, increase our margins and return to consistent profitability in the current economic and competitive environment; (4) our operation in developing markets and uncertainty as to market acceptance of our technology and new products; (5) the availability of funding from federal, state and local governments to facilitate the budgets of law enforcement agencies, including the timing, amount and restrictions on such funding; (6) our ability to deliver our new product offerings as scheduled in 2020, such as the Shield™ disinfectant/sanitizers products and ThermoVU™ temperature screening systems, whether such new products perform as planned or advertised and whether they will help increase our revenues; (7) whether we will be able to increase the sales, domestically and internationally, for our products in the future; (8) our ability to maintain or expand our share of the market for our products in the domestic and international markets in which we compete, including increasing our international revenues; (9) our ability to produce our products in a cost-effective manner; (10) competition from larger, more established companies with far greater economic and human resources; (11) our ability to attract and retain quality employees; (12) risks related to dealing with governmental entities as customers; (13) our expenditure of significant resources in anticipation of sales due to our lengthy sales cycle and the potential to receive no revenue in return; (14) characterization of our market by new products and rapid technological change; (15) our dependence on sales of our EVO-HD, DVM-800, FirstVU HD and DVM-250 products; (16) potential that stockholders may lose all or part of their investment if we are unable to compete in our markets and return to profitability; (17) defects in our products that could impair our ability to sell our products or could result in litigation and other significant costs; (18) our dependence on key personnel; (19) our reliance on third-party distributors and sales representatives for part of our marketing capability; (20) our dependence on a few manufacturers and suppliers for components of our products and our dependence on domestic and foreign manufacturers for certain of our products; (21) our ability to protect technology through patents and to protect our proprietary technology and information as trade secrets and through other similar means; (22) our ability to generate more recurring cloud and service revenues; (23) risks related to our license arrangements; (24) our revenues and operating results may fluctuate unexpectedly from quarter to quarter; (25) sufficient voting power by coalitions of a few of our larger stockholders, including directors and officers, to make corporate governance decisions that could have significant effect on us and the other stockholders; (26) sale of substantial amounts of our common stock, par value $0.001 per share that may have a depressive effect on the market price of the outstanding shares of our common stock; (27) possible issuance of common stock subject to options and warrants that may dilute the interest of stockholders; (28) our nonpayment of dividends and lack of plans to pay dividends in the future; (29) future sale of a substantial number of shares of our common stock that could depress the trading price of our common stock, lower our value and make it more difficult for us to raise capital; (30) our additional securities available for issuance, which, if issued, could adversely affect the rights of the holders of our common stock; (31) the likely high volatility of our stock price due to a number of factors, including a relatively limited public float; (32) whether the litigation against Axon will achieve its intended objectives and result in monetary recoveries for us; (33) whether the USPTO rulings will curtail, eliminate or otherwise have an effect on the actions of Axon and other competitors respecting us, our products and customers; (34) whether our patented VuLink technology will become the de-facto “standard” for agencies engaged in deploying state-of-the-art body-worn and in-car camera systems and will increase our revenues; (35) whether such technology will have a significant impact on our revenues in the long-term and (36) indemnification of our officers and directors.

 

Current Trends and Recent Developments for the Company

 

Overview

 

We produce digital video imaging, storage products and disinfectant and related safety products for use in law enforcement, security and commercial applications. Our current products include in-car digital video/audio recorders contained in a rear-view mirror for use in law enforcement and commercial fleets; a system that provides its law enforcement customers with audio/video surveillance from multiple vantage points and hands-free automatic activation of body-worn cameras and in-car video systems; a miniature digital video system designed to be worn on an individual’s body; and cloud storage solutions. We have active research and development programs to adapt our technologies to other applications. We sell our products to law enforcement agencies, private security customers and organizations and consumer and commercial fleet operators through direct sales domestically and third-party distributors internationally.

 

 30 
 

 

We supply technology-based products utilizing our portable digital video and audio recording capabilities, for the law enforcement and security industries and for the commercial fleet and mass transit markets. We have the ability to integrate electronic, radio, computer, mechanical, and multi-media technologies to create unique solutions to address needs in a variety of other industries and markets, including mass transit, school bus, taxicab and the military. Our products include the DVM-800 in-car digital video mirror systems for use by law enforcement; the FirstVU and the FirstVU HD which are body-worn cameras, our patented VuLink product, which integrates our body-worn cameras with our in-car systems by providing hands-free automatic activation and which we supply to both law enforcement and commercial markets; the DVM-250 and DVM-250 Plus, a commercial line of digital video mirrors that serve as “event recorders” for the commercial fleet and mass transit markets; and FleetVU and VuLink, which are cloud-based evidence management systems. We introduced the EVO-HD product in late June 2019 and began full-scale deliveries in the third quarter 2019. It is designed and built on a new and highly advanced technology platform that we expect to become the platform for a new family of our in-car video solution products for the law enforcement and commercial markets. We believe that the launch of these new products will help to reinvigorate our in-car and body-worn systems revenues while diversifying and broadening the market for our product offerings as circumstances normalize in a post-COVID-19 economy, although we can offer no assurance in this regard. The Company has recently added two new lines of branded products: (1) the ThermoVu™ which is a line of self-contained temperature monitoring stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2) our Shield™ disinfectants and cleansers which are for use against viruses and bacteria and began offering such products to its law enforcement and commercials customers beginning late in the second quarter 2020. We are ramping up our supply chain for both of these new product lines, which are manufactured by third-parties.

 

We experienced operating losses for all of our fiscal quarters during 2020 and 2019 except for the second quarter of 2019, as a result of a patent litigation settlement. The following is a summary of our recent operating results on a quarterly basis:

 

  

June 30,

2020

  

March 31,

2020

  

December 31,

2019

  

September 30,

2019

  

June 30,

2019

 
Total revenue  $1,732,192   $2,425,745   $2,420,437   $2,923,148   $2,546,983 
Gross profit (loss)   392,758    1,265,028    (88,185)   1,188,262    950,812 
Gross profit margin %   22.7%   52.2%   (3.6)%   40.7%   37.3%
Total selling, general and administrative expenses   2,535,912    3,192,396    3,145,633    3,468,709    (1,616,830)
Operating income (loss)   (2,143,154)   (1,927,368)   (3,233,819)   (2,280,447)   2,567,642 
Operating income (loss) %   (123.7)%   (79.5)%   (133.6)%   (78.0)%   100.8%
Net loss  $(497,894)  $(2,334,110)  $(3,426,984)  $(2,985,825)  $(387,730)

 

Our business is subject to substantial fluctuations on a quarterly basis as reflected in the significant variations in revenues and operating results in the above table. These variations result from various factors, including but not limited to: (1) the timing of large individual orders; (2) the traction gained by newer products, such as the recently released EVO-HD, the ThermoVU™ and the Shield™ line; (3) production, quality and other supply chain issues affecting our cost of goods sold; (4) unusual increases in operating expenses, such as the timing of trade shows and bonus compensation; (5) the timing of patent infringement litigation settlements, such as the $6.0 settlement we obtained from WatchGuard during the second quarter of 2019 and (5) the impact of patent infringement and other litigation including all related obligations and expenses respecting such litigation and (6) most recently, the impact of COVID-19 on the economy and our business.

 

 31 
 

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet debt, nor did we have any transactions, arrangements, obligations (including contingent obligations) or other relationships with any unconsolidated entities or other persons that may have material current or future effect on our financial conditions, changes in the financial conditions, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenue or expenses.

 

For the Three Months Ended June 30, 2020 and 2019

 

Results of Operations

 

Summarized immediately below and discussed in more detail in the subsequent sub-sections is an analysis of our operating results for the three months ended June 30, 2020 and 2019, represented as a percentage of total revenues for each respective year:

 

  

Three months ended

June 30,

 
   2020   2019 
Revenue   100%   100%
Cost of revenue   77%   63%
           
Gross profit   23%   37%
Selling, general and administrative expenses:          
Research and development expense   21%   23%
Selling, advertising and promotional expense   28%   48%
Stock-based compensation expense   22%   23%
General and administrative expense   76%   78%
Patent litigation settlement   %   (236)%
           
Total selling, general and administrative expenses   147%   (64)%
           
Operating income (loss)   (124)%   101%
           
Change in fair value of proceeds investment agreement   149%   (116)%
Change in fair value of secured convertible notes   (51)%   %
Other income and interest expense, net   (3)%   %
           
Loss before income tax benefit   (29)%   (15)%
Income tax (provision)   %   %
           
Net loss   (29)%   (15)%
           
Net loss per share information:          
Basic  $(0.03)  $(0.03)
Diluted  $(0.03)  $(0.03)

 

Revenues

 

We sell our products and services to law enforcement and commercial customers in the following manner:

 

  Sales to domestic customers are made directly to the end customer (typically a law enforcement agency or a commercial customer) through our sales force, comprised of our employees. Revenue is recorded when the product is shipped to the end customer.

 

 32 
 

 

  Sales to international customers are made through independent distributors who purchase products from us at a wholesale price and sell to the end user (typically law enforcement agencies or a commercial customer) at a retail price. The distributor retains the margin as its compensation for its role in the transaction. The distributor generally maintains product inventory, customer receivables and all related risks and rewards of ownership. Revenue is recorded when the product is shipped to the distributor consistent with the terms of the distribution agreement.
     
  Repair parts and services for domestic and international customers are generally handled by our inside customer service employees. Revenue is recognized upon shipment of the repair parts and acceptance of the service or materials by the end customer.

 

We may discount our prices on specific orders based upon the size of the order, the specific customer and the competitive landscape.

 

Revenues for each of the second quarters of 2020 and 2019 were derived from the following sources:

 

   Three months ended June 30, 
   2020   2019 
DVM-800   21%   35%
Repair and service   23%   15%
DVM-250 Plus   6%   9%
FirstVu HD   13%   12%
Cloud service revenue   16%   7%
EVO-HD   9%   3%
VuLink   1%   1%
Accessories and other revenues   11%   18%
           
    100%   100%

 

The COVID-19 pandemic had a negative impact on our revenues in the second quarter 2020 and we expect it to adversely affect our revenues during the remainder of 2020.

 

Product revenues for the three months ended June 30, 2020 and 2019 were $1,053,581 and $1,945,724 respectively, a decrease of $892,143 (46%), due to the following factors:

 

  In general, we have experienced pressure on our revenues as our in-car and body-worn systems are facing increased competition because our competitors have released new products with advanced features. Additionally, our law enforcement revenues declined over the prior period due to price-cutting and competitive actions by our competitors, adverse marketplace effects related to our patent litigation proceedings and supply chain issues. We introduced our EVO-HD late in the second quarter of 2019 with the goal of enhancing our product line features to meet these competitive challenges and we started to see traction in late 2019. We expect customers and potential customers to review and test the EVO-HD prior to committing to this new product platform, all of which has been delayed due to the COVID-19 pandemic.
     
  The COVID-19 pandemic delayed the shipment of orders in the second quarter 2020 as police forces and governments dealt with its impact. In addition, our salesmen were generally unable to meet with and demonstrate our products to our law enforcement and commercial customers because of travel and other restrictions imposed by cities and states due to the COVID-19 pandemic. In person demonstration of our products to potential customers is generally required in order to obtain new customers or upgrade existing customers. Our product sales decreased substantially in the second quarter 2020 compared to 2019 primarily due to the impact of the COVID-19 pandemic.

 

 33 
 

 

 

Management has been focusing on migrating customers, in particular commercial customers, from a “hardware sale” to a service fee model. Therefore, we expect a reduction in commercial hardware sales (principally DVM-250’s and FirstVU’s) as we convert these customers to a service model under which we provide the hardware as part of a recurring monthly service fee. In that respect, we introduced a monthly subscription agreement plan for our body worn cameras and related equipment during the second quarter 2020 that allowed law enforcement agencies to pay a monthly service fee to obtain body worn cameras without incurring a significant upfront capital outlay. This program has gained some traction, resulting in decreased product revenues and increasing our service revenues.

     
  Our international revenues decreased to $6,073 (1% of total product revenues) during the three months ended June 30, 2020, compared to $69,266 (4% of total product revenues) during the three months ended June 30, 2019. The COVID-19 pandemic delayed the shipment of orders in the second quarter 2020 as police forces and governments dealt with its impact. In addition, our salesmen were generally unable to meet with and demonstrate our products to our international law enforcement and commercial customers because of travel and other restrictions imposed by the various countries. In person demonstration of our products to potential customers is generally required in order to obtain new customers or upgrade existing customers. Our international sales decreased substantially in the second quarter 2020 compared to 2019 primarily due to the impact of the COVID-19 pandemic. We believe that would have seen an uptick in our international sales activity in 2020 as a result of the recent award of a contract for our FirstVU HD by a sovereign nation’s national police force which was suspended because of the COVID-19 pandemic. The status of this large international contract is unsettled at present.
     
 

During the second quarter of 2020, the Company launched two product lines in direct response to the increased safety precautions that organizations and individuals are taking due to the COVID-19 pandemic. ThermoVu™ was launched as a non-contact temperature-screening instrument that measures temperature through the wrist and controls entry to facilities when temperature measurements exceed pre-determined parameters. ThermoVu™ has optional features such as facial recognition to improve facility security by restricting access based on temperature and/or facial recognition reasons. ThermoVu™ provides an instant pass/fail audible tone with its temperature display and controls access to facilities based on such results. We believe that it can be widely applied in schools, office buildings, subway stations, airports and other public venues. The Company also launched its Shield™ disinfectant/sanitizer product lines to fulfill demand by current customers and others for a disinfectant and sanitizer that is less harsh than many of the traditional products now widely distributed. The Shield™ Cleanser product line contains a cleanser with no harsh chemicals or fumes.

 

   

The Company began offering the Shield™ line of disinfecting products to its first responder customers including police, fire and paramedics during the second quarter 2020. Commercial customers such as cruise lines, taxi-cab and para transit may also be good candidates for the products. The Company is considering enhancing the line of disinfectant products for additional related products including hardware to efficiently and effectively dispense the disinfectants. The Company is hopeful that its law enforcement and commercial customers will adopt this new product offering to combat the spread of the COVID-19 virus as well as other bacteria and viruses.

 

Service and other revenues for the three months ended June 30, 2020 and 2019 were $678,611 and $601,259, respectively, an increase of $77,352 (13%), due to the following factors:

 

  Cloud revenues were $281,008 and $169,874 for the three months ended June 30, 2020 and 2019, respectively, an increase of $111,134 (65%). We have experienced increased interest in our cloud solutions for law enforcement primarily due to the deployment of our new cloud-based EVO-HD in-car system; however, the fallout from the COVID-19 pandemic and related business shut-downs adversely affected our commercial customers usage of cloud services and offset increases in cloud revenues.

 

 34 
 

 

  Revenues from extended warranty services were $334,705 and $343,119 for the three months ended June 30, 2020 and 2019, respectively, a decrease of $8,414 (3%). We have a number of customers that have purchased extended warranty packages, primarily in our DVM-800 premium service program.
     
  Installation service revenues were $49,776 and $31,791 for the three months ended June 30, 2020 and 2019, respectively, an increase of $17,985 (57%). Installation revenues tend to vary more than other service revenue types and are dependent on larger customer implementations. The decrease in installation revenues in 2020 compared to 2019 was attributable to the COVID-19 pandemic lock-down, which prevented our technicians from completing on-site installations during the 2020 period.
     
  Software revenue, non-warranty repair and other revenues were $13,122 and $56,475 for the three months ended June 30, 2020 and 2019, respectively, a decrease of $43,353 (77%). Software revenues were $10,996 for the three months ended June 30, 2020 compared to $20,011 for the three months ended June 30, 2019 and non-warranty repairs were $8,904 for the three months ended June 30, 2020 compared to $32,833 for the three months ended June 30, 2019. Situational security event fees were $10,800 during the three months ended June 30,2020 compared to $-0- during the three months ended June 30, 2019.

 

Total revenues for the three months ended June 30, 2020 and 2019 were $1,732,192 and $2,546,983, respectively, a decrease of $814,791 (32%), due to the reasons noted above.

 

Cost of Revenue

 

Cost of product revenue on units sold for the three months ended June 30, 2020 and 2019 was $1,165,528 and $1,468,828, respectively, a decrease of $303,300 (21%). The decrease in cost of goods sold for products is primarily due to the 46% decrease in product revenues offset by an increase in the cost of goods sold for products as a percentage of product revenues to 111% for the three months ended June 30, 2020 compared to 75% for the three months ended June 30, 2019. During the second quarter of 2020 the Company moved to new and smaller warehouse facilities and during the move sorted through its entire inventory and disposed of all excess and obsolete inventory rather than moving it to the new location, which contributed to the increase in the cost of goods sold for products as a percentage of product revenues to 111% for the three months ended June 30, 2020. In addition, the move to a new facility coupled with the manufacturing slow down caused by the COVID-19 pandemic caused significant unfavorable overhead and labor variances for production in the second quarter of 2020, which management decided to expense as a period cost rather than apply to finished good and work in process inventory.

 

Cost of service and other revenues for the three months ended June 30, 2020 and 2019 was $173,906 and $127,343, respectively, an increase of $46,563 (37%). The increase in service and other cost of goods sold is primarily due to the 13% increase in service and other revenues coupled with an increase in the cost of service and other revenues sold for products as a percentage of service and other revenues to 26% for the three months ended June 30, 2020 compared to 21% for the three months ended June 30, 2019.

 

Total cost of sales as a percentage of revenues was 77% for the three months ended June 30, 2020 compared to 63% for the three months ended June 30, 2019. We believe our gross margins will improve during the remainder of 2020 if we can increase revenues (in particular service and other revenues) in light of the COVID-19 pandemic and continue to reduce product warranty issues.

 

We had $2,000,412 and $4,144,013 in reserves for obsolete and excess inventories at June 30, 2020 and December 31, 2019, respectively. Total raw materials and component parts were $2,575,710 and $4,481,611 at June 30, 2020 and December 31, 2019, respectively, a decrease of $1,905,901 (43%). During June 2020 the Company moved to a new and smaller warehouse facilities and during the move sorted through its entire inventory and disposed of all excess and obsolete inventory rather than moving it to the new location which contributed to the significant decrease in the cost. We scrapped older version inventory component parts that were mostly or fully reserved during the three months ended June 30, 2020, which was the primary cause for the decrease in total raw materials and component parts. Finished goods balances were $4,146,308 and $4,906,956 at June 30, 2020 and December 31, 2019, respectively, a decrease of $760,648 (16%). The decrease in the inventory reserve is primarily due to the scrapping of older version legacy products that were mostly or fully reserved during the three months ended June 30, 2020 as a result of moving our warehouse and office location. The remaining reserve for inventory obsolescence is generally provided for the level of component parts of the older versions of our printed circuit boards and the phase out of our DVM-750, DVM-500 Plus and LaserAlly legacy products. We believe that the reserves are appropriate given our inventory levels at June 30, 2020.

 

 35 
 

 

Gross Profit

 

Gross profit for the three months ended June 30, 2020 and 2019 was $392,758 and $950,812, respectively, a decrease of $558,054 (59%). The decrease is commensurate with the 32% decrease in total revenues and the gross margin percentage decline to 23% during the three months ended June 30, 2020, from 37% during the three months ended June 30, 2019. Our goal is to improve our margins to 60% over the longer-term based on the expected margins of our EVO-HD, DVM-800, VuLink, FirstVU HD, ThermoVU™, Shield™ disinfectants and our cloud evidence storage and management offering, if they gain traction in the marketplace and subject to a normalizing economy in the wake of the COVID-19 pandemic. In addition, if revenues from these products increase, we will seek to further improve our margins from them through economies of scale and more efficiently utilizing fixed manufacturing overhead components. We plan to continue our initiative to more efficiently manage our supply chain through outsourcing production, quantity purchases and more effective purchasing practices.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses were $2,535,912 and $(1,616,830) for the three months ended June 30, 2020 and 2019, respectively, an increase of $4,152,742 (257%). The significant increase was attributable to the patent litigation settlement of $6.0 million that we received in the second quarter of 2019. Exclusive of the patent litigation settlement, overall selling, general and administrative expenses would have decreased by 42% in the second quarter 2020 compared to the same period in 2019. The significant components of selling, general and administrative expenses are as follows:

 

  

Three months ended

June 30,

 
   2020   2019 
Research and development expense  $359,697   $582,905 
Selling, advertising and promotional expense   486,649    1,237,947 
Stock-based compensation expense   376,738    585,195 
Professional fees and expense   217,726    228,476 
Executive, sales, and administrative staff payroll   510,872    1,090,868 
Other   584,230    657,779 
Patent litigation proceeds       (6,000,000)
           
Total  $2,535,912   $(1,616,830)

 

Research and development expense. We continue to focus on bringing new products to market, including updates and improvements to current products. Our research and development expenses totaled $359,697 and $582,905 for the three months ended June 30, 2020 and 2019, respectively, a decrease of $223,208 (38%). Most of our engineers are dedicated to research and development activities for new products primarily the EVO-HD, which was launched in late second quarter of 2019 and a non-mirror based DVM-250 that can be located in multiple places in a vehicle. We expect our research and development activities will decrease in future quarters as we reduce our engineering headcount to reflect lower activity on our EVO-HD product platform. We consider our research and development capabilities and new product focus to be a competitive advantage and will continue to invest in this area on a prudent basis and consistent with our financial resources.

 

Selling, advertising and promotional expenses. Selling, advertising and promotional expense totaled $486,649 and $1,237,847 for the three months ended June 30, 2020 and 2019, respectively, a decrease of $751,198 (61%). The significant decrease was primarily attributable to our sponsorship of a NASCAR race in May 2019 and other related sponsorship opportunities that did not recur in 2020. Salesman salaries and commissions represent the primary components of these costs and were $374,882 and $727,155 for the three months ended June 30, 2020 and 2019, respectively, a decrease of $352,273 (48%). The effective commission rate was 21.6% for the three months ended June 30, 2020 compared to 28.5% for the three months ended June 30, 2019. We reduced the number of salesmen in our law enforcement and commercial channels beginning in the first quarter of 2020, which had a full effect on the second quarter 2020.

 

 36 
 

 

Promotional and advertising expenses totaled $111,767 during the three months ended June 30, 2020 compared to $510,792 during the three months ended June 30, 2019, a decrease of $399,025 (78%). The decrease is primarily attributable to our sponsorship of the NASCAR race in May 2019, the suspension of the 2020 NASCAR season late in the first quarter 2020 and a reduction in attendance at trade shows as a result of the COVID-19 pandemic.

 

Stock-based compensation expense. Stock based compensation expense totaled $376,738 and $585,195 for the three months ended June 30, 2020 and 2019, respectively, a decrease of $208,457 (36%). The decrease is primarily due to the decreased amortization during the three months ended June 30, 2020 related to the restricted stock granted at a lower market price per share during 2020 and 2019 to our officers, directors, and other employees. We relied more on stock-based compensation during 2020 and 2019 as we reduced cash expenses for liquidity reasons.

 

Professional fees and expense. Professional fees and expenses totaled $217,726 and $228,476 for the three months ended June 30, 2020 and 2019, respectively, a decrease of $10,750 (5%). The decrease in professional fees is primarily attributable to legal fees and expenses related to the Axon lawsuit and the resolution of the WatchGuard and PGA lawsuits. We resolved the PGA lawsuit on April 17, 2019 and the WatchGuard lawsuit was settled on May13, 2019. On June 17, 2019, the U.S. District Court granted Axon’s Motion for Summary Judgment and accepted Axon’s position that it did not infringe on our U.S. Patent No. 9,253,452 and dismissed the lawsuit in its entirety. We appealed the U.S. District Court’s ruling and on April 22, 2020, a three-judge panel of the United States Court of Appeals for the Tenth Circuit denied our appeal and affirmed the U.S. District Court’s previous decision to grant Axon summary judgment. The Company filed a motion requesting a rehearing in front of the Court of Appeals which motion was also denied on June 9, 2020.

 

The Company has until November 7, 2020 to decide whether it will appeal the U.S. District Court’s and Court of Appeals’ decisions to the United States Supreme Court. Our spending on legal fees on the Axon case has slowed during 2020 as we waited for the appeal to be heard. The Company’s decision on whether it will appeal the decisions to the United States Supreme Court will impact the trend of legal expenses for the balance of 2020.

 

Executive, sales and administrative staff payroll. Executive, sales and administrative staff payroll expenses totaled $510,872 and $1,090,868 for the three months ended June 30, 2020 and 2019, respectively, a decrease of $579,996 (53%). The primary reason for the decrease in executive, sales and administrative staff payroll was a reduction in our technical support staffing in response to the COVID-19 pandemic and the Company expects such reductions to continue to reduce related staff expenses during the balance of 2020. The COVID-19 pandemic has significantly impacted the Company’s new event security business channel in the second quarter of 2020 as many sporting venues were closed including those served by these service technicians.

 

Other. Other selling, general and administrative expenses totaled $584,230 and $657,779 for the three months ended June 30, 2020 and 2019, respectively, a decrease of $73,549 (11%). The decrease in other expenses during the three months ended June 30, 2020 compared to the same period in 2019 is primarily attributable to lower contract employee expenses and travel costs resulting from the COVID-19 pandemic.

 

Patent litigation settlement. The income attributable to our patent litigation settlement was $-0- and $6,000,000 for the three months ended June 30, 2020 and 2019, respectively. On May 13, 2019 we reached a resolution of the pending patent infringement litigation with WatchGuard and executed a settlement agreement that resulted in the dismissal of this case. As part of such agreement, we received a one-time $6,000,000 payment and granted WatchGuard a perpetual covenant to not sue WatchGuard if its products incorporate agreed-upon modified recording functionality. Additionally, we granted WatchGuard a license to the ‘292 Patent and ‘452 Patent through December 31, 2023. As part of the settlement, we and WatchGuard agreed that WatchGuard was making no admission that it had infringed any of our patents. See Note 9 — “Commitments and Contingencies” to the Company’s condensed consolidated financial statements, included in Part I, Item 1 of this quarterly report on Form 10-Q (the “June 30, 2020 Financial Statements”), for the details respecting the settlement.

 

 37 
 

 

Operating Loss

 

For the reasons stated above, our operating loss was $2,143,154 and our operating income was $2,567,642 for the three months ended June 30, 2020 and 2019, respectively, a deterioration of $4,710,796 (183%).

 

Interest Income

 

Interest income increased to $15,609 for the three months ended June 30, 2020 from $5,628 in 2019, which reflected our higher cash and cash equivalent levels in the second quarter of 2020 compared to the second quarter of 2019. The Company raised significant amounts of cash through the closing of two underwritten public offerings and the exercise of outstanding common stock purchase warrants during June 2020, which will generate interest income in future quarters.

 

Interest Expense

 

We incurred interest expense of $25,636 and $-0- during the three months ended June 30, 2020 and 2019, respectively.

 

The Company issued an aggregate of $1.667 million principal amount of secured convertible notes on April 17, 2020 which bore interest at 8% per annum on the outstanding principal balance. During the three months ended June 30, 2020, the holders of the secured convertible notes exercised their right to convert principal balances aggregating $1.666 million into equity. In addition, the Company exercised its right to prepay in cash the remaining outstanding principal balance aggregating $1,000. Such secured convertible notes are no longer outstanding as of June 30, 2020 as a result of these conversions and prepayments.

 

The Company issued an unsecured promissory note in an aggregate principal amount of $300,000 payable on December 23, 2019 which bore interest at 8% per annum on the outstanding principal balance which has been repaid in full as of June 30, 2020. In addition, during 2020 we issued an unsecured note payable with a related party in the principal amount of $319,000 which bore interest at 6% per annum, which has been repaid in full as of June 30, 2020.

 

On April 4, 2020, the Company entered into a promissory note providing for a PPP Loan of $1,418,900. The PPP Loan has a two-year term and bears interest at a rate of 1.0% per annum. Monthly principal and interest payments are deferred for six months after the date of disbursement and total $79,850.57 per month thereafter. On May 12, 2020 the Company received $150,000 in additional loan funding under the EIDL program administered by the SBA. Under the terms of the EIDL promissory note, interest accrues on the outstanding principal at the rate of 3.75% per annum. The term of the EIDL promissory note is thirty years and monthly principal and interest payments are deferred for twelve months after the date of disbursement and total $731.00 per month thereafter.

 

Secured Convertible Notes Issuance Expenses

 

We elected to account for and record our $1.667 million principal amount of the 2020 Convertible Notes issued in April 2020 on a fair value basis. Accordingly, we were required to expense the related issuance costs to other expense in the condensed consolidated statements of operations. Such costs totaled $34,906 for the three months ended June 30, 2020. The issuance costs primarily included related legal and accounting fees. No similar debt issuances occurred during the three months ended June 30, 2019.

 

Change in Fair Value of Proceeds Investment Agreement

 

We elected to account for the PIA that we entered into with BKI in July of 2018 on its fair value basis. Therefore, we determined the fair value of the 2018 PIA as of June 30, 2020, and March 31, 2020 to be $3,615,000 and $6,193,000, respectively. The change in fair value from March 31, 2020 to June 30, 2020 was $2,578,000, which was recognized as a gain in the Condensed Consolidated Statement of Operations for the three months ended June 30, 2020. The change in fair value from March 31, 2019 to June 30, 2019 was $(2,961,000), which was recognized as a loss in the Condensed Consolidated Statement of Operations for the three months ended June 30, 2019.

 

 38 
 

 

Change in Fair Value of Secured Convertible Notes

 

We elected to account for the secured convertible notes that were issued on April 17, 2020 on their fair value basis. Therefore, we determined the fair value of the secured convertible notes as of their issuance date of April 17, 2020 and through June 12, 2020, when they were paid in full. The change in fair value from their issuance date of April 17, 2020 to their pay-off date was $887,807, which was recognized as a charge in the Condensed Consolidated Statement of Operations for the three months ended June 30, 2020.

 

Loss before Income Tax Benefit

 

As a result of the above, we reported a loss before income tax benefit of $497,894 and $387,730 for the three months ended June 30, 2020 and 2019, respectively, a deterioration of $110,164 (28%).

 

Income Tax Benefit

 

We did not record an income tax related to our losses for the three months ended June 30, 2020 due to our overall net operating loss carryforwards available. We have further determined to continue providing a full valuation reserve on our net deferred tax assets as of June 30, 2020. We had approximately $66,925,000 of net operating loss carryforwards and $1,795,000 of research and development tax credit carryforwards as determined on December 31, 2019 available to offset future net taxable income.

 

Net Loss

 

As a result of the above, we reported net losses of $497,894 and $387,730 for the three months ended June 30, 2020 and 2019, respectively, a deterioration of $110,164 (28%).

 

Basic and Diluted Loss per Share

 

The basic and diluted loss per share was ($0.03) and ($0.03) for the three months ended June 30, 2020 and 2019, respectively, for the reasons previously noted. All outstanding stock options, warrants and convertible securities were considered antidilutive and therefore excluded from the calculation of diluted loss per share for the three months ended June 30, 2020 and 2019 because of the net loss reported for each of such period.

 

For the Six months ended June 30, 2020 and 2019

 

Results of Operations

 

Summarized immediately below and discussed in more detail in the subsequent sub-sections is an analysis of our operating results for the six months ended June 30, 2020 and 2019, represented as a percentage of total revenues for each respective year:

 

  

Six months ended

June 30,

 
   2020   2019 
Revenue   100%   100%
Cost of revenue   60%   58%
           
Gross profit   40%   42%
Selling, general and administrative expenses:          
Research and development expense   20%   21%
Selling, advertising and promotional expense   28%   39%
Stock-based compensation expense   17%   26%
General and administrative expense   73%   84%
Patent litigation settlement   %   (118)%
           
Total selling, general and administrative expenses   138%   52%
           
Operating income (loss)   (98)%   (10)%
           
Change in fair value of proceeds investment agreement   69%   (60)%
Change in fair value of secured convertible notes   (31)%   %
Other income and interest expense, net   (8)%   %
           
Loss before income tax benefit   (68)%   (70)%
Income tax (provision)   %   %
           
Net loss   (68)%   (70)%
           
Net loss per share information:          
Basic  $(0.17)  $(0.32)
Diluted  $(0.17)  $(0.32)

 

 39 
 

 

Revenues

 

We sell our products and services to law enforcement and commercial customers as noted earlier in this quarterly report on Form 10-Q.

 

We may discount our prices on specific orders based upon the size of the order, the specific customer and the competitive landscape.

 

Revenues for each of the six months ended June 30, 2020 and 2019 were derived from the following sources:

 

   Six months ended June 30, 
   2020   2019 
DVM-800   29%   39%
Repair and service   19%   14%
DVM-250 Plus   5%   8%
FirstVu HD   14%   15%
Cloud service revenue   13%   7%
EVO-HD   8%   1%
VuLink   2%   2%
Accessories and other revenues   10%   14%
           
    100%   100%

 

 40 
 

 

The COVID-19 pandemic had a negative impact on our revenues during the six months ended June 30, 2020 and we expect it to adversely affect our revenues during the remainder of 2020.

  

Product revenues for the six months ended June 30, 2020 and 2019 were $2,820,116 and $3,866,188 respectively, a decrease of $1,046,072 (27%), due to the following factors:

 

  In general, we have experienced pressure on our revenues as our in-car and body-worn systems are facing increased competition because our competitors have released new products with advanced features. Additionally, our law enforcement revenues declined over the prior period due to price-cutting and competitive actions by our competitors, adverse marketplace effects related to our patent litigation proceedings and supply chain issues. We introduced our EVO-HD late in second quarter of 2019 with the goal of enhancing our product line features to meet these competitive challenges and we started to see traction in late 2019. We expect customers and potential customers to review and test the EVO-HD prior to committing to this new product platform, all of which has been delayed due to the COVID-19 pandemic.
     
  Our salesmen were generally unable to meet with and demonstrate our products to our law enforcement and commercial customers because of travel and other restrictions imposed by cities and states due to the COVID-19 pandemic. In person demonstration of our products to potential customers is generally required in order to obtain new customers or upgrade existing customers. Our product sales decreased substantially in the first half of 2020 compared to 2019 primarily due to the impact of the COVID-19 pandemic.
     
  In addition, the COVID-19 pandemic delayed the shipment of orders late in the first quarter of 2020 as police forces and governments dealt with its impact. Specifically, we were unable to ship the initial purchase orders under a substantial contract awarded by  a foreign country for the expected deployment of body cameras to its entire national police force. The contract was expected to include up to 5,000 body cameras with our web-based software infrastructure service over a three-year period. The contract was suspended pending the government’s decision to freeze the planned deployment until such time as the pandemic is contained within its population. The initial purchase order was expected to ship during the first quarter 2020 and we believed that it would have made a substantial impact on our product revenues for such quarter. At this point, we are unable to forecast if and when this major project will be restarted or how it may be modified as a result of the pandemic. Upon completion, the original contract would have been the largest body camera deployment in our history and the largest contract for recurring service revenues for our web-based software related to the Company’s body cameras.
     
  Management has been focusing on migrating customers, in particular commercial customers from a “hardware sale” to a service fee model. Therefore, we expect a reduction in commercial hardware sales (principally DVM-250’s and FirstVU’s) as we convert these customers to a service model under which we provide the hardware as part of a recurring monthly service fee. In that respect, we introduced a monthly subscription agreement plan for our body worn cameras and related equipment during the second quarter 2020 which allowed law enforcement agencies to pay a monthly service fee to obtain body worn cameras without incurring a significant upfront capital outlay. This program has gained some traction which is resulting in decreased product revenues and increasing our service revenues.
     
  Our international revenues decreased to $60,121 (3% of total product revenues) during the six months ended June 30, 2020, compared to $105,720 (4% of total product revenues) during the six months ended June 30, 2019. The COVID-19 pandemic delayed the shipment of orders in the second quarter 2020 as police forces and governments dealt with its impact. In addition, our salesmen were generally unable to meet with and demonstrate our products to our international law enforcement and commercial customers because of travel and other restrictions imposed by the various countries. In person demonstration of our products to potential customers is generally required in order to obtain new customers or upgrade existing customers. Our international sales decreased substantially in the second quarter of 2020 compared to 2019 primarily due to the impact of the COVID-19 pandemic. We believe that we would have seen an uptick in our international sales activity in 2020 as a result of the recent award of a contract for our FirstVU HD by a sovereign nation’s national police force, which was suspended because of the COVID-19 pandemic as noted above.

 

 41 
 

 

 

During the second quarter 2020, the Company launched ThermoVuä and Shieldä Disinfectant/Sanitizer products, two product lines in direct response to the increased safety precautions that organizations and individuals are taking due to the COVID-19 pandemic, as discussed earlier in this quarterly report on Form 10-Q.

 

Service and other revenues for the six months ended June 30, 2020 and 2019 were $1,337,820 and $1,231,591, respectively, an increase of $106,229 (9%), due to the following factors:

 

  Cloud revenues were $508,132 and $349,337 for the six months ended June 30, 2020 and 2019, respectively, an increase of $158,795 (45%). We have experienced increased interest in our cloud solutions for law enforcement primarily due to the deployment of our new cloud-based EVO-HD in-car system; however, the fallout from the COVID-19 pandemic and related business shut-downs adversely affected our commercial customers usage of cloud services and offset increases in cloud revenues.
     
  Revenues from extended warranty services were $668,073 and $670,689 for the six months ended June 30, 2020 and 2019, respectively, a decrease of $2,616 (0%). We have a number of customers that have purchased extended warranty packages, primarily in our DVM-800 premium service program.
     
  Installation service revenues were $86,432 and $82,827 for the six months ended June 30, 2020 and 2019, respectively, an increase of $3,605 (4%). Installation revenues tend to vary more than other service revenue types and are dependent on larger customer implementations. The decrease in installation revenues in 2020 compared to 2019 was attributable to the COVID-19 pandemic lock-down, which prevented our technicians from completing on-site installations during the 2020 period.
     
  Software revenue, non-warranty repair and other revenues were $75,182 and $128,738 for the six months ended June 30, 2020 and 2019, respectively, a decrease of $53,556 (42%). Software revenues were $28,851 during the six months ended June 30, 2020 compared to $58,975 in the 2019 period and non-warranty repairs were $27,489 during the six months ended June 30, 2020 compared to $63,134 in the 2019 period. Situational security event fees were $10,800 during the six months ended June 30, 2020 compared to $-0- in the 2019 period.

 

Total revenues for the six months ended June 30, 2020 and 2019 were $4,157,936 and $5,097,779, respectively, a decrease of $939,843 (18%), due to the reasons noted above.

 

 42 
 

 

Cost of Revenue

 

Cost of product revenue on units sold for the six months ended June 30, 2020 and 2019 was $2,154,774 and $2,731,899, respectively, a decrease of $577,125 (21%). The decrease in cost of goods sold for products is primarily due to the 27% decrease in product revenues coupled with an increase in the cost of goods sold for products as a percentage of product revenues to 76% for the six months ended June 30, 2020 compared to 71% for the six months ended June 30, 2019. During June 2020 the Company moved to new and smaller warehouse facilities and during the move sorted through its entire inventory and disposed of all excess and obsolete inventory rather than moving it to the new location, which contributed to the increase in the cost of goods sold for products as a percentage of product revenues to 76% for the six months ended June 30, 2020. In addition, the move to a new facility coupled with the manufacturing slow down caused by the COVID-19 pandemic caused significant unfavorable overhead and labor variances for production in the first half of 2020, which management decided to expense as a period cost rather than apply to finished good and work in process inventory.

 

Cost of service and other revenues for the six months ended June 30, 2020 and 2019 was $345,374 and $233,328, respectively, an increase of $112,046 (48%). The increase in service and other cost of goods sold is primarily due to the 9% increase in service and other revenues coupled with an increase in the cost of service and other revenues sold for products as a percentage of service and other revenues to 26% for the six months ended June 30, 2020 compared to 19% for the six months ended June 30, 2019.

 

Total cost of sales as a percentage of revenues was 60% for the six months ended June 30, 2020 compared to 58% for the six months ended June 30, 2019. We believe our gross margins will improve during the remainder of 2020 if we can increase revenues (in particular service and other revenues) and continue to reduce product warranty issues.

  

We had $2,000,412 and $4,144,013 in reserves for obsolete and excess inventories at June 30, 2020 and December 31, 2019, respectively. Total raw materials and component parts were $2,575,710 and $4,481,611 at June 30, 2020 and December 31, 2019, respectively, a decrease of $1,905,901 (43%). During the six months ended June 30, 2020 the Company moved to a new and smaller warehouse facilities and during the move sorted through its entire inventory and disposed of all excess and obsolete inventory rather than moving it to the new location which contributed to the significant decrease in the cost. We scrapped older version inventory component parts that were mostly or fully reserved during the six months ended June 30, 2020, which was the primary cause for the decrease in total raw materials and component parts. Finished goods balances were $4,146,308 and $4,906,956 at June 30, 2020 and December 31, 2019, respectively, a decrease of $760,648 (16%). The decrease in the inventory reserve is primarily due to the scrapping of older version legacy products that were mostly or fully reserved during the six months ended June 30, 2020, as a result of moving our warehouse and office location. The remaining reserve for inventory obsolescence is generally provided for the level of component parts of the older versions of our PCB boards and the phase out of our DVM-750, DVM-500 Plus and LaserAlly legacy products. We believe the reserves are appropriate given our inventory levels at June 30, 2020.

 

Gross Profit

 

Gross profit for the six months ended June 30, 2020 and 2019 was $1,657,788 and $2,132,552, respectively, a decrease of $474,764 (22%). The decrease is commensurate with the 18% decrease in total revenues and the gross margin percentage decrease to 40% during the six months ended June 30, 2020, from 42% during the six months ended June 30, 2019. Our goal is to improve our margins to 60% over the longer-term based on the expected margins of our EVO-HD, DVM-800, VuLink and FirstVU HD ThermoVuä products, Shieldä disinfectant/sanitizer products and our cloud evidence storage and management offering, if they gain traction in the marketplace and subject to a normalizing economy in the wake of the COVID-19 pandemic. In addition, if revenues from these products increase, we will seek to further improve our margins from them through economies of scale and more efficiently utilizing fixed manufacturing overhead components. We plan to continue our initiative to more efficiently manage of our supply chain through outsourcing production, quantity purchases and more effective purchasing practices.

 

 43 
 

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses were $5,728,307 and $2,651,068 for the six months ended June 30, 2020 and 2019, respectively, an increase of $3,077,239 (116%). The significant increase was attributable to the patent litigation settlement of $6.0 million that we received in 2019. Exclusive of the patent litigation settlement, overall selling, general and administrative expenses would have decreased by $922,761 (11%) in the first half of 2020 compared to the same period in 2019. The significant components of selling, general and administrative expenses are as follows:

 

  

Six months ended

June 30,

 
   2020   2019 
Research and development expense  $845,445   $1,045,076 
Selling, advertising and promotional expense   1,169,030    1,993,936 
Stock-based compensation expense   688,415    1,310,393 
Professional fees and expense   557,318    1,169,452 
Executive, sales, and administrative staff payroll   1,231,650    1,705,289 
Other   1,236,449    1,426,922 
Patent litigation proceeds       (6,000,000)
           
Total  $5,728,307   $2,651,068 

 

Research and development expense. We continue to focus on bringing new products to market, including updates and improvements to current products. Our research and development expenses totaled $845,445 and $1,045,076 for the six months ended June 30, 2020 and 2019, respectively, a decrease of $199,631 (19%). Most of our engineers are dedicated to research and development activities for new products primarily the EVO-HD, which was launched late in the second quarter of 2019 and a non-mirror based DVM-250 that can be located in multiple places in a vehicle. We expect our research and development activities will decrease in future quarters as we reduce our engineering headcount to reflect lower activity on our EVO-HD product platform. We consider our research and development capabilities and new product focus to be a competitive advantage and will continue to invest in this area on a prudent basis and consistent with our financial resources.

 

Selling, advertising and promotional expenses. Selling, advertising and promotional expense totaled $1,169,030 and $1,993,936 for the six months ended June 30, 2020 and 2019, respectively, a decrease of $824,906 (41%). Salesman salaries and commissions represent the primary components of these costs and were $952,832 and $1,359,129 for the six months ended June 30, 2020 and 2019, respectively, a decrease of $406,297 (30%). The effective commission rate was 22.9% for the six months ended June 30, 2020 compared to 26.7% for the six months ended June 30, 2019. We reduced the number of salesmen in our law enforcement and commercial channels in 2020. We expect continued reductions in salesman commissions and travel for the balance of 2020 while the effects of the COVID-19 pandemic continue.

 

Promotional and advertising expenses totaled $216,198 during the six months ended June 30, 2020 compared to $634,807 during the six months ended June 30, 2019, a decrease of $19,584 (16%). The decrease is primarily attributable to our sponsorship of the 2019 NASCAR race in Kansas City and the suspension of the 2020 NASCAR season in 2020 and a reduction in attendance at trade shows as a result of the COVID-19 pandemic.

 

Stock-based compensation expense. Stock based compensation expense totaled $688,415 and $1,310,393 for the six months ended June 30, 2020 and 2019, respectively, a decrease of $621,978 (47%). The decrease is primarily due to the decreased amortization during the six months ended June 30, 2020 related to the restricted stock granted at a lower market price per share during 2020 and 2019 to our officers, directors, and other employees. We relied more on stock-based compensation during 2020 and 2019 as we attempted to reduce cash expenses for liquidity reasons.

 

 44 
 

 

Professional fees and expense. Professional fees and expenses totaled $557,318 and $1,169,452 for the six months ended June 30, 2020 and 2019, respectively, a decrease of $612,134 (52%). The decrease in professional fees is primarily attributable to legal fees and expenses related to the Axon lawsuit and the resolution of the WatchGuard and PGA lawsuits. We resolved the PGA lawsuit on April 17, 2019 and the WatchGuard lawsuit was settled on May13, 2019. On June 17, 2019, the U.S. District Court granted Axon’s motion for summary judgment and accepted Axon’s position that it did not infringe on our ‘452 Patent and dismissed the lawsuit in its entirety. We appealed the U.S District Court’s ruling and on April 22, 2020, a three-judge panel of the United States Court of Appeals denied our appeal and affirmed the U.S. District Court’s previous decision to grant Axon summary judgment. The Company filed a motion requesting a rehearing in front of the Court of Appeals which was denied on June 9, 2020.

 

The Company has until November 7, 2020 to decide whether it will appeal the U.S. District Court’s and Court of Appeals’ decisions to the United States Supreme Court. Our spending on legal fees on the Axon case has slowed during 2020 as we waited for the appeal to be heard. The Company’s decision on whether it will appeal the decisions to the United States Supreme Court will impact the trend of legal expenses for the balance of 2020.

 

Executive, sales and administrative staff payroll. Executive, sales and administrative staff payroll expenses totaled $1,231,650 and $1,705,289 for the six months ended June 30, 2020 and 2019, respectively, a decrease of $473,639 (28%). The primary reason for the decrease in executive, sales and administrative staff payroll was a reduction in our technical support staffing in response to the COVID-19 pandemic and we expect such reductions to continue to reduce related staff expenses during the balance of 2020. The COVID-19 pandemic has significantly impacted the Company’s new event security business channel in 2020 as many sporting venues were closed including those served by these service technicians.

 

Other. Other selling, general and administrative expenses totaled $1,236,449 and $1,426,922 for the six months ended June 30, 2020 and 2019, respectively, a decrease of $190,473 (13%). The decrease in other expenses during the six months ended June 30, 2020 compared to the 2019 period is primarily attributable to lower contract employee expenses and travel costs, a result of the COVID-19 pandemic.

 

Patent litigation settlement. The income attributable to our patent litigation settlement was $-0- and $6,000,000 for the six months ended June 30, 2020 and 2019, respectively. On May 13, 2019 we reached a resolution of the pending patent infringement litigation with WatchGuard and executed a settlement agreement that resulted in the dismissal of this case. As part of such agreement, we received a one-time $6,000,000 payment and granted WatchGuard a perpetual covenant to not sue WatchGuard if its products incorporate agreed-upon modified recording functionality. Additionally, we granted WatchGuard a license to the ‘292 Patent and ‘452 Patent through December 31, 2023. As part of the settlement, we and WatchGuard agreed that WatchGuard was making no admission that it had infringed any of our patents. See Note 9 -- “Commitments and Contingencies” to the June 30, 2020 Financial Statements, for the details respecting the settlement.

 

Operating Loss

 

For the reasons stated above, our operating loss was $4,070,519 and $518,516 for the six months ended June 30, 2020 and 2019, respectively, a deterioration of $3,552,003 (685%). Operating loss as a percentage of revenues improved to 82% in 2020, from 121% in 2019. 

 

Interest Income

 

Interest income increased to $21,869 for the six months ended June 30, 2020 from $23,612 in the 2019 period, which reflected our lower cash and cash equivalent levels in 2020 compared to first quarter 2019. The Company raised significant amounts of cash through the closing of two underwritten public offerings and the exercise of outstanding common stock purchase warrants during June 2020, which will generate interest income in future quarters.

 

 45 
 

 

Interest Expense

 

We incurred interest expense of $333,196 and $-0- during the six months ended June 30, 2020 and 2019, respectively.

 

The Company issued an aggregate of $1.667 million principal amount of secured convertible notes on April 20, 2020 which bore interest at 8% per annum on the outstanding principal balance. During the six months ended June 30, 2020, the holders of the secured convertible notes exercised their right to convert principal balances aggregating $1.666 million into equity. In addition, the Company exercised its right to prepay in cash the remaining outstanding principal balance aggregating $1,000. Such secured convertible notes are no longer outstanding as of June 30, 2020, as a result of these conversions and prepayments.

 

The Company issued an aggregate of $2.778 million principal amount of secured convertible notes on August 5, 2019 which bore interest at 8% per annum on the outstanding principal balance. During the six months ended June 30, 2020, the holders of the secured convertible notes exercised their right to convert principal balances aggregating $1,259,074 into equity. In addition, the Company paid regular monthly principal payments totaling $172,839 during the six months ended June 30, 2020 and on March 3, 2020, the Company exercised its right to prepay in cash the remaining outstanding principal balance aggregating $574,341. Such secured convertible notes are no longer outstanding as of June 30, 2020, as a result of these conversions and prepayments.

 

The Company issued an unsecured promissory note in an aggregate principal amount of $300,000 on December 23, 2019 which bore interest at 8% per annum on the outstanding principal balance and which has been repaid in full as of June 30, 2020. In addition, during 2020 we issued an unsecured note payable with a related party in the principal amount of $319,000 which bore interest at 6% per annum and which has been repaid in full as of June 30, 2020 and we issued an aggregate of $100,000 principal amount of unsecured promissory note payable which bore interest at 8% per annum on the outstanding principal balance which remained outstanding until it was paid in full as of June 30, 2020.

 

On April 4, 2020, the Company entered into a promissory note providing for a PPP Loan of $1,418,900. The PPP Loan has a two-year term and bears interest at a rate of 1.0% per annum. Monthly principal and interest payments are deferred for six months after the date of disbursement and total $79,850.57 per month thereafter. On May 12, 2020 the Company received $150,000 in additional loan funding under the EIDL program administered by the SBA. Under the terms of the EIDL promissory note, interest accrues on the outstanding principal at the rate of 3.75% per annum. The term of the EIDL promissory note is thirty years and monthly principal and interest payments are deferred for twelve months after the date of disbursement and total $731.00 per month thereafter.

 

Secured Convertible Notes Issuance Expenses

 

We elected to account for and record our $1.667 million principal amount of the 2020 Convertible Notes issued in April 2020 on a fair value basis. Accordingly, we were required to expense the related issuance costs to other expense in the condensed consolidated statements of operations. Such costs totaled $34,906 for the six months ended June 30, 2020. The issuance costs primarily included related legal and accounting fees. No similar debt issuances occurred during the six months ended June 30, 2019.

 

Change in Fair Value of Proceeds Investment Agreement

 

We elected to account for the PIA on its fair value basis. Therefore, we determined the fair value of the 2018 PIA as of June 30, 2020 and December 31, 2020 to be $3,615,000 and $6,500,000, respectively. The change in fair value from December 31, 2020 to June 30, 2020 was $2,885,000, which was recognized as a gain in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2020. The change in fair value from December 31, 2018 to June 30, 2019 was $(3,098,000), which was recognized as a loss in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2019.

 

 46 
 

 

Change in Fair Value of Secured Convertible Notes

 

We elected to account for the secured convertible notes that were issued on April 17, 2020 on their fair value basis. Therefore, we determined the fair value of the secured convertible notes as of their issuance date of April 17, 2020 and through June 12, 2020, when they were paid in full. The change in fair value from their issuance date of April 17, 2020 to their pay-off date was $887,807, which was recognized as a charge in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2020.

 

We elected to account for the secured convertible notes that were issued in August of 2019 on their fair value basis. Therefore, we determined the fair value of the secured convertible notes as of their issuance date on December 31, 2019 until they were paid in full on March 3, 2020. The change in fair value from December 31, 2019 to their pay-off date was $412,445, which was recognized as a charge in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2020.

 

Loss before Income Tax Benefit

 

As a result of the above, we reported a loss before income tax benefit of $2,832,004 and $3,592,904 for the six months ended June 30, 2020 and 2019, respectively, an improvement of $760,900 (21%).

 

Income Tax Benefit

 

We did not record an income tax related to our losses for the six months ended June 30, 2020 due to our overall net operating loss carryforwards available. We have further determined to continue providing a full valuation reserve on our net deferred tax assets as of June 30, 2020. We had approximately $66,925,000 of net operating loss carryforwards and $1,795,000 of research and development tax credit carryforwards as determined on December 31, 2019 available to offset future net taxable income.

 

Net Loss

 

As a result of the above, we reported net losses of $2,832,004 and $3,592,904 for the six months ended June 30, 2020 and 2019, respectively, an improvement of $760,900 (21%).

 

Basic and Diluted Loss per Share

 

The basic and diluted loss per share was ($0.17) and ($0.32) for the six months ended June 30, 2020 and 2019, respectively, for the reasons previously noted. All outstanding stock options, warrants and convertible securities were considered antidilutive and therefore excluded from the calculation of diluted loss per share for the six months ended June 30, 2020 and 2019 because of the net loss reported for such periods.

 

Liquidity and Capital Resources and Going Concern

 

Overall:

 

Management’s Liquidity Plan and Going Concern. The June 30, 2020 Financial Statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred operating losses for the six months ended June 30, 2020 and for the year ended December 31, 2019 primarily due to reduced revenues and gross margins caused by a variety of factors, including the COVID-19 pandemic and its related effects on our customers and our supply chain, and by competitors’ introduction of newer products with more advanced features together with significant price cutting of their products. The Company incurred net losses of approximately $2.8 million during the six months ended June 30, 2020 and $10.0 million for the year ended December 31, 2019 and it had an accumulated deficit of $90.2 million as of June 30, 2020. During 2019, the Company settled one of its patent infringement cases and received a lump sum payment of $6.0 million, which was used to pay its obligations under its Proceeds Investment Agreement, as more fully described in Note 4 – “Proceeds Investment Agreement Obligation” to the June 30, 2020 Financial Statements. In recent years the Company has accessed the public and private capital markets to raise funding through the issuance of debt and equity. In that regard, the Company raised $12.8 million in underwritten public offerings of common stock, $5.2 million through the exercise of common stock purchase warrants and options, $1.6 million through the issuance of promissory notes under the SBA’s PPP and EIDL programs, raised $1.5 million through the issuance of secured convertible notes and $419,000 in unsecured promissory notes and detachable warrants during the six months ended June 30, 2020. In addition, the Company raised $1,564,000 in the year ended December 31, 2019 from the exercise of warrants, borrowed $300,000 pursuant to a short-term promissory note payable on December 23, 2019 with detachable warrants to purchase 107,000 shares of common stock and on August 5, 2019, and raised funds from the issuance of $2.78 million principal balance of secured convertible notes with detachable warrants to purchase 571,248 shares of common stock with the net proceeds used for working capital purposes as more fully described in Note 3—“Debt Obligations” to the June 30, 2020 Financial Statements. These debt and equity raises were utilized to fund the Company’s operations and management expects to continue this pattern until the Company achieves positive cash flows from operations, although it can offer no assurance in this regard.

 

 47 
 

 

On April 4, 2020, the Company issued a promissory note in connection with the receipt of a loan of $1,418,900 (the “PPP Loan”) under the SBA’s PPP under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The PPP Loan has a two-year term and bears interest at a rate of 1% per annum. Monthly principal and interest payments are deferred for six months after the date of disbursement. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Such promissory note contains events of default and other provisions customary for a loan of this type. The PPP provides that the PPP Loan may be partially or wholly forgiven if the funds are used for certain qualifying expenses as described in the CARES Act. The Company intends to use the majority of the PPP Loan amount for qualifying expenses and to apply for forgiveness of the loan in accordance with the terms of the CARES Act. As of June 30, 2020, the Company has used the entirety of the PPP Loan proceeds for purposes consistent with the PPP and has not taken any actions that it believes will reduce the amount eligible for forgiveness. As such, the Company believes that the entire amount of the PPP Loan will be forgiven. However, to the extent any portion of the PPP Loan is determined to be ineligible for forgiveness, we will be required to repay any portion of the outstanding principal that is not forgiven, along with accrued interest, and we cannot provide any assurance that we will be eligible for loan forgiveness or that any amount of the PPP Loan will ultimately be forgiven by the SBA. On April 23, 2020, the SBA issued guidance stating that it is unlikely that a public company with substantial market value and access to capital markets will be able to make the certification required to obtain a PPP loan in good faith. The lack of clarity regarding loan eligibility under the CARES Act PPP has resulted in significant media coverage and controversy with respect to public companies applying for and receiving loans. If, despite our good-faith belief that we satisfied all eligible requirements for the PPP Loan, we are later determined to have violated any of the laws or governmental regulations that apply to us in connection with the PPP Loan, such as the False Claims Act, or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be subject to penalties, including significant civil, criminal and administrative penalties, and could be required to repay the PPP Loan in its entirety. In addition, our receipt of the PPP Loan may result in adverse publicity and damage to our reputation, and a review or audit by the SBA or other government entity or claims under the False Claims Act could consume significant financial and management resources.

 

On July 2, 2020 the SEC declared the Company’s Shelf Registration Statement effective. The Shelf Registration Statement will provide the Company with access to liquidity from the public markets should it decide to utilize it for such purposes. The Shelf Registration Statement allows the Company to offer and sell, from time to time in one or more offerings, any combination of our common stock, debt securities, debt securities convertible into common stock or other securities in any combination thereof, rights to purchase shares of common stock or other securities in any combination thereof, warrants to purchase shares of common stock or other securities in any combination thereof or units consisting of common stock or other securities in any combination thereof having an aggregate initial offering price not exceeding $125,000,000.  

 

The Company will have to restore positive operating cash flows and profitability over the next year and/or raise additional capital to fund its operational plans, meet its customary payment obligations and otherwise execute its business plan. There can be no assurance that it will be successful in restoring positive cash flows and profitability, or that it can raise additional financing when needed, and obtain it on terms acceptable or favorable to the Company.

 

The Company has increased its addressable market to non-law enforcement customers and obtained new non-law enforcement contracts in 2020 and 2019, which contracts include recurring revenue during the period from 2020 to 2023. The Company believes that its quality control and cost cutting initiatives, expansion to non-law enforcement sales channels and new product introduction will eventually restore positive operating cash flows and profitability, although it can offer no assurances in this regard. The extent to which our future operating results are affected by COVID-19 will largely depend on future developments which cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy, our customers’ demand for our products and services, and our ability to provide our products and services, particularly as result of our employees working remotely and/or the closure of certain offices and facilities. While these factors are uncertain, we believe that the COVID-19 pandemic or the perception of its effects will have a material adverse effect on our business, financial condition, results of operations and cash flows.

  

 48 
 

 

Based on the uncertainties described above, the Company believes its business plan does not alleviate the existence of substantial doubt about its ability to continue as a going concern within one year from the date of the issuance of these unaudited condensed consolidated financial statements. The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Cash, cash equivalents: As of June 30, 2020, we had cash and cash equivalents with an aggregate balance of $16,165,550, an increase from a balance of $359,685 at December 31, 2019. Summarized immediately below and discussed in more detail in the subsequent subsections are the main elements of the $15,805,865 net increase in cash during the six months ended June 30, 2020:

 

  Operating activities: $4,057,003 of net cash used in operating activities. Net cash used in operating activities was $4,057,003 the six months ended June 30, 2020 and net cash provided by operations of $1,269,447 for the six months ended June 30, 2019, a deterioration of $5,326,450. The deterioration was attributable to the net loss incurred for 2020 and the usage of cash to decrease accounts payable during the six months ended June 30, 2020 compared to 2019.  
       
  Investing activities: $163,109 of net cash used in investing activities. Cash used in investing activities was $163,109 and $100,589 for the six months ended June 30, 2020 and 2019 respectively. In 2020, we incurred costs for the build out of the new office and warehouse space, for the tooling of new products, an integrated display system and for patent applications on our proprietary technology utilized in our new products and included in intangible assets.
       
  Financing activities: $20,025,977 of net cash provided by financing activities. Cash provided by financing activities was $20,025,977 for the six months ended June 30, 2020 and net cash used in financing activities was $4,436,000 for the six months ended June 30, 2019. We closed several underwritten public offerings of our common stock in 2020 which generated $12.8 million of cash, we received total proceeds of $5.2 million from the exercise of common stock purchase warrants and we received a total of $1.6 million in borrowings under the PPP and EIDL programs administered by the SBA in 2020. In April 2020, we received net proceeds of $1,500,000 from the issuance of the convertible notes with detachable common stock purchase warrants. In addition, we received $419,000 in proceeds from the issuance of unsecured promissory notes payable during the six months ended June 30, 2020. These 2020 financing cash inflows were offset by the repayment of principal on the secured convertible notes and unsecured promissory notes. During 2019 we also received $1,564,000 of proceeds from the exercise of common stock purchase warrants offset by the $6 million payment on the PIA.

 

The net result of these activities was an increase in cash of $15,805,865 for the six months ended June 30, 2020 to $16,165,550 as of June 30, 2020.

  

Commitments:

 

We had $16,165,550 of cash and cash equivalents and net positive working capital $14,777,559 as of June 30, 2020. Accounts receivable balances represented $1,619,234 of our net working capital at June 30, 2020. We intend to collect our outstanding receivables on a timely basis and reduce the overall level during the balance of 2020, which would help to provide cash to support our operations during 2020. Inventory represented $4,752,285 of our net working capital at June 30, 2020 and finished goods represented $4,146,308 of total inventory at June 30, 2020. We are actively managing the level of inventory and our goal is to reduce such level during the balance of 2020 by our sales activities.

 

 49 
 

 

Capital Expenditures. We had no material commitments for capital expenditures at June 30, 2020.

 

Lease commitments.

 

On May 13, 2020, the Company entered into a lease agreement for new warehouse and office space which will serve as the company’s new principal executive office and primary business location. The terms of the lease include no base rent for the first six months and monthly payments ranging from $12,398 to $13,693 thereafter, with a termination date of December 2026. The Company is responsible for property taxes, utilities, insurance and its proportionate share of common area costs related to its new location. The Company took possession of the leased facilities on June 15, 2020. The remaining lease term for the Company’s office and warehouse operating lease as of June 30, 2020 was seventy-eight months. The Company’s previous office and warehouse space lease expired in April 2020 and the Company paid holdover rent for the time period until it moved to and commenced occupying the new space on June 15, 2020.

 

The Company entered into an operating lease with a third party in October 2019 for copiers used for office and warehouse purposes. The terms of the lease include 48 monthly payments of $1,598 with a maturity date of October 2023. The Company has the option to Purchase the equipment at maturity for its estimated fair market value at that point in time. The remaining lease term for the Company’s copier operating lease as of June 30, 2020 was 40 months.

 

Lease expense related to the office space and copier operating leases were recorded on a straight-line basis over their respective lease terms. Total lease expense was $252,290 for the six months ended June 30, 2020.

 

The discount rate implicit within the Company’s operating leases was not generally determinable and therefore the Company determined the discount rate based on its incremental borrowing rate on the information available at commencement date. As of commencement date, the operating lease liabilities reflect a weighted average discount rate of 8%.

  

The following sets forth the operating lease right of use assets and liabilities as of June 30, 2020:

 

Assets:     
Operating lease right of use assets  $769,635 
      
Liabilities:     
Operating lease obligations-Long-term portion  $731,334 
Operating lease obligations-Current portion  $44,308 
Total operating lease obligations  $775,642 

 

The components of lease expense were as follows for the six months ended June 30, 2020:

 

Selling, general and administrative expenses  $252,290 

 

Following are the minimum lease payments for each year and in total.

 

Year ending December 31:    
2020 (July 1, to December 31, 2020)  $21,986 
2021   169,691 
2022   172,666 
2023   172,542 
2024   159,703 
Thereafter   310,259 
Total undiscounted minimum future lease payments   1,006,847 
Imputed interest   (231,205)
Total operating lease liability  $775,642 

 

 50 
 

 

Debt obligations is comprised of the following:

 

   June 30,
2020
   December 31, 2019 
PPP Loan  $1,418,900   $ 
EIDL Loan   150,000     
2019 secured convertible notes, at fair value       1,593,809 
Unsecured promissory notes payable, less unamortized discount of $-0- and $66,061 at June 30, 2020 and December 31, 2019, respectively       233,939 
           
Debt obligations   1,568,900    1,827,748 
Less: current maturities of debt obligations   552,258    1,827,748 
Debt obligations, long-term  $1,016,642   $ 

 

Debt obligations mature as follows as of June 30, 2020:

 

  

June 30,

2020

 
2020 (July 1, 2020 to December 31, 2020)  $68,241 
2021   948,391 
2022   401,321 
2023   3,166 
2024   3,286 
2025 and thereafter   144,495 
      
Total  $1,568,900 

 

The PIA obligation comprises of the following:

 

  

June 30,

2020

   December 31, 2019 
Proceeds investment agreement, at fair value  $3,615,000   $6,500,000 
Less: Current portion   (3,615,000)    
           
Proceeds investment agreement, at fair value - Long-term  $   $6,500,000 

 

On July 20, 2020, the Company and BKI executed a Termination Agreement and Mutual Release. Under the terms of the Termination Agreement the parties agreed to terminate the PIA and to release one another from any further liability under the PIA’s obligation. See Note 4 -- Proceeds Investment Agreement Obligation to the June 30, 2020 Financial Statements.

 

Under the terms of the Agreement, upon payment of $1,250,000 by the Company to BKI both parties agreed to terminate the PIA and to release each other from any further liability thereunder. Such $1,250,000 payment was made on July 22, 2020. In addition to the $1,250,000 payment, the Company further agreed to pay BKI the following: (a) a contingent payment in the amount of $2,750,000 following the closing of an asset purchase, membership interest purchase, or similar transaction between the Company and a specified third-party (the “Purchase Transaction”) and (b) any and all future proceeds received from WatchGuard and its successors and assigns by the Company for WatchGuard’s use of the ‘292 and ‘452 patents. For clarity, the parties further agreed that the payment of the contingent payment would only be due and payable upon the closing of the specified Purchase Transaction and the relevant contingent payment portion of the Agreement, and any obligations stemming therefrom, would automatically terminate if the specified Purchase Transaction is abandoned prior to its closing, including its failure to close within three years from the date of the Agreement. The specified Purchase Transaction has not yet occurred and there is no binding agreement to complete such Purchase Transaction.

 

 51 
 

 

Inflation and Seasonality

 

Inflation has not materially affected us during the past fiscal year. We do not believe that our business is seasonal in nature; however, we usually generate higher revenues during the second half of the calendar year than in the first half.

 

Potential Impacts of the COVID-19 Pandemic on Our Business and Operations

 

The COVID-19 pandemic represents a fluid situation that presents a wide range of potential impacts of varying durations for different global geographies, including locations where we have offices, employees, customers, vendors and other suppliers and business partners.

 

Like most US-based businesses, the COVID-19 pandemic and efforts to mitigate the same began to have impacts on our business in March 2020. By that time, much of our first fiscal quarter was completed. During the quarter ended June 30, 2020, we have observed recent decreases in demand from certain customers, primarily our law-enforcement and commercial customers.

 

Given the fact that our products are sold through a variety of distribution channels, we expect our sales will experience more volatility as a result of the changing and less predictable operational needs of many customers as a result of the COVID-19 pandemic. We are aware that many companies, including many of our suppliers and customers, are reporting or predicting negative impacts from COVID-19 on future operating results. Although we observed significant declines in demand for our products from certain customers during the three months ended June 30, 2020, we believe that it remains too early for us to know the exact impact COVID-19 will have on the long-term demand for our products. We also cannot be certain how demand may shift over time as the impacts of the COVID-19 pandemic may go through several phases of varying severity and duration.

 

In light of broader macro-economic risks and already known impacts on certain industries that use our products and services, we have taken and are taking targeted steps to lower our operating expenses because of the COVID-19 pandemic. We continue to monitor the impacts of COVID-19 on our operations closely and this situation could change based on a significant number of factors that are not entirely within our control and are discussed in this and other sections of this quarterly report on Form 10-Q. We do not expect there to be material changes to our assets on our balance sheet or our ability to timely account for those assets. Further, in connection with the preparation of this quarterly report on Form 10-Q and the interim financial statements contained herein, we reviewed the potential impacts of the COVID-19 pandemic on goodwill and intangible assets and have determined there to be no material impact at this time. We have also reviewed the potential impacts on future risks to the business as it relates to collections, returns and other business-related items.

 

To date, travel restrictions and border closures have not materially impacted our ability to obtain inventory or manufacture or deliver products or services to customers. However, if such restrictions become more severe, they could negatively impact those activities in a way that would harm our business over the long term. Travel restrictions impacting people can restrain our ability to assist our customers and distributors as well as impact our ability to develop new distribution channels, but at present we do not expect these restrictions on personal travel to be material to our business operations or financial results. We have taken steps to restrain and monitor our operating expenses and therefore we do not expect any such impacts to materially change the relationship between costs and revenues.

 

Like most companies, we have taken a range of actions with respect to how we operate to assure we comply with government restrictions and guidelines as well as best practices to protect the health and well-being of our employees and our ability to continue operating our business effectively. To date, we have been able to operate our business effectively using these measures and to maintain all internal controls as documented and posted. We also have not experienced challenges in maintaining business continuity and do not expect to incur material expenditures to do so. However, the impacts of COVID-19 and efforts to mitigate the same have remained unpredictable and it remains possible that challenges may arise in the future.

 

 52 
 

 

The actions we have taken so far during the COVID-19 pandemic include, but are not limited to:

 

  requiring all employees who can work from home to work from home;
     
  increasing our IT networking capability to best assure employees can work effectively outside the office; and
     
  for employees who must perform essential functions in one of our offices:

 

  Having employees maintain a distance of at least six feet from other employees whenever possible;
     
  Having employees work in dedicated shifts to lower the risk all employees who perform similar tasks might become infected by COVID-19;
     
  Having employees stay segregated from other employees in the office with whom they require no interaction; and
     
  Requiring employees to wear masks while they are in the office whenever possible.

 

We currently believe revenue for the three months ended September 30, 2020 may decline year over year due to the conditions noted. In April 2020, we implemented a COVID-19 mitigation plan designed to further reduce our operating expenses for the three months ending June 30, 2020. Actions taken to date include work hour and salary reductions for senior management. These cost reductions are in addition to the significant restructuring actions we initiated in the first quarter of 2020. Based on our current cash position, our projected cash flow from operations and our cost reduction and cost containment efforts to date, we believe that we will have sufficient capital and or have access to sufficient capital through public and private equity and debt offerings to sustain operations for a period of one year following the date of this filing. If business interruptions resulting from COVID-19 were to be prolonged or expanded in scope, our business, financial condition, results of operations and cash flows would be negatively impacted. We will continue to actively monitor this situation and will implement actions necessary to maintain business continuity. 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Not Applicable.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

The Company maintains disclosure controls and procedures, as such terms are defined in Rules 13a-15(e) under the Exchange Act. The Company, under the supervision and with the participation of its management, including its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of such disclosure controls and procedures for this quarterly report on Form 10Q. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2020 to provide reasonable assurance that material information required to be disclosed by the Company in this quarterly report on Form 10Q was recorded, processed, summarized and communicated to the Company’s management as appropriate and within the time periods specified in SEC rules and forms.

 

Changes in Internal Control over Financial Reporting

 

There have not been any changes in the Company’s internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during its last fiscal quarter that have materially affected, or are reasonably likely to materially affect its internal control over financial reporting.

 

 53 
 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The information regarding certain legal proceedings in which we are involved as set forth in Note 9 – Commitments and Contingencies of the Notes to the Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report on Form 10-Q) is incorporated by reference into this Item 1.

 

In addition to such legal proceedings, we are involved in various other claims and legal proceedings arising in the normal course of our businesses. At this time, we do not believe any material losses under such other claims and proceedings to be probable. While the ultimate outcome of such legal proceedings cannot be predicted with certainty, it is in the opinion of management, after consultation with legal counsel, that the final outcome in such proceedings, in the aggregate, would not have a material adverse effect on our consolidated financial condition, results of operations or cash flows.

 

Item 1A. Risk Factors

 

As a smaller reporting company, we are not required to provide the information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

On April 17, 2020, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with two accredited investors (the “Investors”) providing for the issuance of (i) the Company’s 8% Senior Secured Convertible Promissory Notes due April 16, 2021 (the “Notes”) with an aggregate principal face amount of $1,666,666, which Notes are, subject to certain conditions, convertible into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price per share of $1.01 and (ii) five-year warrants (the “Warrants”) to purchase an aggregate of up to 1,237,624 shares of Common Stock (the “Warrant Shares”) at an exercise price of $1.31 per share, subject to customary adjustments (the “Warrants”), which Warrants are immediately exercisable upon issuance and on a cashless basis if the Warrant Shares have not been registered 180 days after the date of issuance. Pursuant to the Purchase Agreement, an aggregate of $500,000 of principal amount of the Notes and the underlying shares of Common Stock issuable upon conversion of such Notes were registered in a registered direct offering. Notes in an additional aggregate principal amount of $1,166,666 and the Warrants were issued to the Investors in a concurrent private placement (the “Private Placement”).

 

The offers and sales of the Notes and Warrant Shares were made pursuant to an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, including pursuant to Rule 506 thereunder. Such offers and sales were made solely to “accredited investors” under Rule 506 and were made without any form of general solicitation and with full access to any information requested by the investor regarding the Company or the securities offered in the Private Placement.

 

Item 3. Defaults upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Not applicable.

 

 54 
 

 

Item 6. Exhibits.

 

(a) Exhibits.

 

  10.101 Paycheck Protection Program Promissory Note and Agreement, dated April 6, 2020, by and between First Citizens Bank and Trust Company and the Company.
     
  10.102 Termination Agreement and Mutual Release, dated July 20, 2020, between the Company and Brickell Key Investments LP.
     
  21.1 Subsidiaries of Registrant
     
  31.1 Certificate of Stanton E. Ross pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as amended.
     
  31.2 Certificate of Thomas J. Heckman pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as amended.
     
  32.1 Certificate of Stanton E. Ross pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended.
     
  32.2 Certificate of Thomas J. Heckman pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended.

 

 55 
 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: August 13, 2020

 

 

DIGITAL ALLY, INC.,

a Nevada corporation

     
    /s/ Stanton E. Ross
  Name: Stanton E. Ross
  Title: President and Chief Executive Officer
     
    /s/ Thomas J. Heckman
  Name: Thomas J. Heckman
  Title: Chief Financial Officer, Secretary, Treasurer and Principal Accounting Officer

 

 56 
 

 

EXHIBIT INDEX

 

Exhibit   Description
     
10.101   Paycheck Protection Program Promissory Note and Agreement, dated April 6, 2020, by and between First Citizens Bank and Trust Company and the Company.
     
10.102   Termination Agreement and Mutual Release, dated July 20, 2020, between the Company and Brickell Key Investments LP.
     
21.1   Subsidiaries of Registrant
     
31.1   Certificate of Stanton E. Ross pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as amended.
     
31.2   Certificate of Thomas J. Heckman pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as amended.
     
32.1   Certificate of Stanton E. Ross pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended.
     
32.2   Certificate of Thomas J. Heckman pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended.

 

 57 

 

EXHIBIT 10.101

 

PAYCHECK PROTECTION PROGRAM LOAN AGREEMENT

 

This Paycheck Protection Program Loan Agreement (this “Agreement”), made and entered into by and between ______ DIGITAL ALLY, INC _____________________________________________________________, a Nevada ___________ entity (collectively, whether one or more, the “Borrower”) and FIRST-CITIZENS BANK & TRUST COMPANY (“Lender”).

 

RECITALS:

 

Borrower has requested that Lender provide financing to Borrower, and Lender is willing to make a loan to Borrower subject to the terms and conditions set forth in this Agreement; NOW, THEREFORE, for good and valuable consideration contained in this Agreement, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legal bound, agree to be bound as follows:

 

ARTICLE I

LOAN AND NOTE

 

1.1 LOAN. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) has authorized the funding of loans under the Paycheck Protection Program which are fully guaranteed by the U.S. Small Business Administration (“SBA”), pursuant to which Lender has agreed to make SBA Loan Number ____34804373-01 _______________________ in the original principal amount of ____ ONE MILLION FOUR HUNDRED EIGHTEEN THOUSAND NINE HUNDRED AND NO/100 ________________________________________________________________ DOLLARS (___$1,418,900.00_____________________) (the “Loan”) to Borrower subject to the terms and conditions

contained in this Agreement.

 

   
 

 

1.2 NOTE. Borrower has executed and delivered to Lender that certain SBA Note (the “Note”), dated of even date herein, which evidences the indebtedness of Borrower to Lender in the original principal amount of _______________________________________________________ DOLLARS (__________________________). Payment of the Note shall be made at Lender’s office at 100 E. TRYON ROAD, DAC 90, ATTN: SBA LOAN OPERATIONS, RALEIGH, NORTH CAROLINA 27603 as set forth in the Note, unless otherwise directed in writing by Lender. The Note shall bear interest at the fixed rate of ONE PERCENT (1.00%) per annum, in accordance with the terms of the Note. The term “Note” as used in this Agreement shall be inclusive of any and all future renewals, extensions, increases, substitutions and other modifications of the Note.

 

1.3 LOAN FORGIVENESS. Pursuant to Section 1106 of the CARES Act, the Loan can be forgiven up to the full principal amount of the Loan and any accrued interest if Borrower (i) uses all proceeds for eligible purposes as set forth in the CARES Act; (ii) maintains employment levels; and (iii) maintains compensation levels. Borrower agrees and acknowledges that SBA will issue further guidance on loan forgiveness under the CARES Act and that Lender has made no representations and warranties regarding the applicability, eligibility or determination of forgiveness of the Loan under the CARES Act. Borrower agrees and understands that if the Loan proceeds are used for any other unauthorized purposes, the federal government may pursue criminal fraud charges against Borrower and all principals of Borrower. Borrower acknowledges that knowingly making a false statement to obtain a guaranteed loan from SBA is punishable under 18 USC 1001 and 3571 by imprisonment of not more than five years and/or a fine of up to $250,000; under 15 USC 645 by imprisonment of not more than two years and/or a fine of not more than $5,000; and, if submitted to a Federally insured institution, under 18 USC 1014 by imprisonment of not more than thirty years and/or a fine of not more than $1,000,000.

 

ARTICLE II

CONDITIONS OF LENDING

 

2.1 CONDITIONS PRECEDENT. The obligation of Lender to make the Loan to Borrower is expressly subject to the performance by Borrower of all of their obligations under this Agreement and to the following further conditions: (i) Borrower shall execute and deliver to Lender this Agreement, the Note, and any and all documents, applications, certifications or other agreements evidencing or otherwise related to the Loan (collectively, the “Loan Documents”) which may be required in the sole and absolute discretion of Lender; (ii) all representations and warranties of Borrower as set forth in this Agreement, the Note and the Loan Documents are true and correct.

 

2.2 USE OF PROCEEDS. Borrower shall only use the proceeds of the Loan for payroll costs, costs related to the continuation of group health care benefits during periods of paid sick, medical, or family leave, insurance premiums, employee salaries, commissions or similar compensations, payments of interest on any mortgage obligation (which shall not include any prepayment of or payment of principal on a mortgage obligation), utilities, rent (including rent under a lease agreement) and interest on any other debt obligations that were incurred prior to February 15, 2020. Borrower shall not use any proceeds of the Loan for (i) personal, family or household purposes; (ii) payments, distributions or loans to Borrower or any associate or principal of Borrower, except for compensation actually rendered at a fair and reasonable rate; (iii) payments of delinquent Internal Revenue Service (“IRS”) withholding/payroll taxes; or (iv) payments towards personal debt.

 

   
 

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF BORROWER

 

Borrower, understanding that Lender is relying upon Borrower’s representations and warranties set forth below in making the Loan, represents and warrants to Lender as follows:

 

3.1 POWER AND AUTHORIZATION. Borrower has duly authorized the execution and delivery of this Agreement, the Note, and the Loan Documents, and the execution and delivery to Lender thereof will not violate any applicable law or agreement to which Borrower is a party to or may be bound or affected by.

 

3.2 BINDING AGREEMENTS. This Agreement, the Note and the Loan Documents constitute legal, valid and binding obligations of Borrower which are enforceable against the Borrower by Lender.

 

3.3 VALID ORGANIZATION AND GOOD STANDING. For any Borrower which is an entity, they are duly organized, validly existing and in good standing under the laws of the State(s) in which they were formed and authorized to conduct business, have the full power and authority to carry on its business operations and are duly licensed or qualified under the laws of each jurisdiction in which they operate.

 

3.4 OWNERSHIP INTERESTS. All ownership interests of Borrower, including, but not limited to, membership interests, stock, options, warrants and any and all other agreements affecting the ownership, control or voting rights of such ownership interests of Borrower are properly and accurately reflected in this Agreement, the Note and the Loan Documents.

 

3.5 FINANCIAL INFORMATION. The payroll reports, disclosures, statements and other financial information (collectively, the “Financial Information”) submitted by Borrower in writing to Lender in connection with the Loan fairly and accurately reflect the payroll and other financial condition of Borrower for the periods defined therein.

 

3.6 ILLEGAL ACTIVITY. Borrower is not engaged in any activity that is illegal under federal, state or local law, including business operations which directly or indirectly support the end use of marijuana, whether medicinal or recreational.

 

3.7 ACCURACY OF REPRESENTATIONS AND WARRANTIES. Any and all representations and warranties by Borrower contained in this Agreement, the Note and the Loan Documents are true and correct. There is no material fact or circumstance that Borrower has knowledge of which has not been disclosed to Lender.

 

ARTICLE IV

COVENANTS OF BORROWER

 

Until all the obligations under the Loan as evidenced by this Agreement, the Note and the Loan Documents have been performed and paid in full, Borrower covenants and agrees as follows:

 

4.1 MAINTENANCE AND EXISTENCE. For any Borrower which is a corporate entity, they shall remain in good standing under the laws of the State(s) in which they were formed and conduct business. Further, Borrower shall comply with all valid and applicable statutes, ordinances, rules and regulations and shall keep in force and effect all licenses, permits, bonds and other agreements or approvals necessary to conduct business.

 

4.2 PATRIOT ACT. Borrower certifies that they are, and will remain, in compliance with the United States of America Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Patriot Act”) and shall continue to provide evidence satisfactory to and sufficient for the Lender to verify the identity of the Borrower, as required under the Patriot Act. Borrower shall notify Lender promptly of any change in such information.

 

   
 

 

4.3 ERRORS AND OMISSIONS. Borrower shall, during and after the closing of the Loan, execute and deliver to Lender any and all documents, reports, financial statements, affidavits, certifications or other agreements to correct, supplement or modify the Loan Documents which may be reasonably requested by Lender. Borrower shall not be obligated to execute and deliver to Lender any documents or agreements which contain any covenant, provision, term or condition which constitutes a material and adverse variance from the Loan Documents.

 

4.4 STRICT COMPLIANCE. Borrower shall (i) perform and comply, in a timely manner, with all terms, conditions, and provisions of this Agreement, the Note and the Loan Documents; and (ii) immediately notify Lender in writing of an Event of Default in connection with this Agreement, the Note and the Loan Documents.

 

ARTICLE V

EVENTS OF DEFAULT

 

5.1 EVENT OF DEFAULT. An event of default (an “Event of Default”) shall be deemed to have occurred hereunder upon any of the following:

 

(a) Nonpayment, when due, of any principal, accrued interest, premium, fee or other charge due under the Note;

(b) Any representation, warranty, or statement made or furnished to Lender by or on behalf of Borrower under this Agreement, the Note and the Loan Documents is false or misleading in any material respect, or becomes false or misleading in any material respect at any time thereafter;

 

(c) The failure or violation of Borrower to keep, perform, observe, or comply with any covenant, agreement, term, or condition required under provisions of this Agreement, the Note or the Loan Documents;

 

(d) The occurrence of any event or condition which constitutes a default under the terms of the Note or the Loan Documents;

 

(e) If this Agreement, the Note or the Loan Documents cease to be in full force and effect;

 

(f) If Borrower revokes or disputes the validity or enforceability of their obligations under this Agreement, the Note or the Loan Documents;

 

(g) If Borrower (i) makes a general assignment for the benefit of its creditors; (ii) files a voluntary petition in bankruptcy; (iii) is adjudicated as bankrupt or insolvent; (iv) files any petition or answer seeking, consenting to, or acquiescing in, reorganization, arrangement, composition, liquidation, dissolution or similar relief, under any present or future statute, law or regulation; (v) files an answer admitting or failing to deny the material allegations of the petition against it for any such relief; or (vii) discontinues business.

 

ARTICLE VI

REMEDIES ON EVENT OF DEFAULT

 

6.1 DECLARE NOTE DUE. Upon the occurrence of an Event of Default as defined in this Agreement, the Note or the Loan Documents, Lender may declare the entire unpaid balance of the Note and all other indebtedness of Borrower to Lender, including but not limited to accrued interest, fees and other costs to be immediately due and payable without presentment, protest or further demand or notice of any kind, all of which are hereby expressly waived. Lender may, in addition to declaring the entire unpaid balance of the Note immediately due and payable, exercise each and every right and remedy granted to Lender under this Agreement, the Note, the Loan Documents and under any other applicable law or at equity. The rights, remedies, powers and privileges provided for in this Agreement shall not be deemed exclusive but shall be cumulative and shall be in addition to all other rights, remedies, powers and privileges in Lender’s favor at law or in equity.

 

   
 

 

6.2 RIGHT OF SETOFF. Following an Event of Default, to the extent permitted by applicable law and under the CARES Act, Lender shall have a right of setoff against any and all of Borrower’s accounts with Lender, including but not limited to any balance of any deposit, trust or agency account, or any other bank account with Lender. Lender may administratively freeze all such accounts to protect its rights under this Agreement.

 

6.3 RELATIONSHIP TO STATE LAW. Notwithstanding any other provision of this Agreement, the Note or the Loan Documents, if any provision of applicable law requires that Borrower be granted a longer notice period or a greater opportunity to cure, that provision of law shall control; provided, however, that the applicable notice period set forth in this Agreement, the Note or the Loan Documents shall run concurrently with the notice period required by law.

 

6.4 NO WAIVER. Neither the failure nor delay on the part of Lender to exercise any right, remedy, power or privilege under this Agreement, the Note or the Loan Documents upon the occurrence of any Event of Default or otherwise shall operate as a waiver thereof or impair any such right, remedy, power or privilege of Lender. No course of dealing between Lender and Borrower shall operate as or be deemed to constitute a waiver of Lender’s rights under this Agreement, the Note or the Loan Documents or affect the duties or obligations of Borrower thereunder.

 

ARTICLE VII

MISCELLANEOUS

 

7.1 INTEGRATED AGREEMENT. This Agreement, together with the Note and Loan Documents, constitute the entire understanding and agreement of the parties as to the matters set forth herein. The Loan Documents shall be construed as integrated and complementary of each other, and as augmenting and not restricting Lender’s rights, powers, and remedies. The Loan Documents supersede all prior statements, agreements and understandings between the parties with respect to the Loan.

 

7.2 AMENDMENTS AND APPROVALS. No amendment of any provision of this Agreement, the Note, or any of the Loan Documents, nor consent by Lender to Borrower for any departure thereof, shall be effective unless the same shall be in writing and signed by Lender and Borrower.

 

7.3 NOTICES. Any and all notices, elections or demands permitted or required to be given under this Agreement, the Note and the Loan Documents shall be in writing, signed by or on behalf of the party giving such notice, election or demand, and shall be deemed to have been properly given and shall be effective upon being personally delivered, or upon being deposited in the United States mail, postage prepaid, certified with return receipt required, and shall be deemed to have been received on the earlier of the date shown on the receipt or three (3) business days after the postmarked date thereof, to the other party at the address of such other party set forth below or such other address within the continental United States as such other party may designate by specifically designating as a notice of change of address and given in accordance herewith. No notice of change of address shall be effective until the date of receipt thereof. Personal delivery to a partner or any officer, partnership, agent or employee of such party at said address shall constitute receipt. Rejection or other refusal to accept or inability to deliver because of changed address of which no notice has been given shall also constitute receipt. Any such notice, election, demand, request or response shall be addressed as follows:

 

If given to Lender:

 

FIRST-CITIZENS BANK & TRUST COMPANY 100 E. TRYON ROAD, DAC 90 ATTN: SBA LOAN OPERATIONS RALEIGH, NORTH CAROLINA 27603

 

If given to Borrower:

 

DIGITAL ALLY, INC. 9705 LOIRET BLVD, LENEXA, KS 66219

____________________________________________________________

____________________________________________________________

____________________________________________________________

____________________________________________________________

 

   
 

 

7.4 GOVERNING LAW AND PARTIES BOUND. This Agreement, the Note and the Loan Documents shall be governed by and construed in accordance with the laws of the State of North Carolina. However, in the event that the enforceability or validity of any provision of this Agreement, the Note or the Loan Documents is challenged or questioned, such provision shall be governed by which whichever applicable state or federal law would uphold or enforce such challenged or questioned provision. Borrower waives any objection which they may have based on lack of personal jurisdiction, improper venue or forum non conveniens.

 

7.5 NO ASSIGNMENT BY BORROWER. No commitment or other agreement issued by Lender to Borrower relating to the Loan nor any of Borrower’s rights under this Agreement, the Note or the Loan Documents shall be assignable by Borrower without the express prior written consent of Lender in its sole and absolute discretion.

 

7.6 SEVERABILITY. In the event that any clause or provisions of this Agreement, the Note or the Loan Documents is held to be invalid, illegal or unenforceable by any court of competent jurisdiction, the invalidity of such clause or provision shall not affect the validity, legality or enforceability any of the remaining portions or provisions of this Agreement, the Note or the Loan Documents. If feasible, the offending provision shall be considered modified so that it becomes legal, valid, and enforceable. If the offending provision cannot be so modified, it shall be considered deleted from this Agreement, the Note or the Loan Documents, as the case may be.

 

7.7 INCONSISTENCY WITH OTHER LOAN DOCUMENTS. In the event of any inconsistency between provisions contained within this Agreement, the Note and the Loan Documents, it is intended that the provisions of this Agreement shall be controlling.

 

7.8 FORCE MAJURE. If Lender is delayed, hindered, or prevented from performing any act required under this Agreement by reason of pandemic, war, governmental restrictions, civil commotion, shortage of labor or materials, strikes, fire, or any other reason beyond the control of Lender, the performance of such act shall be excused for the period of delay.

 

7.9 COUNTERPARTS. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same instrument.

 

   
 

 

7.10 JOINT AND SEVERAL LIABILITY. If there is more than one Borrower, the liability of each Borrower under this Agreement shall be joint and several.

 

7.11 DEFINED TERMS. Capitalized words and terms have the meanings given to them in this Agreement, the Note and the Loan Documents. All references to dollar amounts shall mean amounts in lawful money of the United States of America. Words and terms used in the singular shall include the plural, and words and terms used in the plural shall include the singular, as the context may require.

 

7.12 SURVIVAL. All covenants, agreements, representations and warranties made by Borrower in connection with the Loan shall survive the execution and delivery of this Agreement, the Note and the Loan Documents.

 

7.13 CAIVRS. Lender is required by the Debt Collection Improvement Act of 1996 and by the SBA to comply with the provisions of 31 U.S.C. §3711 and report information relating to the extension of the Loan to consumer or commercial reporting agencies or bureaus, as appropriate (collectively, the “Reporting Agencies”). The Borrower acknowledges this requirement and further, by execution of this Loan Agreement, agree that the Lender may in the future report further information concerning the Loan, including delinquent payments, other Loan defaults, or charge offs to Reporting Agencies. This information may be reflected in reports issued by Reporting Agencies. Further, Borrower acknowledges and agrees that if the small business defaults on the SBA-guaranteed loan and SBA suffers a loss, Lender is required to report any Loan charge offs to the Department of Treasury’s delinquent debtor databases, including without limitation, to the Credit Alert Interactive Voice Response System (“CAIVRS”) and Debt Check, which may affect their eligibility for further financial assistance.

 

7.14 SUCCESSORS AND ASSIGNS. All representations, warranties, covenants, and agreements by or on behalf of Borrower contained in this Agreement, the Note and the Loan Documents shall bind Borrower’s successors and assigns and shall inure to the benefit of Lender and its successors and assigns.

 

7.15 WAIVER BY BORROWER. In connection with any proceeding under this Agreement, the Note and Loan Documents, Borrower waives (i) presentment for payment, demand, notice of demand, notice of non-payment, protest and notice of protest of the Note; and (ii) all rights to claim or recover attorney’s fees and costs in the event that Borrower is successful in any action to remove, suspend or prevent the enforcement of a judgment entered by confession.

 

7.16 INDEMNIFICATION OF LENDER. Borrower agrees to indemnify, defend, and hold Lender and its officers, directors, employees, and agents harmless from and against any and all claims, suits, obligations, damages, losses, costs, expenses (including, without limitation, reasonable attorneys’ fees), demands, liabilities, penalties, fines, and forfeitures of any nature whatsoever and whenever made that may be asserted against or incurred by Lender or its officers, directors, employees, and agents arising out of, relating to, or in any manner occasioned by, (i) this Agreement, the Note and the Loan Documents; (ii) a breach by Borrower of this Agreement, the Note or the Loan Documents; (iii) any dispute as to the applicability, eligibility or determination of forgiveness of the Loan under the CARES Act; or (iv) the exercise of the rights and remedies granted to Lender under this Agreement, the Note or the Loan Documents. The provisions of this Section 7.16 shall survive the payment of the Note and the expiration, cancellation, or termination of this Agreement.

 

7.17 LENDER EXPENSES. Borrower agrees to pay upon demand any and all of Lender’s reasonable costs and expenses, actually incurred, in connection the enforcement of this Agreement, the Note and the Loan Documents, whether or not an action or claim is filed. Such Lender costs and expenses include, but are not limited to, Lender’s reasonable attorneys’ fees and legal expenses incurred in connection with litigation, alternative dispute resolution proceedings, bankruptcy proceedings, appeals, anticipated post-judgment collection services and any fees or costs as may be directed by a court of competent jurisdiction. All such reasonable expenses actually incurred or paid by Lender as set forth herein will become part of the indebtedness secured by the Note and are payable on demand.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

   
 

 

The parties have executed and entered into this Agreement as of _________________.

 

LENDER:

 

FIRST-CITIZENS BANK & TRUST COMPANY

 

BY:  
  JULIE ADOLPHSEN  
TITLE: VICE PRESIDENT  

 

BORROWER:

 

A _______________________ entity

 

BY:  
TITLE:  
     
BY:  
TITLE:  
     
BY:  
TITLE:  

 

   

 

Exhibit 10.102

 

July 20, 2020

VIA EMAIL (stan.ross@digitalallyinc.com)

Digital Ally, Inc.

9705 Loiret Boulevard

Lenexa, Kansas. 66219 Attn: Stanton E. Ross

 

Re: Termination Agreement and Mutual Release (the “Agreement”)

 

Dear Mr. Ross:

 

We are writing in regards to that certain Proceeds Investment Agreement (the “Investment Agreement”) dated July 31, 2018 by and between Digital Ally, Inc. (“DAI”) and Brickell Key Investments LP (“BKI”). All terms not otherwise defined herein shall have their respective meanings in the Investment Agreement.

 

Pursuant to recent discussions between BKI and DIA relating to an infringement action filed by DAI on January 14, 2016 against Axon Enterprise, Inc. (“Axon”) for which a part of the BKI investment under the Investment Agreement was used, the parties have agreed to terminate the Investment Agreement and to release one another from any further liability thereunder.

 

For other good and valuable consideration, the sufficiency of which is acknowledged by the parties, each of BKI and DAI hereby terminates the Investment Agreement and releases one another from any further liability thereunder upon receipt by BKI of a payment by wire transfer from DAI in the amount of $1,250,000, such payment to be received by BKI no later than July 20, 2020. In addition, DAI further agrees to pay to BKI (a) a contingent payment in the amount of $2,750,000 to be paid by wire transfer within ten (10) Business Days following the closing of an asset purchase, membership interest purchase, or similar transaction between DAI and ________ wherein DAI may acquire certain assets of ___________ (the “_____________”) in the future (the “Contingent Payment”) and (b) all proceeds (defined below) received and to be received from Enforcement Video, LLC d/b/a Watchguard Video and its successors and assigns (“Watchguard”) by DAI for Watchguard’s use of U.S. Patent Nos. 8,781,292 and 9,253,452 (the “VuLink Patents”) from and after the date hereof (the “Watchguard Proceeds”). For clarity, DAI and BKI acknowledge that the payment of the Contingent Payment is due and payable only upon the closing of the _______Purchase Agreement, and the Contingent Payment portion of this Agreement, and any obligations stemming therefrom, shall automatically terminate if the _______________Purchase Agreement is abandoned prior to its closing, including its failure to close within three (3) years from the date of this Agreement (the “Contingent Payment Termination Date”); provided that DAI will exercise its best efforts to keep BKI timely informed about the status of negotiations and the closing of the _____________Purchase Agreement.

 

For all purposes herein “Watchguard Proceeds” means any and all gross, pre-tax monetary recoveries from Watchguard’s use of the VuLink Patents (whether through damages, recoveries, royalties, monies, lump-sum payments, upfront payments, settlement amounts, distribution of property, cash value of equities, license fees or other revenues or other assets or amounts) paid by Watchguard or an affiliate of Watchguard to DAI or any of its affiliates, or to an attorney on behalf of DAI, or recovered, received or receivable by DAI or any of its affiliates, or to an attorney on behalf of DAI, plus any interest in connection therewith agreed to in a settlement or awarded in a judgment.

 

For clarity, nothing herein terminates, annuls or redeems that certain Common Stock Purchase Warrant (the “Warrant”) in the common stock of DAI issued to BKI on July 31, 2018, which Warrant remains outstanding and not exercised by BKI, in whole or in part, as of the date hereof.

 

BKI hereby irrevocably and unconditionally releases and absolutely and forever discharges DAI and each of its directors, officers, shareholders, members, successors, assigns, heirs and legal personal representatives (all such persons and entities hereinafter collectively called the “DAI Releasees”) of and from all manner of actions, causes of action, suits, claims, demands, debts, loans, indebtedness, liabilities, accounts, covenants, contracts, damages, amounts, losses, attorneys’ fees, costs and expenses or any nature or kind whatsoever (collectively, “Claims”), which BKI and its partners, directors, officers, members, shareholders, managers, successors, assigns, heirs and legal personal representatives ever had, now has or may in the future have against any of the DAI Releasees for or by reason of any cause, matter or thing relating, directly or indirectly, to the Investment Agreement. Notwithstanding the above, nothing herein releases or waives BKI’s rights and Claims against the DAI Releasees arising from or relating to a breach of this Agreement, failure to pay the Contingent Payment if due, the Warrant and / or payment of the Watchguard Proceeds.

 

 
 

 

DAI hereby irrevocably and unconditionally releases and absolutely and forever discharges BKI and its partners, directors, officers, shareholders, members, managers, successors, assigns, heirs and legal personal representatives (all such persons and entities hereinafter collectively called the “BKI Releasees”) of and from all Claims which DAI and its directors, officers, shareholders, members, successors, assigns, heirs and legal personal representatives ever had, now has or may in the future have against any of the BKI Releasees for or by reason of any cause, matter or thing relating, directly or indirectly, to the Investment Agreement. Notwithstanding the above, nothing herein releases or waives DAI’s rights and Claims against the BKI Releasees arising from or relating to a breach of this Agreement.

 

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH DELAWARE LAW, WITHOUT REGARD TO ITS CONFLICT OF LAWS RULES.

 

Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by confidential arbitration administered by the American Arbitration Association under its Commercial Arbitration Rules. The arbitration hearings shall be held in Miami, Florida, before a single arbitrator and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. For the avoidance of doubt, the parties agree that even claims for emergency equitable relief, such as a temporary restraining order, may be sought only in arbitration pursuant to this paragraph. The arbitrator will have the authority to: (a) compel adequate discovery for the resolution of the dispute, (b) award any and all remedies that either party would be entitled to seek in a court of law, and (c) determine its own jurisdiction by interpreting the scope of this arbitration clause and whether a controversy or claim arises out of or relates to this Agreement. The prevailing party in any arbitration pursuant to this arbitration provision, as determined by the arbitrator, shall be entitled to recover its reasonable attorneys’ fees, expert witness fees, costs, and expenses incurred in connection with the arbitration, in addition to any other relief to which such prevailing party may be entitled. By agreeing to binding arbitration, the parties irrevocably and voluntarily waive any right they may have to a trial by jury in respect of any claim arising out of or relating to this Agreement, or the breach thereof. Furthermore, without intending in any way to limit this agreement to arbitrate, to the extent any claim is not arbitrated, the parties irrevocably and voluntarily waive any right they may have to a trial by jury in respect of such claim.

 

The parties agree that the existence of this Agreement shall be held in strictest confidence unless the parties agree in writing to disclose certain information or as otherwise required by applicable law.

 

 
 

 

Neither party shall assign or delegate its rights or obligations under this Agreement without the prior written consent of the other party; provided, however, that, in connection with an eventual syndication by BKI of its rights to potential proceeds from its portfolio of claims, including the proceeds hereunder, BKI may, without the consent of DAI or any other person, assign or transfer to a third party all or part of its interest in (i) proceeds under this Agreement, and (ii) any other rights, licenses or obligations hereunder. Notwithstanding the above, BKI may assign, in whole or in part and without the consent of DAI or any other person, the rights, benefits and obligations of this Agreement to another pooled investment vehicle managed by Brickell Key Asset Management Limited, a Guernsey limited company, or its Affiliates or their respective successors and assigns.

 

No amendment of any provision of this Agreement shall be effective unless it is in writing and signed by each of the parties. This Agreement embodies the final, entire agreement of the parties hereto and supersedes any and all prior commitments, agreements, representations, and understandings, whether written or oral, relating to the subject matter hereof and shall not be contradicted or varied by evidence of prior, contemporaneous, or subsequent oral agreements or discussions of the parties hereto.

 

Each party agrees to (a) execute and deliver, or cause to be executed and delivered, all such other and further agreements, documents, and instruments and (b) take or cause to be taken all such other and further actions as the other party may reasonably request to effectuate the intent and purposes, and carry out the terms, of this Agreement.

 

If any provision of this Agreement is held invalid, the remainder of this Agreement shall nevertheless remain in full force and effect, and the application of such provision to one party or circumstance shall not render that provision invalid or unenforceable as to the other party or circumstance. If feasible, any such offending provision shall be deemed to be modified to be within the limits of enforceability or validity; provided, however, that if the offending provision cannot be so modified, it shall be stricken and all other provisions of this Agreement in all other respects shall remain valid and enforceable.

 

All notices given pursuant to this Agreement shall be in writing and shall be deemed effective upon: (a) personal delivery to the party to be notified; (b) in the case of e-mail, upon the receiving party of such e-mail acknowledging receipt in writing; or (c) one (1) business day after deposit with a nationally recognized overnight courier for next business day delivery with written verification of receipt. Communications shall be sent to the appropriate addresses as set forth in this Agreement or to such e-mail address or address as subsequently modified by written notice given in accordance with this paragraph.

 

This Agreement may be executed in multiple counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument. Transmission by facsimile, electronic mail or other form of electronic transmission of an executed counterpart of this Agreement shall be deemed to constitute due and sufficient delivery of such counterpart. Each fully executed counterpart of this Agreement shall be deemed to be a duplicate original.

 

Agreeing to be legally bound, the parties have caused this Agreement to be executed below by their duly authorized representatives, effective as of July 16, 2020.

 

Sincerely,

 

BRICKELL KEY INVESTMENTS LP

 

     
Name:    
Title: Director for and on behalf of Brickell Key Partners GP Limited, as General Partner of Brickell Key Investments LP  

 

ACCEPTED AND AGREED:

 

DIGITAL ALLY, INC.

 

By:    
Name: Stanton E. Ross  
Title: Chief Executive Officer  

 

 

 

Exhibit 21.1

 

Subsidiaries of Registrant

 

Subsidiary Legal Name

 

Status

 

State of Organization

 

Type of Organization

  Entity
Organizational ID #
                 
Digital Ally International, Inc.   Subsidiary   Nevada   Corporation   NV20091423731
Shield Products, LLC   Subsidiary   Kansas   Limited Liability Company   9656117

 

 

 

 

EXHIBIT 31.1

 

DIGITAL ALLY, INC.

 

CERTIFICATIONS

 

I, Stanton E. Ross, Chief Executive Officer of Digital Ally, Inc., certify that:

 

  1. I have reviewed this report on Form 10-Q for the six months ended June 30, 2020 of Digital Ally, Inc.
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
    (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
     
    (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: August 13, 2020

 

/s/ Stanton E. Ross  
Stanton E. Ross  
Chief Executive Officer  

 

 

 

EXHIBIT 31.2

 

DIGITAL ALLY, INC.

 

CERTIFICATIONS

 

I, Thomas J. Heckman, Chief Financial Officer of Digital Ally, Inc., certify that:

 

  1. I have reviewed this report on Form 10-Q for the six months ended June 30, 2020 of Digital Ally, Inc.
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
    (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
     
    (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: August 13, 2020

 

/s/ Thomas J. Heckman  
THOMAS J. HECKMAN  
Chief Financial Officer  

 

 

 

EXHIBIT 32.1

 

DIGITAL ALLY, INC.

 

CERTIFICATION PURSUANT TO

19 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Digital Ally, Inc. (the “Company”) on Form 10-Q for the six months ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stanton E. Ross, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Stanton E. Ross  
Stanton E. Ross  
Chief Executive Officer  
August 13, 2020  

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Digital Ally, Inc. and will be retained by Digital Ally, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

EXHIBIT 32.2

 

DIGITAL ALLY, INC.

 

CERTIFICATION PURSUANT TO

19 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Digital Ally, Inc. (the “Company”) on Form 10-Q for the six months ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas J. Heckman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Thomas J. Heckman  
THOMAS J. HECKMAN  
Chief Financial Officer  
August 13, 2020  

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Digital Ally, Inc. and will be retained by Digital Ally, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

v3.20.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2020
Aug. 12, 2020
Cover [Abstract]    
Entity Registrant Name DIGITAL ALLY INC  
Entity Central Index Key 0001342958  
Document Type 10-Q  
Document Period End Date Jun. 30, 2020  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business Flag true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   26,581,600
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2020  
v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 16,165,550 $ 359,685
Accounts receivable-trade, less allowance for doubtful accounts of $123,224 - 2020 and 2019 1,080,884 1,071,018
Accounts receivable-other 538,350 514,730
Inventories, net 4,752,285 5,280,412
Income tax refund receivable, current 44,650 44,650
Prepaid expenses 574,456 381,090
Total current assets 23,156,175 7,651,585
Furniture, fixtures and equipment, net 208,291 197,063
Intangible assets, net 431,006 413,268
Operating lease right of use assets 769,635 122,459
Other assets 452,519 532,500
Total assets 25,017,626 8,916,875
Current liabilities:    
Accounts payable 1,535,865 2,339,985
Accrued expenses 838,747 845,881
Operating lease obligations - Current 44,308 159,160
Contract liabilities - Current 1,756,402 1,707,943
Proceeds investment agreement obligation, at fair value - Current 3,615,000
Debt obligations - Current 552,258 1,827,748
Income taxes payable 1,158 5,934
Total current liabilities 8,343,738 6,886,651
Long-term liabilities:    
Proceeds investment agreement obligation, at fair value - Long-term 6,500,000
Operating lease obligation - Long-term 731,334 44,460
Debt obligations - Long-term 1,016,642
Contract liabilities - Long-term 1,580,085 1,803,143
Total liabilities 11,671,799 15,234,254
Commitments and contingencies
Stockholders' Equity (Deficit):    
Common stock, $0.001 par value per share; 50,000,000 shares authorized; shares issued: 26,645,118 - June 30, 2020 and 12,079,095 - December 31, 2019 26,645 12,079
Additional paid in capital 105,697,031 83,216,387
Treasury stock, at cost (63,518 shares) (2,157,226) (2,157,226)
Accumulated deficit (90,220,623) (87,388,619)
Total stockholders' equity (deficit) 13,345,827 (6,317,379)
Total liabilities and stockholders' equity (deficit) $ 25,017,626 $ 8,916,875
v3.20.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable $ 123,224 $ 123,224
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 26,645,118 12,079,095
Treasury stock, shares 63,518 63,518
v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue:        
Total revenue $ 1,732,192 $ 2,546,983 $ 4,157,936 $ 5,097,779
Cost of revenue:        
Total cost of revenue 1,339,434 1,596,171 2,500,148 2,965,227
Gross profit 392,758 950,812 1,657,788 2,132,552
Selling, general and administrative expenses:        
Research and development expense 359,697 582,905 845,445 1,045,076
Selling, advertising and promotional expense 486,649 1,237,947 1,169,030 1,993,936
Stock-based compensation expense 376,738 585,195 688,415 1,310,393
General and administrative expense 1,312,828 1,977,123 3,025,417 4,301,663
Patent litigation settlement (6,000,000) (6,000,000)
Total selling, general and administrative expenses 2,535,912 (1,616,830) 5,728,307 2,651,068
Operating (loss) income (2,143,154) 2,567,642 (4,070,519) (518,516)
Other income (expense)        
Interest income 15,609 5,628 21,869 23,612
Interest expense (25,636) (333,196)
Secured convertible notes issuance expense (34,906) (34,906)
Change in fair value of proceeds investment agreement 2,578,000 (2,961,000) 2,885,000 (3,098,000)
Change in fair value of secured convertible notes (887,807) (1,300,252)
Total other income (expense) 1,645,260 (2,955,372) 1,238,515 (3,074,388)
Loss before income tax benefit (497,894) (387,730) (2,832,004) (3,592,904)
Income tax benefit
Net loss $ (497,894) $ (387,730) $ (2,832,004) $ (3,592,904)
Net loss per share information:        
Basic $ (0.03) $ (0.03) $ (0.17) $ (0.32)
Diluted $ (0.03) $ (0.03) $ (0.17) $ (0.32)
Weighted average shares outstanding:        
Basic 18,976,724 11,305,248 16,430,214 11,124,222
Diluted 18,976,724 11,305,248 16,430,214 11,124,222
Product [Member]        
Revenue:        
Total revenue $ 1,053,581 $ 1,945,724 $ 2,820,116 $ 3,866,188
Cost of revenue:        
Total cost of revenue 1,165,528 1,468,828 2,154,774 2,731,899
Service and other [Member]        
Revenue:        
Total revenue 678,611 601,259 1,337,820 1,231,591
Cost of revenue:        
Total cost of revenue $ 173,906 $ 127,343 $ 345,374 $ 233,328
v3.20.2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid in Capital [Member]
Treasury Stock [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2018 $ 10,445 $ 78,117,507 $ (2,157,226) $ (77,382,906) $ (1,412,180)
Balance, shares at Dec. 31, 2018 10,445,445        
Stock-based compensation 725,198 725,198
Restricted common stock grant $ 522 (522)
Restricted common stock grant, shares 522,110        
Restricted common stock forfeitures $ (2) 2
Restricted common stock forfeitures, shares (2,500)        
Issuance of common stock upon exercise of common stock purchase warrants $ 161 515,839 516,000
Issuance of common stock upon exercise of common stock purchase warrants, shares 161,000        
Net loss (3,205,174) (3,205,174)
Balance at Mar. 31, 2019 $ 11,126 79,358,024 (2,157,226) (80,588,080) (3,376,156)
Balance, shares at Mar. 31, 2019 11,126,055        
Balance at Dec. 31, 2018 $ 10,445 78,117,507 (2,157,226) (77,382,906) (1,412,180)
Balance, shares at Dec. 31, 2018 10,445,445        
Net loss         (3,592,904)
Balance at Jun. 30, 2019 $ 11,494 80,990,851 (2,157,226) (80,975,810) (2,130,691)
Balance, shares at Jun. 30, 2019 11,494,055        
Balance at Dec. 31, 2018 $ 10,445 78,117,507 (2,157,226) (77,382,906) (1,412,180)
Balance, shares at Dec. 31, 2018 10,445,445        
Net loss         10,000,000
Balance at Dec. 31, 2019 $ 12,079 83,216,387 (2,157,226) (87,388,619) (6,317,379)
Balance, shares at Dec. 31, 2019 12,079,095        
Balance at Mar. 31, 2019 $ 11,126 79,358,024 (2,157,226) (80,588,080) (3,376,156)
Balance, shares at Mar. 31, 2019 11,126,055        
Stock-based compensation 585,195 585,195
Issuance of common stock upon exercise of common stock purchase warrants $ 368 1,047,632 1,048,000
Issuance of common stock upon exercise of common stock purchase warrants, shares 368,000        
Net loss (387,730) (387,730)
Balance at Jun. 30, 2019 $ 11,494 80,990,851 (2,157,226) (80,975,810) (2,130,691)
Balance, shares at Jun. 30, 2019 11,494,055        
Balance at Dec. 31, 2019 $ 12,079 83,216,387 (2,157,226) (87,388,619) (6,317,379)
Balance, shares at Dec. 31, 2019 12,079,095        
Stock-based compensation 311,677 311,677
Restricted common stock grant $ 530 (530)
Restricted common stock grant, shares 530,050        
Restricted common stock forfeitures $ (23) 23
Restricted common stock forfeitures, shares (22,500)        
Issuance of common stock through underwritten public offering at $1.65 per share (net of offering expenses and underwriters' discount) $ 2,522 2,499,614 2,502,136
Issuance of common stock through underwritten public offering at $1.65 per share (net of offering expenses and underwriters' discount), shares 2,521,740        
Issuance of common stock upon conversion of secured convertible notes and interest $ 960 1,342,400 1,343,360
Issuance of common stock upon conversion of secured convertible notes and interest, shares 959,543        
Issuance of common stock purchase warrants in connection with issuance of unsecured promissory note payable 20,806 20,806
Net loss (2,334,110) (2,334,110)
Balance at Mar. 31, 2020 $ 16,068 87,390,377 (2,157,226) (89,722,729) (4,473,510)
Balance, shares at Mar. 31, 2020 16,067,928        
Balance at Dec. 31, 2019 $ 12,079 83,216,387 (2,157,226) (87,388,619) (6,317,379)
Balance, shares at Dec. 31, 2019 12,079,095        
Net loss         (2,832,004)
Balance at Jun. 30, 2020 $ 26,645 105,697,031 (2,157,226) (90,220,623) 13,345,827
Balance, shares at Jun. 30, 2020 26,645,118        
Balance at Mar. 31, 2020 $ 16,068 87,390,377 (2,157,226) (89,722,729) (4,473,510)
Balance, shares at Mar. 31, 2020 16,067,928        
Stock-based compensation 376,738 376,738
Restricted common stock grant $ 135 (135)
Restricted common stock grant, shares 135,450        
Restricted common stock forfeitures $ (13) 13
Restricted common stock forfeitures, shares (12,750)        
Issuance of common stock through underwritten public offering at $1.65 per share (net of offering expenses and underwriters' discount) $ 3,554 5,346,859 5,350,413
Issuance of common stock through underwritten public offering at $1.65 per share (net of offering expenses and underwriters' discount), shares 3,554,545        
Issuance of common stock through underwritten public offering at $2.15 per share (net of offering expenses and underwriters' discount) $ 2,540 4,974,152 4,976,692
Issuance of common stock through underwritten public offering at $2.15 per share (net of offering expenses and underwriters' discount), shares 2,539,534        
Issuance of common stock upon conversion of secured convertible notes and interest $ 1,665 1,679,660 1,681,325
Issuance of common stock upon conversion of secured convertible notes and interest, shares 1,664,669        
Issuance of common stock upon exercise of common stock purchase warrants $ 2,694 5,200,428 5,203,122
Issuance of common stock upon exercise of common stock purchase warrants, shares 2,693,867        
Issuance of common stock upon exercise of stock options $ 2 7,798 7,800
Issuance of common stock upon exercise of stock options, shares 1,875        
Issuance of common stock purchase warrants in connection with issuance of secured convertible notes 721,141 721,141
Net loss (497,894) (497,894)
Balance at Jun. 30, 2020 $ 26,645 $ 105,697,031 $ (2,157,226) $ (90,220,623) $ 13,345,827
Balance, shares at Jun. 30, 2020 26,645,118        
v3.20.2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)
Jun. 30, 2020
$ / shares
Public Offering [Member]  
Common stock issued price per share $ 1.65
Public Offering One [Member]  
Common stock issued price per share $ 2.15
v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Cash Flows From Operating Activities:              
Net loss $ (497,894) $ (2,334,110) $ (387,730) $ (3,205,174) $ (2,832,004) $ (3,592,904) $ 10,000,000
Adjustments to reconcile net loss to net cash flows (used in) provided by operating activities:              
Depreciation and amortization         134,143 206,969  
Stock based compensation 376,738   585,195   688,415 1,310,393  
Provision for inventory obsolescence         238,957 371,494  
Amortization of discount on unsecured promissory notes         86,867  
Change in fair value of secured convertible notes 887,807     1,300,252  
Change in fair value of proceeds investment agreement (2,578,000)   2,961,000   (2,885,000) 3,098,000  
Provision for doubtful accounts receivable         20,000  
Debt issuance costs         34,906  
(Increase) decrease in:              
Accounts receivable - trade         (9,866) 215,840  
Accounts receivable - other         (23,620) (118,556)  
Inventories         289,170 (164,483)  
Prepaid expenses         (193,366) 135  
Operating lease right of use assets         (647,176) 224,413  
Other assets         79,981 (133,000)  
Increase (decrease) in:              
Accounts payable         (804,120) 1,073,021  
Accrued expenses         92,811 (1,018,433)  
Income taxes payable         (4,776) 244  
Operating lease obligations         572,022 (143,252)  
Contract liabilities         (174,599) (80,434)  
Net cash (used in) provided by operating activities         (4,057,003) 1,269,447  
Cash Flows from Investing Activities:              
Purchases of furniture, fixtures and equipment         (96,011) (73,705)  
Additions to intangible assets         (67,098) (26,884)  
Net cash used in investing activities         (163,109) (100,589)  
Cash Flows from Financing Activities:              
Proceeds from unsecured promissory note payable, related party         319,000  
Proceeds from unsecured promissory note payable         100,000  
Proceeds from promissory notes payable         1,568,900  
Proceeds from issuance of common stock upon exercise of warrants         5,203,122 1,564,000  
Proceeds from issuance of secured convertible notes payable         1,500,000  
Proceeds from sale of common stock in underwritten public offering         12,829,241  
Proceeds from exercise of stock options         7,800  
Principal payment on subordinated notes payable         (400,000)  
Principal payment on secured convertible notes         (748,180)  
Principal payments on unsecured promissory note payable, related party         (319,000)  
Debt issuance costs         (34,906)  
Principal payment on proceeds investment agreement         (6,000,000)  
Net cash provided by (used in) financing activities         20,025,977 (4,436,000)  
Net increase (decrease) in cash and cash equivalents         15,805,865 (3,267,142)  
Cash, cash equivalents, beginning of period   $ 359,685   $ 3,598,807 359,685 3,598,807 3,598,807
Cash, cash equivalents, end of period $ 16,165,550   $ 331,655   16,165,550 331,655 $ 359,685
Supplemental disclosures of cash flow information:              
Cash payments for interest         128,911  
Cash payments for income taxes         4,776 5,756  
Supplemental disclosures of non-cash investing and financing activities:              
Restricted common stock grant         664 522  
Restricted common stock forfeitures         36 2  
Cashless exercise of common stock purchase warrants         7  
Impact of Adoption of ASC 842 - obtaining right of use asset for lease liability         500,751  
Issuance of common stock upon conversion of secured convertible notes         3,024,685  
Amounts allocated to common stock purchase warrants in connection with issuance of unsecured promissory note payable         $ 741,947  
v3.20.2
Nature of Business and Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Summary of Significant Accounting Policies

NOTE 1. NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations:

 

Digital Ally, Inc. its wholly-owned subsidiaries, Digital Ally International, Inc. and Shield Products, LLC (collectively, “Digital Ally,” “Digital,” the “Company”) produces digital video imaging, storage products and disinfectant and related safety products for use in law enforcement, security and commercial applications. The Company’s products include in-car digital video/audio recorders contained in a rear-view mirror for use in law enforcement and commercial fleets; a system that provides its law enforcement customers with audio/video surveillance from multiple vantage points and hands-free automatic activation of body-worn cameras and in-car video systems; a miniature digital video system designed to be worn on an individual’s body; and cloud storage solutions. The Company has recently added two new lines of branded products: (1) the ThermoVu™ line, which is a line of self-contained temperature monitoring stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2) the Shield™ disinfectant and cleanser line, which is for use against viruses and bacteria and which we began offering to the Company’s law enforcement and commercials customers beginning late in the second quarter of 2020. Both product lines are manufactured by third parties. In addition, the Company has active research and development programs to adapt its technologies to other applications. It can integrate electronic, radio, computer, mechanical, and multi-media technologies to create unique solutions to address needs in a variety of other industries and markets, including mass transit, school bus, taxicab and the military. The Company sells its products to law enforcement agencies, private security customers and organizations and consumer and commercial fleet operators through direct sales domestically and third-party distributors internationally.

 

The Company was originally incorporated in Nevada on December 13, 2000 as Vegas Petra, Inc. and had no operations until 2004. On November 30, 2004, Vegas Petra, Inc. entered into a Plan of Merger with Digital Ally, Inc., at which time the merged entity was renamed Digital Ally, Inc.

 

Basis of Presentation:

 

The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month period ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

 

The balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements.

 

For further information, refer to the audited financial statements and footnotes included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 and the unaudited financial statements and footnotes included in the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2020.

 

COVID-19 pandemic:

 

The World Health Organization has declared the outbreak of COVID-19, or coronavirus, which began in December 2019, a pandemic and the U.S. federal government has declared it a national emergency. The COVID-19 pandemic had a negative impact on our revenues in the first and second quarters of 2020  and we expect it will adversely affect our business and operations during the remainder of 2020. While its full and continued impact cannot be determined at present, we do expect it will have a material adverse effect on our future business, financial condition, results of operations, and cash flows. The global spread of COVID-19 has already created significant volatility, uncertainty and economic disruption in the markets in which we operate. Governments, public institutions, and other organizations in countries and localities where cases of COVID-19 have been detected are taking certain emergency measures to mitigate its spread, including implementing travel restrictions and closing factories, schools, public buildings, and businesses. We are closely monitoring the spread of COVID-19 and continually assessing its potential effects on our business. In response to the impact that the COVID-19 pandemic and other future pandemics may have on the Company’s customers and legacy products, the Company has recently added two new lines of branded products: (1) the ThermoVu™ which is a line of self-contained temperature monitoring stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2) the Shield™ disinfectant and cleanser line which is for use against viruses and bacteria and which we began offering to the Company’s law enforcement and commercials customers beginning late in the second quarter of 2020.

 

The extent to which our future results are affected by COVID-19 will largely depend on future developments that cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy, our customers’ demand for our products and services, and our ability to provide our products and services, particularly as result of our employees working remotely and/or the closure of certain offices and facilities.

 

Management’s Liquidity Plan and Going Concern:

 

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred operating losses for the six months ended June 30, 2020 and for the year ended December 31, 2019 primarily due to reduced revenues and gross margins caused by a variety of factors, including the COVID-19 pandemic and its related effects on our customers and our supply chain, and by competitors’ introduction of newer products with more advanced features together with significant price cutting of their products. The Company incurred net losses of approximately $2.8 million during the six months ended June 30, 2020 and $10.0 million for the year ended December 31, 2019 and it had an accumulated deficit of $90.2 million as of June 30, 2020. During 2019, the Company settled one of its patent infringement cases and received a lump sum payment of $6.0 million, which was used to pay its obligations under its Proceeds Investment Agreement, as more fully described in Note 4 — “Proceeds Investment Agreement Obligation.”. In recent years the Company has accessed the public and private capital markets to raise funding through the issuance of debt and equity. In that regard, the Company raised $12.8 million in underwritten public offerings of its common stock, raised $5.2 million through the exercise of common stock purchase warrants and options, raised $1.6 million through the issuance of promissory notes through the Small Business Administration’s (“SBA”) Paycheck Protection Program (“PPP”) and the Economic Injury Disaster Loan (“EIDL”) programs, raised $1.5 million through the issuance of secured convertible notes and raised $419,000 in unsecured promissory notes and detachable warrants during the six months ended June 30, 2020. In addition, the Company raised $1,564,000 in the year ended December 31, 2019 from the exercise of warrants, the Company borrowed $300,000 pursuant to a short-term promissory note payable on December 23, 2019 with detachable warrants to purchase 107,000 shares of common stock and on August 5, 2019, it raised funds from the issuance of $2.78 million principal balance of secured convertible notes with detachable warrants to purchase 571,248 shares of common stock with the net proceeds being used for working capital purposes as more fully described in Note 3 – “Debt Obligations”. These debt and equity raises were utilized to fund its operations and management expects to continue this pattern until it achieves positive cash flows from operations, although it can offer no assurance in this regard.

 

The Company will have to restore positive operating cash flows and profitability over the next year and/or raise additional capital to fund its operational plans, meet its customary payment obligations and otherwise execute its business plan. There can be no assurance that it will be successful in restoring positive cash flows and profitability, or that it can raise additional financing when needed, and obtain it on terms acceptable or favorable to the Company.

 

The Company has increased its addressable market to non-law enforcement customers and obtained new non-law enforcement contracts in 2020 and 2019, which contracts include recurring revenue during the period 2020 to 2023. Further, it added two new product lines in response to the Covid-19 pandemic. The Company believes that its quality control and cost cutting initiatives, expansion to non-law enforcement sales channels and new product introductions will eventually restore positive operating cash flows and profitability, although it can offer no assurances in this regard. The extent to which its future operating results are affected by COVID-19 will largely depend on future developments which cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy, our customers’ demand for our products and services, and our ability to provide our products and services, particularly as result of our employees working remotely and/or the closure of certain offices and facilities. While degree of impact of these factors is uncertain, we believe that the COVID-19 pandemic or the perception of its effects will have a material adverse effect on our business, financial condition, results of operations, and cash flows.

 

Based on the uncertainties described above, the Company believes its business plan does not alleviate the existence of substantial doubt about its ability to continue as a going concern within one year from the date of the issuance of these unaudited condensed consolidated financial statements. The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Basis of Consolidation:

 

The accompanying financial statements include the consolidated accounts of Digital Ally and its wholly-owned subsidiaries, Digital Ally International, Inc. and Shield Products, LLC. All intercompany balances and transactions have been eliminated during consolidation.

 

The Company formed Digital Ally International, Inc. during August 2009 to facilitate the export sales of its products. The Company formed Shield Products, LLC in May 2020 to facilitate the sales of its Shield™ line of disinfectant/cleanser products and ThermoVu™ line of temperature monitoring equipment.

 

Revenue Recognition:

 

The Company applies the provisions of Accounting Standards Codification (ASC) 606-10, Revenue from Contracts with Customers, and all related appropriate guidance. The Company recognizes revenue under the core principle to depict the transfer of control to its customers in an amount reflecting the consideration to which it expects to be entitled. In order to achieve that core principle, the Company applies the following five-step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.

 

The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with the customer. In situation where sales are to a distributor, the Company had concluded its contracts are with the distributor as the Company holds a contract bearing enforceable rights and obligations only with the distributor. As part of part of its consideration for the contract, the Company evaluates certain factors including the customers’ ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. As the Company’s standard payment terms are less than one year, it has elected the practical expedient under ASC 606-10-32-18 to not assess whether a contract has a significant financing component. The Company allocates the transaction price to each distinct product based on its relative standalone selling price. The product price as specified on the purchase order is considered the standalone selling price as it is an observable input which depicts the price as if sold to a similar customer in similar circumstances. Revenue is recognized when control of the product is transferred to the customer (i.e. when the Company’s performance obligations is satisfied), which typically occurs at shipment. Further in determining whether control has been transferred, the Company considers if there is a present right to payment and legal title, along with risks and rewards of ownership having transferred to the customer. Customers do not have a right to return the product other than for warranty reasons for which they would only receive repair services or replacement product. The Company has also elected the practical expedient under ASC 340-40-25-4 to expense commissions for product sales when incurred as the amortization period of the commission asset the Company would have otherwise recognized is less than one year.

 

The Company sells its products and services to law enforcement and commercial customers in the following manner:

 

  Sales to domestic customers are made direct to the end customer (typically a law enforcement agency or a commercial customer) through its sales force, which is composed of its employees. Revenue is recorded when the product is shipped to the end customer.
     
  Sales to international customers are made through independent distributors who purchase products from the Company at a wholesale price and sell to the end user (typically law enforcement agencies or a commercial customer) at a retail price. The distributor retains the margin as its compensation for its role in the transaction. The distributor generally maintains product inventory, customer receivables and all related risks and rewards of ownership. Accordingly, upon application of steps one through five above, revenue is recorded when the product is shipped to the distributor consistent with the terms of the distribution agreement.
     
  Repair parts and services for domestic and international customers are generally handled by its inside customer service employees. Revenue is recognized upon shipment of the repair parts and acceptance of the service or materials by the end customer.

 

Sales taxes collected on products sold are excluded from revenues and are reported as accrued expenses in the accompanying balance sheets until payments are remitted.

 

Service and other revenue is comprised of revenues from extended warranties, repair services, cloud revenue and software revenue. Revenue is recognized upon shipment of the product and acceptance of the service or materials by the end customer for repair services. Revenue for extended warranty, cloud service or other software-based products is over the term of the contract warranty or service period. A time-elapsed method is used to measure progress because the Company transfers control evenly over the contractual period. Accordingly, the fixed consideration related to these revenues is generally recognized on a straight-line basis over the contract term, as long as the other revenue recognition criteria have been met.

 

Contracts with some of the Company’s customers contain multiple performance obligations that are distinct and accounted for separately. The transaction price is allocated to the separate performance obligations on a relative standalone selling price (“SSP”). The Company determined SSP for all the performance obligations using observable inputs, such as standalone sales and historical pricing. SSP is consistent with the Company’s overall pricing objectives, taking into consideration the type of service being provided. SSP also reflects the amount the Company would charge for the performance obligation if it were sold separately in a standalone sale. Multiple performance obligations consist of product, software, cloud subscriptions and extended warranties.

 

The Company’s multiple performance obligations may include future in-car or body-worn camera devices to be delivered at defined points within a multi-year contract, and in those arrangements, the Company allocates total arrangement consideration over the life of the multi-year contract to future deliverables using management’s best estimate of selling price.

 

Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract and are reported separately as current liabilities and non-current liabilities in the Condensed Consolidated Balance Sheets. Such amounts consist of extended warranty contracts, prepaid cloud services and prepaid installation services and are generally recognized as the respective performance obligations are satisfied. Total contract liabilities consist of the following: Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract and are reported separately as current liabilities and non-current liabilities in the Condensed Consolidated Balance Sheets. Such amounts consist of extended warranty contracts, prepaid cloud services and prepaid installation services and are generally recognized as the respective performance obligations are satisfied.

 

Accounts Receivable:

 

Accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a weekly basis. The Company determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded when received.

 

A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than thirty (30) days beyond terms. No interest is charged on overdue trade receivables.

 

Segments of Business:

 

Management has determined that its operations comprise one reportable segment: the sale of digital audio and video recording and speed detection devices. For the three and six months ended June 30, 2020 and 2019, sales by geographic area were as follows:

 

    Three Months Ended June 30,     Six Months Ended June 30,  
    2020     2019     2020     2019  
Sales by geographic area:                                
United States of America   $ 1,726,119     $ 2,477,717     $ 4,097,815     $ 4,992,059  
Foreign     6,073       69,266       60,121       105,720  
                                 
Total   $ 1,732,192     $ 2,546,983     $ 4,157,936     $ 5,097,779  

 

Sales to customers outside of the United States are denominated in U.S. dollars. All Company assets are physically located within the United States.

 

Recent Accounting Pronouncements:

 

In February 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-02, Leases (“Topic 842”). The guidance requires lessees to put most leases on their balance sheets but recognize expenses on their income statements in a manner similar to today’s accounting. Lessees initially recognize a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The lease liability is measured at the present value of the lease payments over the lease term. The right-of-use asset is measured at the lease liability amount, adjusted for lease prepayments, lease incentives received and the lessee’s initial direct costs. The standard is effective for public business entities for annual reporting periods beginning after December 15, 2018, and interim periods within that reporting period, which was the first quarter of 2019 for the Company.

 

The Company adopted the new guidance on January 1, 2019 using the optional transitional method and elected to use the package of three practical expedients which allows the Company not to reassess whether contracts are or contain leases, lease classification and whether initial direct costs qualify for capitalization. The Company has completed its assessment of the impact of the standard and determined that the only lease that the Company held was an operating lease for its office and warehouse space. Upon adoption of the standard, the Company recorded Right of Use (ROU) assets of approximately $501,000 and lease liabilities of approximately $582,000 related to it office and warehouse space operating leases. The Company also removed deferred rent of approximately $81,000 when adopting the new guidance.

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission (the “SEC”) to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation will not be required until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

 

In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. Furthermore, an entity is permitted to early adopt any removed or modified disclosures upon issuance of the update and delay adoption of the additional disclosures until their effective date. The Company implemented the revised disclosure requirements upon adoption of ASU 2018-13.

 

In August 2018, the FASB issued ASU No. 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40), or ASU 2018-15. ASU 2018-15 updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes - simplifying the accounting for income taxes (Topic 740), which is meant to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, Income Taxes. The amendment also improves consistent application and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

v3.20.2
Inventories
6 Months Ended
Jun. 30, 2020
Inventory Disclosure [Abstract]  
Inventories

NOTE 2. INVENTORIES

 

Inventories consisted of the following at June 30, 2020 and December 31, 2019:

 

    June 30, 2020     December 31, 2019  
Raw material and component parts   $ 2,575,710     $ 4,481,611  
Work-in-process     30,679       35,858  
Finished goods     4,146,308       4,906,956  
                 
Subtotal     6,752,697       9,424,425  
Reserve for excess and obsolete inventory     (2,000,412 )     (4,144,013 )
                 
Total   $ 4,752,285     $ 5,280,412  

 

Finished goods inventory includes units held by potential customers and sales agents for test and evaluation purposes. The cost of such units totaled $140,158 and $80,711 as of June 30, 2020 and December 31, 2019, respectively.

v3.20.2
Debt Obligations
6 Months Ended
Jun. 30, 2020
Debt Disclosure [Abstract]  
Debt Obligations

NOTE 3. DEBT OBLIGATIONS

 

Debt obligations is comprised of the following:

 

    June 30, 2020     December 31, 2019  
Payroll protection program loan (PPP)   $ 1,418,900     $  
Economic injury disaster loan (EIDL)     150,000        
2019 Secured convertible notes, at fair value           1,593,809  
Unsecured promissory notes payable, less unamortized discount of $-0- and $66,061 at June 30, 2020 and December 31, 2019, respectively           233,939  
                 
Debt obligations     1,568,900       1,827,748  
Less: current maturities of debt obligations     552,258       1,827,748  
Debt obligations, long-term   $ 1,016,642     $  

 

Debt obligations mature as follows as of June 30, 2020:

 

    June 30, 2020  
2020 (July 1, 2020 to December 31, 2020)   $ 68,241  
2021     948,391  
2022     401,321  
2023     3,166  
2024     3,286  
2025 and thereafter     144,495  
         
Total   $ 1,568,900  

 

2020 Small Business Administration Notes.

 

On April 4, 2020, the Company issued a promissory note in connection with the receipt of the PPP Loan of $1,418,900 under the SBA’s PPP Program under the CARES Act. The PPP Loan has a two-year term and bears interest at a rate of 1.0% per annum. Monthly principal and interest payments are deferred for six months after the date of disbursement and total $79,850.57 per month thereafter. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. The promissory note contains events of default and other provisions customary for a loan of this type. The PPP provides that the PPP Loan may be partially or wholly forgiven if the funds are used for certain qualifying expenses as described in the CARES Act. The Company intends to use the majority of the PPP Loan amount for qualifying expenses and to apply for forgiveness of the PPP Loan in accordance with the terms of the CARES Act.

 

On May 12, 2020 the Company received $150,000 in loan funding from the SBA under the EIDL program administered by the SBA, which program was expanded pursuant to the recently enacted CARES Act. The EIDL is evidenced by a promissory note, dated May 8, 2020, in the original principal amount of $150,000 with the SBA, the lender.

 

Under the terms of the note issued under the EIDL program, interest accrues on the outstanding principal at the rate of 3.75% per annum. The term of such note is thirty years, though it may be payable sooner upon an event of default under such note. Monthly principal and interest payments are deferred for twelve months after the date of disbursement and total $731.00 per month thereafter. Such note may be prepaid in part or in full, at any time, without penalty.

  

2019 Secured Convertible Notes.

 

On August 5, 2019, the Company, entered into a securities purchase agreement with several accredited investors providing for the issuance of (i) the Company’s 8% secured convertible notes due August 4, 2020 with a principal face amount of $2,777,777.78, which convertible notes are, subject to certain conditions, convertible into 1,984,126 shares of the Company’s common stock, at a price per share of $1.40 (the “2019 Convertible Notes”); (ii) five-year warrants to purchase an aggregate of 571,428 shares of Common Stock at an exercise price of $1.8125, which warrants are immediately exercisable upon issuance and on a cashless basis if the Warrants have not been registered 180 days after the date of issuance; and (iii) the issuance of shares of common stock equal to 5% of the aggregate purchase price of the convertible notes, with an aggregate value of $125,000 (the “Commitment Shares”). The accredited investors purchased the foregoing securities for an aggregate cash purchase price of $2,500,000.

 

Under the purchase agreement, the convertible notes and warrants contain provisions whereby the accredited investors are prohibited from exercising their rights to convert the notes or exercise the warrants if, as a result of such conversion or exercise, such holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. However, the investors may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to the Company.

 

The Company elected to account for the secured convertible notes on the fair value basis. Therefore, the Company determined the fair value of the (1) secured convertible notes, (2) the Commitment Shares and (3) the common stock purchase warrants which yielded estimated fair values of the secured convertible notes including their embedded derivatives, the Commitment Shares and the detachable common stock purchase warrants. The following represents the resulting fair value as determined on August 5, 2019, the date of origination:

 

Secured convertible notes   $ 1,845,512  
Common stock issued as Commitment Shares     118,749  
Common stock purchase warrants     535,739  
         
Gross cash proceeds   $ 2,500,000  

 

During the six months ended June 30, 2020, the holders of the 2019 Convertible Notes exercised their right to convert principal balances aggregating $1,259,074 into equity. In addition, the Company paid regular monthly principal payments totaling $172,839 during the six months ended June 30, 2020 and on March 3, 2020, the Company exercised its right to prepay in cash the remaining outstanding principal balance aggregating $574,341. There remains no outstanding 2019 Convertible Notes as of June 30, 2020 as a result of these conversions and prepayments.

 

Under the fair value basis, the Company determines the fair value of the secured convertible notes and adjusts the carrying value of the secured convertible notes at each reporting date with the resulting charge or credit being reflected in the condensed consolidated statement of operations. Following is an analysis of the activity in the secured convertible notes during the six months ended June 30, 2020:

 

    Amount  
Balance at December 31, 2019   $ 1,593,809  
Principal repaid during the period by issuance of common stock     (1,259,074 )
Principal repaid during the period by payment of cash     (747,180 )
Change in fair value of secured convertible note during the period     412,445  
         
Balance at June 30, 2020   $  

 

Following is a range of certain estimates and assumptions utilized as of December 31, 2019 to determine the fair value of secured convertible notes:

 

    December 31, 2019  
    Assumptions  
Volatility – range     115 %
Risk-free rate     1.60 %
Contractual term     0.6 years  
Calibrated stock price   $ 1.06  
Debt yield     123.6 %

 

2020 Secured Convertible Notes.

 

On April 17, 2020, the Company entered into a securities purchase agreement with several accredited investors providing for the issuance of (i) the Company’s 8% secured convertible notes due April 16, 2021 with a principal face amount of $1,666,666, which convertible notes are, subject to certain conditions, convertible into 1,650,164 shares of the Company’s common stock, at a price per share of $1.01 (the “2020 Convertible Notes”), and (ii) five-year warrants to purchase an aggregate of 1,237,624 shares of Common Stock at an exercise price of $1.31, which warrants are immediately exercisable upon issuance and on a cashless basis if the Warrants have not been registered 180 days after the date of issuance. The accredited investors purchased the foregoing securities for an aggregate cash purchase price of $1,500,000.

 

Under the purchase agreement, the convertible notes and warrants contain provisions whereby the accredited investors are prohibited from exercising their rights to convert the notes or exercise the warrants if, as a result of such conversion or exercise, such holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. However, the investors may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to the Company.

 

The Company elected to account for the secured convertible notes on the fair value basis. Therefore, the Company determined the fair value of the secured convertible notes and the common stock purchase warrants which yielded estimated fair values of the secured convertible notes including their embedded derivatives and the detachable common stock purchase warrants. The following represents the resulting fair value as determined on April 17, 2020, the date of origination:

 

Secured convertible notes   $ 778,859  
Common stock purchase warrants     721,141  
         
Gross cash proceeds   $ 1,500,000  

 

During the six months ended June 30, 2020, the holders of the 2020 Convertible Notes exercised their right to convert principal balances aggregating $1,665,666 into equity. In addition, on June 12, 2020, the Company exercised its right to prepay in cash the remaining outstanding principal balance aggregating $1,000. There remains no outstanding 2020 Convertible notes as of June 30, 2020 as a result of these conversions and prepayments.

 

Under the fair value basis, the Company determines the fair value of the secured convertible notes and adjusts the carrying value of the secured convertible notes at each reporting date with the resulting charge or credit being reflected in the condensed consolidated statement of operations. Following is an analysis of the activity in the secured convertible notes during the six months ended June 30, 2020:

 

    Amount  
Balance at December 31, 2019   $  
Issuance of 2020 convertible notes at fair value     778,859  
Principal repaid during the period by issuance of common stock     (1,665,666 )
Principal repaid during the period by payment of cash     (1,000 )
Change in fair value of secured convertible note during the period     887,807  
         
Balance at June 30, 2020   $  

 

Following is a range of certain estimates and assumptions utilized as of the April 17, 2020 issuance date to determine the fair value of secured convertible notes:

 

    April 17, 2020  
    Assumptions  
Volatility – range     90 %
Risk-free rate     0.36 %
Contractual term     1.0 years  
Stock price   $ 0.92  
Debt yield     132.2 %

 

Unsecured Promissory Notes Payable.

 

On December 23, 2019, the Company, borrowed $300,000 under an unsecured note payable to a private, third-party lender. The promissory note bore interest at the rate of 8% per annum with principal and accrued interest payable on or before its maturity date of March 31, 2020 (this note was repaid in full on May 6, 2020). The Company granted the lender warrants exercisable to purchase a total of 107,000 shares of its common stock at an exercise price of $1.40 per share until December 23, 2024. The Company allocated $71,869 of the proceeds of the promissory note to additional paid-in-capital, which represented the grant date relative fair value of the warrants issued to the lender. The discount was amortized to interest expense ratably over the term of the promissory note which approximates the effective interest method. The amortization of discount resulted in $66,061 of the discount amortized to interest expense during the six months ended June 30, 2020.

 

On January 17, 2020, the Company, borrowed $100,000 under an unsecured note payable to a private, third-party lender. The promissory note bore interest at the rate of 8% per annum with principal and accrued interest payable on or before its maturity date of April 17, 2020. The Company granted the lender warrants exercisable to purchase a total of 35,750 shares of its common stock at an exercise price of $1.40 per share until January 17, 2025. The Company allocated $20,806 of the proceeds of the promissory note to additional paid-in-capital, which represented the grant date relative fair value of the warrants issued to the lender. The note was repaid in full on March 12, 2020 and the discount was amortized to interest expense through the date of payment. The amortization of discount resulted in $20,806 of the discount amortized to interest expense during the six months ended June 30, 2020.

 

Unsecured Promissory Notes Payable – Related party

 

During February and April 2020, the Company borrowed a total of $319,000 from the Company’s Chairman, CEO & President under an unsecured promissory note bearing interest at 6% through its May 28, 2020 maturity date. The proceeds from the note were used for general corporate purposes. The principal balance and related accrued interest was paid in full during the six months ended June 30, 2020. Total interest accrued and paid on this note was $5,236.

v3.20.2
Proceeds Investment Agreement Obligation
6 Months Ended
Jun. 30, 2020
Proceeds Investment Agreement Obligation  
Proceeds Investment Agreement Obligation

NOTE 4. PROCEEDS INVESTMENT AGREEMENT OBLIGATION

 

The proceeds investment agreement obligations is comprised of the following:

 

    June 30, 2020     December 31, 2019  
Proceeds investment agreement, at fair value   $ 3,615,000     $ 6,500,000  
Less: Current portion     (3,615,000 )      
                 
Proceeds investment agreement, at fair value - Long-term   $     $ 6,500,000  

 

On July 31, 2018, the Company entered into a Proceeds Investment Agreement (the “PIA”) with Brickell Key Investments LP (“BKI”), pursuant to which BKI funded an aggregate of $500,000 (the “First Tranche”) to be used (i) to fund the Company’s litigation proceedings relating to the infringement of certain patent assets listed in the PIA and (ii) to repay the Company’s existing debt obligations and for certain working capital purposes set forth in the PIA. Pursuant to the PIA, BKI was granted an option to provide the Company with an additional $9.5 million, at BKI’s sole discretion (the “Second Tranche”). On August 21, 2018, BKI exercised its option on the Second Tranche for $9.5 million which completed the $10.0 million funding.

 

Pursuant to the PIA and in consideration for the $10.0 million in funding, the Company agreed to assign to BKI (i) 100% of all gross, pre-tax monetary recoveries paid by any defendant(s) to the Company or its affiliates agreed to in a settlement or awarded in judgment in connection with the patent assets, plus any interest paid in connection therewith by such defendant(s) (the “Patent Assets Proceeds”), up to the minimum return (as defined in the PIA) and (ii) if BKI has not received its minimum return by the earlier of a liquidity event (as defined in the PIA) and July 31, 2020, then the Company agreed to assign to BKI 100% of the Patent Asset Proceeds until BKI has received an amount equal to the minimum return on $4.0 million.

 

Pursuant to the PIA, the Company granted BKI (i) a senior security interest in the Patent Assets, the claims (as defined in the PIA) and the Patent Assets Proceeds until such time as the minimum return is paid, in which case, the security interest on the patent assets, the claims and the Patent Assets Proceeds will be released, and (ii) a senior security interest in all other assets of the Company until such time as the minimum return is paid on $4.0 million, in which case, the security interest on such other assets will be released.

 

The security interest is enforceable by BKI if the Company is in default under the PIA which would occur if (i) the Company fails, after five (5) days’ written notice, to pay any due amount payable to BKI under the PIA, (ii) the Company fails to comply with any provision of the PIA or any other agreement or document contemplated under the PIA Agreement, (iii) the Company becomes insolvent or insolvency proceedings are commenced (and not subsequently discharged) with respect to the Company, (iv) the Company’s creditors commence actions against the Company (which are not subsequently discharged) that affect material assets of the Company, (v) the Company, without BKI’s consent, incurs indebtedness other than immaterial ordinary course indebtedness up to $500,000, (vi) the Company fails, within five (5) business days following the closing of the second tranche, to fully satisfy its obligations to certain holders of the Company’s senior secured convertible promissory notes listed in the PIA and fails to obtain unconditional releases from such holders as to the Company’s obligations to such holders and the security interests in the Company held by such holders or (vii) there is an uncured non-compliance of the Company’s obligations or misrepresentations by the Company under the PIA.

 

Under the PIA, the Company issued BKI a warrant to purchase up to 465,712 shares of the Company’s common stock (the “PIA Warrant”), at an exercise price of $2.60 per share provided that the holder of the PIA Warrant will be prohibited from exercising the PIA Warrant if, as a result of such exercise, such holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. However, such holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to the Company. The PIA Warrant is exercisable for five years from the date of issuance and is exercisable on a cashless exercise basis if there is no effective registration statement. No contractual registration rights were given.

 

The Company elected to account for the PIA on the fair value basis. Therefore, the Company determined the fair value of the PIA and PIA Warrants which yielded estimated fair values of the PIA including their embedded derivatives and the detachable PIA Warrants as follows:

 

Proceeds investment agreement   $ 9,067,513  
Common stock purchase warrants     932,487  
         
Gross cash proceeds   $ 10,000,000  

 

The Company utilized a probability weighted present value of expected patent asset proceeds for the litigation involving both Axon Enterprises, Inc. (“Axon,” formerly known as Taser International, Inc.) and WatchGuard (see Note 9 – “Commitments and Contingencies”) which involved estimates of the amount and timing of the expected patent asset proceeds from the alleged patent infringement. The fair value of the PIA is updated for actual and estimated activity affecting the probability weighted present value of expected patent asset proceeds at each reporting date with the change charged/credited to operations. Following is a range of certain estimates and assumptions utilized as of June 30, 2020 and December 31, 2019 to probability weighted present value of expected patent asset proceeds for the litigation involving both Axon and WatchGuard:

 

    June 30, 2020     December 31, 2019  
Discount rate     15.13% -15.18%       3.0% -16.6%  
Expected term to patent asset proceeds payment     0.33 years – 3.75 .06 - .29 years       0.58 years - 4 years  
Probability of success     90.0 %     5.9% -38.5%  
Estimated minimum return payable to BKI     $ 4 million       $ 21 million  
Negotiation discount     0.0 %     43.3 %

 

In May 2019, the Company settled its patent infringement litigation with WatchGuard whereby it received a lump-sum payment of $6.0 million as further described in Note 9 – “Commitments and Contingencies”. In accordance with the terms of the PIA, the Company remitted the $6.0 as a principal payment toward its minimum return payment obligations under the PIA.

 

The following represents activity in the PIA during the six months ended June 30, 2020:

 

Beginning balance as of December 31, 2019   $ 6,500,000  
Repayment of obligation      
Change in the fair value during the period     (2,885,000 )
Ending balance as of June 30, 2020   $ 3,615,000  

 

Based on the recent unfavorable decisions by the United States Court of Appeals for the Tenth Circuit (see Note 9 – “Commitments and Contingencies”) the estimated future payments to BKI pursuant to the PIA has been reduced substantially resulting in the significant change in fair value (income) during the six months ended June 30, 2020. Subsequent to June 30, 2020 the Company also entered into a settlement agreement with BKI which may further reduce its obligations under the PIA. (See Note 14 – “Subsequent Events”).

v3.20.2
Fair Value Measurement
6 Months Ended
Jun. 30, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurement

NOTE 5. FAIR VALUE MEASUREMENT

 

In accordance with ASC Topic 820 — Fair Value Measurements and Disclosures (“ASC 820”), the Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets, liabilities or a group of assets or liabilities, such as a business.

 

ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1 — Quoted prices in active markets for identical assets and liabilities
   
Level 2 — Other significant observable inputs (including quoted prices in active markets for similar assets or liabilities)
   
Level 3 — Significant unobservable inputs (including the Company’s own assumptions in determining the fair value)

 

The following table represents the Company’s hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2020 and December 31, 2019:

 

    June 30, 2020  
    Level 1     Level 2     Level 3     Total  
Liabilities:                                
Secured convertible notes   $     $     $     $  
Proceeds investment agreement obligation                 3,615,000       3,615,000  
    $     $     $ 3,615,000     $ 3,615,000  

 

    December 31, 2019  
    Level 1     Level 2     Level 3     Total  
Liabilities:                                
Secured convertible notes   $     $     $ 1,593,809     $ 1,593,809  
Proceeds investment agreement obligation                 6,500,000       6,500,000  
    $     $     $ 8,093,809     $ 8,093,809  

 

The following table represents the change in Level 3 tier value measurements:

 

    2019     2020              
    Secured     Secured     Proceeds        
    Convertible     Convertible     Investment        
    Notes     Notes     Agreement     Total  
                         
Balance, December 31, 2019   $ 1,593,809     $     $ 6,500,000     $ 8,093,809  
                                 
Issuance of secured convertible debt           778,859             778,859  
                                 
Conversion of secured convertible debentures     (1,259,074 )     (1,665,666 )           (2,924,740 )
                                 
Repayment of secured convertible notes     (747,180 )     (1,000 )           (748,180 )
Change in fair value of secured convertible debentures and proceeds investment agreement     412,445       887,807       (2,885,000 )     (1,548,748 )
                                 
Balance, June 30, 2020   $     $     $ 3,615,000     $ 3,615,000  
v3.20.2
Accrued Expenses
6 Months Ended
Jun. 30, 2020
Payables and Accruals [Abstract]  
Accrued Expenses

NOTE 6. ACCRUED EXPENSES

 

Accrued expenses comprised of the following at June 30, 2020 and December 31, 2019:

 

    June 30, 2020     December 31, 2019  
Accrued warranty expense   $ 30,711     $ 17,838  
Accrued litigation costs     250,000       295,000  
Accrued sales commissions     25,772       28,480  
Accrued payroll and related fringes     181,970       233,254  
Accrued insurance     60,894       78,579  
Accrued sales returns and allowances     10,267       18,258  
Accrued sales taxes     43,900       50,136  
Other     235,233       124,336  
                 
    $ 838,747     $ 845,881  

 

Accrued warranty expense comprised of the following for the six months ended June 30, 2020:

 

Beginning balance   $ 17,838  
Provision for warranty expense     52,796  
Charges applied to warranty reserve     (39,923 )
         
Ending balance   $ 30,711  
v3.20.2
Income Taxes
6 Months Ended
Jun. 30, 2020
Income Tax Disclosure [Abstract]  
Income Taxes

NOTE 7. INCOME TAXES

 

The effective tax rate for the six months ended June 30, 2020 and 2019 varied from the expected statutory rate due to the Company continuing to provide a 100% valuation allowance on net deferred tax assets. The Company determined that it was appropriate to continue the full valuation allowance on net deferred tax assets as of June 30, 2020 primarily because of the Company’s history of operating losses.

 

The Company has incurred operating losses in recent years and it continues to be in a three-year cumulative loss position at June 30, 2020. Accordingly, the Company determined there was not sufficient positive evidence regarding its potential for future profits to outweigh the negative evidence of our three-year cumulative loss position under the guidance provided in ASC 740. Therefore, it determined to continue to provide a 100% valuation allowance on its net deferred tax assets. The Company expects to continue to maintain a full valuation allowance until it determines that it can sustain a level of profitability that demonstrates its ability to realize these assets. To the extent the Company determines that the realization of some or all of these benefits is more likely than not based upon expected future taxable income, a portion or all of the valuation allowance will be reversed. As of June 30, 2020, it had approximately $66,925,000 of net operating loss carryforwards and $1,795,000 of research and development tax credit carryforwards as determined on December 31, 2019 available to offset future net taxable income.

v3.20.2
Operating Leases
6 Months Ended
Jun. 30, 2020
Leases [Abstract]  
Operating Leases

NOTE 8. OPERATING LEASES

 

On May 13, 2020, the Company entered into an operating lease for new warehouse and office space which will serve as its new principal executive office and primary business location. The terms of the lease include no base rent for the first six months and monthly payments ranging from $12,398 to $13,693 thereafter, with a termination date of December 2026. The Company is responsible for property taxes, utilities, insurance and its proportionate share of common area costs related to its new location. The Company took possession of the leased facilities on June 15, 2020. The remaining lease term for the Company’s office and warehouse operating lease as of June 30, 2020 was seventy-eight months. The Company’s previous office and warehouse space lease expired in April 2020 and the Company paid holdover rent for the time period until it moved to and commenced occupying the new space on June 15, 2020.

 

The Company entered into an operating lease with a third party in October 2019 for copiers used for office and warehouse purposes. The terms of the lease include 48 monthly payments of $1,598 with a maturity date of October 2023. The Company has the option to purchase the equipment at maturity for its estimated fair market value at that point in time. The remaining lease term for the Company’s copier operating lease as of June 30, 2020 was 40 months.

 

Lease expense related to the office space and copier operating leases were recorded on a straight-line basis over their respective lease terms. Total lease expense was $252,290 for the six months ended June 30, 2020.

 

The discount rate implicit within the Company’s operating leases was not generally determinable and therefore it determined the discount rate based on its incremental borrowing rate on the information available at commencement date. As of commencement date, the operating lease liabilities reflect a weighted average discount rate of 8%.

 

The following sets forth the operating lease right of use assets and liabilities as of June 30, 2020:

 

Assets:        
Operating lease right of use assets   $ 769,635  
         
Liabilities:        
Operating lease obligations-Long-term portion   $ 731,334  
Operating lease obligations-Current portion   $ 44,308  
Total operating lease obligations   $ 775,642  

 

The components of lease expense were as follows for the six months ended June 30, 2020:

 

Selling, general and administrative expenses   $ 252,290  

 

Following are the minimum lease payments for each year and in total.

 

Year ending December 31:      
2020 (July 1, to December 31, 2020)   $ 21,986  
2021     169,691  
2022     172,666  
2023     172,542  
2024     159,703  
Thereafter     310,259  
Total undiscounted minimum future lease payments     1,006,847  
Imputed interest     (231,205 )
Total operating lease liability   $ 775,642  
v3.20.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

NOTE 9. COMMITMENTS AND CONTINGENCIES

 

COVID-19 pandemic

 

The World Health Organization has declared the outbreak of COVID-19, or coronavirus, which began in December 2019, a pandemic and the U.S. federal government has declared it a national emergency. Our business, financial condition, results of operations and cash flows could be materially and adversely affected by the effects of COVID-19. The global spread of COVID-19 has already created significant volatility, uncertainty and economic disruption in the markets in which we operate. Governments, public institutions, and other organizations in countries and localities where cases of COVID-19 have been detected are taking certain emergency measures to mitigate its spread, including implementing travel restrictions and closing factories, schools, public buildings, and businesses. While the full impact of this outbreak is not yet known, we are closely monitoring the spread of COVID-19 and continually assessing its potential effects on our business.

 

The extent to which our results are affected by COVID-19 will largely depend on future developments which cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy, our customers’ demand for our products and services, and our ability to provide our products and services, particularly as result of our employees working remotely and/or the closure of certain offices and facilities.

 

Litigation.

 

From time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. It is our policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of the amount of the loss or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We reevaluate and update accruals as matters progress over time.

 

While the ultimate resolution is unknown, based on the information currently available, we do not expect that these lawsuits will individually, or in the aggregate, have a material adverse effect to our results of operations, financial condition and cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows.

 

Axon

 

The Company owns U.S. Patent No. 9,253,452 (the “ ‘452 Patent”), which generally covers the automatic activation and coordination of multiple recording devices in response to a triggering event, such as a law enforcement officer activating the light bar on the vehicle.

 

The Company filed suit on January 15, 2016 in the U.S. District Court for the District of Kansas (the “U.S. District Court”) (Case No: 2:16-cv-02032) against Axon, alleging willful patent infringement against Axon’s body camera product line and Signal auto-activation product. The Company is seeking both monetary damages and a permanent injunction against Axon for infringement of the ‘452 Patent.

 

In December 2016 and January 2017, Axon filed two petitions for Inter Partes Review (“IPR”) against the ‘452 Patent. The United States Patent and Trademark Office (“USPTO”) rejected both of Axon’s petitions. Axon is now statutorily precluded from filing any more IPR petitions against the ‘452 Patent.

 

The U.S. District Court litigation was temporarily stayed following the filing of the petitions for IPR. However, on November 17, 2017, the U.S. District Court of Kansas rejected Axon’s request to maintain the stay. With this ruling, the parties proceeded towards trial, after which the parties filed motions for summary judgment on January 31, 2019.

 

On June 17, 2019, the U.S. District Court granted Axon’s motion for summary judgment that Axon did not infringe on the Company’s patent and dismissed the case. The U.S. District Court’s ruling did not find that the ‘452 Patent was invalid. It also did not address any other issue, such as whether the Company’s requested damages were appropriate, and it did not impact the Company’s ability to file additional lawsuits to hold other competitors accountable for patent infringement. This ruling solely related to an interpretation of the Company’s claims as they relate to Axon and was unrelated to the supplemental briefing the Company filed on its damages claim and the WatchGuard settlement. Those issues are separate and the U.S. District Court’s ruling on the motion for summary judgment had nothing to do with the Company’s damages request.

 

The Company filed an opening appeal brief on August 26, 2019 with the U.S. Court of Appeals for the Tenth Circuit (the “Court of Appeals”), appealing the U.S. District Court’s granting of Axon’s motion for summary judgment. Axon responded by filing a responsive brief on November 6, 2019 and we then filed a reply brief responding to Axon on November 27, 2019. The Court of Appeals scheduled oral arguments on our appeal of the U.S. District Court’s summary judgment ruling on April 6, 2020. This appeal was intended to address the Company’s position that the U.S. District Court incorrectly dismissed our claims against Axon. If the Court of Appeals overturns the ruling of the U.S. District Court, the case will be remanded to the U.S District Court before a new judge. On March 12, 2020, the panel of judges for the Court of Appeals issued an order cancelling the oral arguments previously set for April 6, 2020, having determined that the appeal will be decided solely based on the parties’ briefs. On April 22, 2020, a three-judge panel of the United States Court of Appeals denied our appeal and affirmed the District Court’s previous decision to grant Axon summary judgment. On May 22, 2020, we filed a petition for panel rehearing requesting that we be granted a rehearing of our appeal of the U.S. District Court’s summary judgment ruling. Furthermore, we requested that we be given an opportunity to make our case through oral argument in front of the three-judge panel of the Court of Appeals, which was also denied. The Company is reviewing its alternatives at this point.

 

WatchGuard

 

On May 27, 2016, the Company filed suit against WatchGuard (Case No. 2:16-cv-02349-JTM-JPO) alleging patent infringement based on WatchGuard’s VISTA Wifi and 4RE In-Car product lines.

 

On May 13, 2019, the parties resolved the dispute and executed a settlement agreement in the form of a Release and License Agreement. The litigation has been dismissed as a result of this settlement.

 

The Release and License Agreement contains the following key terms:

 

  WatchGuard paid Digital Ally a one-time, lump settlement payment of $6,000,000.
     
  Digital Ally granted WatchGuard a perpetual covenant not to sue if WatchGuard’s products incorporate agreed-upon modified recording functionality. Digital Ally also granted WatchGuard a license to the ‘292 Patent and the ‘452 Patent (and related patents, now existing and yet-to-issue) through December 31, 2023. The parties agreed to negotiate in good faith to attempt to resolve any alleged infringement that occurs after the license period expires.
     
  The parties further agreed to release each other from all claims or liabilities pre-existing the settlement.
     
  As part of the settlement, the parties agreed that WatchGuard made no admission that it infringed any of Digital Ally’s patents.

 

Upon receipt of the $6,000,000 the parties filed a joint motion to dismiss the lawsuit with the court, which was granted.

 

NASDAQ LISTING.

 

On July 11, 2019, we were officially notified by The Nasdaq Stock Market LLC that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (the “MVLS”) for our Common Stock was below the $35 million minimum MVLS requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we had 180 calendar days, or until January 7, 2020, to regain compliance with the MVLS Rule, or in the alternative, the minimum stockholders’ equity requirement of $2,500,000. To regain compliance with the MVLS Rule, the minimum MVLS for our Common Stock must have been at least $35 million for a minimum of 10 consecutive business days at any time during this 180-day period. If we failed to regain compliance with either the MVLS Rule or the minimum stockholders’ equity requirement by January 7, 2020, we could have been delisted from Nasdaq.

 

On January 8, 2020, we received a determination letter from the staff of The Nasdaq Stock Market LLC stating that we had not regained compliance with the MVLS Standard, since our Common Stock was below the $35 million minimum MVLS requirement for continued listing on Nasdaq under the MLVS Rule and had not been at least $35 million for a minimum of 10 consecutive business days at any time during the 180-day grace period granted to us. Pursuant to the Letter, unless we requested a hearing to appeal this determination by January 15, 2020, our Common Stock would have been delisted from Nasdaq, trading of our Common Stock would have been suspended at the opening of business on January 17, 2020, and a Form 25-NSE would have been filed with the SEC, which would have removed our Common Stock from listing and registration on Nasdaq.

 

On January 13, 2020, we requested a hearing before the Nasdaq Hearings Panel to appeal the Letter and a hearing was held on February 20, 2020, when we appeared before the Panel to discuss our plan to regain compliance, including, but not limited to, complying with Nasdaq Listing Rule 5550(b)(1), which is the minimum stockholders’ equity standard for continued listing, which requires that companies listed on Nasdaq maintain a minimum of $2,500,000 in stockholders’ equity (“Rule 5550(b)(1)”). On March 6, 2020, we received written notice from the Panel indicating that, based on the plan of compliance that we had presented at such hearing, the Panel granted our request for the continued listing of our Common Stock on Nasdaq, subject to, among other things, us keeping the Staff updated on the progress of our compliance plan and ultimately being able to evidence shareholder equity in an amount greater than or equal to $2,500,000 in accordance with Rule 5550(b)(1) no later than June 30, 2020. During this time, our Common Stock remained listed and trading on Nasdaq.

 

On June 4, 2020 and June 10, 2020, we consummated underwritten public offerings, pursuant to underwriting agreements and raised aggregate gross proceeds of approximately $11.3 million, before underwriting discounts and commissions and other estimated expenses of such offerings. As a result of such offerings, we achieved compliance with Rule 5550(b)(1) and on June 18, 2020 we received written notice from the Staff stating that we had regained compliance with such rule and the matter is now closed.

 

On April 22, 2020, we received a written notification from the Nasdaq Stock Market LLC indicating that we were not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price for our Common Stock was below $1.00 per share for the last thirty (30) consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we were granted a 180-calendar day compliance period to regain compliance with the minimum bid price requirement. Subsequently, the 180-day grace period to regain compliance with such minimum bid price requirement under applicable Nasdaq Stock Market LLC rules was extended due to the global market impact caused by COVID-19. More specifically, the Nasdaq Stock Market LLC has stated that the compliance periods for any company previously notified about non-compliance will be suspended effective April 16, 2020, through June 30, 2020. On July 1, 2020, companies not in compliance would receive the balance of any pending compliance period exception to come back into compliance with such minimum bid price requirement. As a result of this extension, we had until December 28, 2020, to regain compliance with such minimum bid price requirement. During the compliance period, our Common Stock would still continue to be listed and traded on Nasdaq. To regain compliance, the closing bid price of the Common Stock had to have met or exceeded $1.00 per share for at least ten (10) consecutive business days by December 28, 2020. On June 112020, our Common Stock met such minimum bid price requirement, as the closing sale price of our Common Stock had equaled or exceeded $1.00 per share on Nasdaq at the close of each trading day since May 29, 2020, and we received written notice from the Staff stating that the Company regained compliance with such requirement and the matter is now closed.

v3.20.2
Stock-Based Compensation
6 Months Ended
Jun. 30, 2020
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation

NOTE 10. STOCK-BASED COMPENSATION

 

The Company recorded pretax compensation expense related to the grant of stock options and restricted stock issued of $376,738 and $585,195 for the three months ended June 30, 2020 and 2019 and $688,415 and $1,310,393 for the six months ended June 30, 2020 and 2019, respectively.

 

As of June 30, 2020, the Company had adopted seven separate stock option and restricted stock plans: (i) the 2005 Stock Option and Restricted Stock Plan (the “2005 Plan”), (ii) the 2006 Stock Option and Restricted Stock Plan (the “2006 Plan”), (iii) the 2007 Stock Option and Restricted Stock Plan (the “2007 Plan”), (iv) the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), (v) the 2011 Stock Option and Restricted Stock Plan (the “2011 Plan”), (vi) the 2013 Stock Option and Restricted Stock Plan (the “2013 Plan”), (vii) the 2015 Stock Option and Restricted Stock Plan (the “2015 Plan”) and (vii) the 2018 Stock Option and Restricted Stock Plan (the “2018 Plan”). The 2005 Plan, 2006 Plan, 2007 Plan, 2008 Plan, 2011 Plan, 2013 Plan, 2015 Plan and 2018 Plan are referred to as the “Plans.”

 

These Plans permit the grant of stock options or restricted stock to its employees, non-employee directors and others for up to a total of 4,175,000 shares of common stock. The 2005 Plan terminated during 2015 with 19,678 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2005 Plan that remain unexercised and outstanding as of June 30, 2020 total 7,563. The 2006 Plan terminated during 2016 with 25,849 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2006 Plan that remain unexercised and outstanding as of June 30, 2020 total 39,750. The 2007 Plan terminated during 2017 with 89,651 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2007 Plan that remain unexercised and outstanding as of June 30, 2020 total 5,000. The 2008 Plan terminated during 2018 with 9,249 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2008 Plan that remain unexercised and outstanding as of June 30, 2020 total 31,250.

 

Our Board of Directors adopted the 2020 Stock Option and Restricted Stock Plan (the “2020 Plan”) on June 30, 2020. At the annual meeting of the Company’s stockholders to be held on September 9, 2020 (the “Annual Meeting”) the Company is asking its stockholders to approve the 2020 Plan and the reservation of 1,500,000 shares of common stock issuable under the 2020 Plan. The 2020 Plan would authorize us to issue 1,500,000 shares of Common Stock upon exercise of options and grant of restricted stock awards. No options have been granted under the 2020 Plan to date. The 2020 Plan would also authorize us to grant (i) to the key employees incentive stock options to purchase shares of Common Stock and non-qualified stock options to purchase shares of Common Stock and restricted stock awards and (ii) to non-employee directors and consultants non-qualified stock options and restricted stock. As of June 30, 2020, approximately 78 employees, two executive officers, and three non-employee directors were eligible to participate in the 2020 Plan.

 

The Company believes that such awards better align the interests of our employees with those of its stockholders. Option awards have been granted with an exercise price equal to the market price of its stock at the date of grant with such option awards generally vesting based on the completion of continuous service and having ten-year contractual terms. These option awards typically provide for accelerated vesting if there is a change in control (as defined in the Plans). The Company has registered all shares of common stock that are issuable under its Plans with the SEC, except for shares of Common Stock issuable under the 2020 Plan, which the Company expects to register after the Annual Meeting, if the 2020 Plan is approved by the Company’s stockholders. A total of 1,437 shares remained available for awards under the various Plans (other than the 2020 Plan) as of June 30, 2020, and a total of 1,500,000 shares of Common Stock remained available for awards under the 2020 Plan as of June 30, 2020, which awards are not available for grant until the 2020 Plan is approved by the Company’s stockholders at the Annual Meeting, or which awards are terminable if such approval is not obtained, depending on the type of award available under the 2020 Plan.

 

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model.

 

Activity in the various Plans during the six months ended June 30, 2020:

 

Options  

Number of

Shares

   

Weighted

Average

Exercise Price

 
Outstanding at December 31, 2019     589,125     $ 3.74  
Granted            
Exercised     (1,875 )     4.16  
Forfeited     (3,937 )     (12.14 )
Outstanding at June 30, 2020     583,313     $ 3.69  
Exercisable at June 30, 2020     583,313     $ 3.69  

 

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model. The total estimated grant date fair value stock options issued during the six months ended June 30, 2020 was $-0- as there were no grants during that period.

 

The Plans allow for the cashless exercise of stock options. This provision allows the option holder to surrender/cancel options with an intrinsic value equivalent to the purchase/exercise price of other options exercised. There were no shares surrendered pursuant to cashless exercises during the six months ended June 30, 2020 and 2019.

 

At June 30, 2020, the aggregate intrinsic value of options outstanding was approximately $187,800 and the aggregate intrinsic value of options exercisable was approximately $187,800. No options were exercised in the six months ended June 30, 2019.

 

As of June 30, 2020, the unrecognized portion of stock compensation expense on all existing stock options was $-0-.

 

The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable options under the Company’s option plans as of June 30, 2020:

 

      Outstanding options   Exercisable options  

Exercise price

range

   

Number of

options

   

Weighted average

remaining

contractual life

 

Number of

options

   

Weighted average

remaining

contractual life

 
                         
$ 0.01 to $3.49       470,313     7.9 years     470,313       7.9 years  
$ 3.50 to $4.99       64,000     3.8 years     64,000       3.8 years  
$ 5.00 to $6.49           — years           — years  
$ 6.50 to $7.99       7,250     1.3 years     7,250       1.3 years  
$ 8.00 to $9.99       2,500     0.9 years     2,500       0.9 years  
$ 10.00 to $19.99       39,250     0.5 years     39,250       0.5 years  
                                 
          583,313     6.8 years     583,313       6.8 years  

 

Restricted stock grants. The Board of Directors has granted restricted stock awards under the Plans. Restricted stock awards are valued on the date of grant and have no purchase price for the recipient. Restricted stock awards typically vest over one to four years corresponding to anniversaries of the grant date. Under the Plans, unvested shares of restricted stock awards may be forfeited upon the termination of service to or employment with the Company, depending upon the circumstances of termination. Except for restrictions placed on the transferability of restricted stock, holders of unvested restricted stock have full stockholder’s rights, including voting rights and the right to receive cash dividends.

 

A summary of all restricted stock activity under the equity compensation plans for the six months ended June 30, 2020 is as follows:

 

   

Number of

Restricted

shares

   

Weighted

average

grant date

fair

value

 
Nonvested balance, January 1, 2020     514,875     $ 2.97  
Granted     665,500       1.05  
Vested     (410,375 )     (2.14 )
Forfeited     (35,250 )     (1.84 )
Nonvested balance, June 30, 2020     734,750     $ 1.75  

 

The Company estimated the fair market value of these restricted stock grants based on the closing market price on the date of grant. As of June 30, 2020, there were $505,271 of total unrecognized compensation costs related to all remaining non-vested restricted stock grants, which will be amortized over the next 18 months in accordance with their respective vesting scale.

 

The nonvested balance of restricted stock vests as follows:

 

Years ended  

Number of

shares

 
       
2020 (April 1, 2020 through December 31, 2020)     13,125  
2021     480,250  
2022     241,375  
v3.20.2
Common Stock Purchase Warrants
6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Common Stock Purchase Warrants

NOTE 11. COMMON STOCK PURCHASE WARRANTS

 

The Company has issued common stock purchase warrants in conjunction with various debt and equity issuances. The warrants are either immediately exercisable, or have a delayed initial exercise date, no more than six months from their respective issue date and allow the holders to purchase up to 3,393,364 shares of common stock at $1.40 to $16.50 per share as of June 30, 2020. The warrants expire from July 15, 2020 through January 17, 2025 and allow for cashless exercise.

 

The following table summarizes information about shares issuable under warrants outstanding during the six months ended June 30, 2020:

 

    Warrants    

Weighted

average

exercise

price

 
Vested Balance, January 1, 2020     4,824,573     $ 5.15  
Granted     1,273,374       1.31  
Exercised     (2,704,583 )     (1.95 )
Cancelled            
Vested Balance, June 30, 2020     3,393,364     $ 6.26  

 

The total intrinsic value of all outstanding warrants aggregated $295,836 as of June 30, 2020 and the weighted average remaining term is 21.8 months.

 

During the six months ended June 30, 2020, warrants to purchase 2,686,582 common shares were exercised for cash proceeds of $5,203,122 and warrants to purchase 18,000 common shares were exercised on a cashless basis through the forfeiture of 10,715 common shares.

 

The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable warrants to purchase common shares as of June 30, 2020:

 

      Outstanding and exercisable warrants  
Exercise price     Number of warrants    

Weighted average

remaining

contractual life

 
$ 2.60       465,712       3.1 years  
$ 3.00       316,800       2.8 years  
$ 3.36       166,667       1.7 years  
$ 3.36       566,666       2.7 years  
$ 3.65       167,000       2.0 years  
$ 3.75       25,753       2.1 years  
$ 5.00       800,000       1.5 years  
$ 13.43       879,766       0.6 years  
$ 16.50       5,000       0.1 years  
                     
          3,393,364       1.8 years  
v3.20.2
Stockholders' Equity (Deficit)
6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Stockholders' Equity (Deficit)

NOTE 12. STOCKHOLDERS’ EQUITY (DEFICIT)

 

Underwritten Public Offerings

 

On March 3, 2020, the Company entered into an underwriting agreement with Aegis Capital Corp., as the representative of the underwriters and sole book-running manager, pursuant to which the Company agreed to sell to the underwriters in a firm commitment underwritten public offering (the “Offering”) an aggregate of 2,521,740 shares of the Company’s common stock at a public price of $1.15 per share. The Company also granted the underwriters a forty-five (45)-day option to purchase up to an additional 378,261 shares of common stock to cover over-allotments, if any. The Offering was registered and the common stock was issued pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-225227), which was initially filed with the SEC on May 25, 2018 and was declared effective on June 6, 2018.

 

The underwriting agreement contained customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters. The Underwriters received discounts and commissions of seven percent (7%) of the gross cash proceeds received by the Company from the sale of the common stock in the Offering. In addition, the Company agreed to pay the Underwriters (a) a non-accountable expense reimbursement of 1% of the gross proceeds received and (b) “road show” expenses, diligence fees and the fees and expenses of the Underwriters’ legal counsel not to exceed $50,000. The net proceeds to the Company from the Offering totaled approximately $2,502,136, after deducting underwriting discounts and commissions and estimated expenses payable by the Company.

 

On June 2, 2020, the Company entered into an underwriting agreement with Aegis Capital Corp., as the representative of the underwriters and sole book-running manager, pursuant to which the Company agreed to sell to the underwriters in a firm commitment underwritten public offering an aggregate of 3,090,909 shares of the Company’s common stock, at a public price of $1.65 per share (the “June 2nd Offering”). The Company also granted the underwriters a forty-five (45)-day option to purchase up to an additional 463,636 shares of common stock to cover over-allotments, if any (the “June 2nd Option Shares”). The June 2nd Offering was registered and the common stock was issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-225227), which was initially filed with the SEC on May 25, 2018 and was declared effective on June 6, 2018.

 

On June 8, 2020, the Underwriters fully exercised their over-allotment option to acquire the June 2nd Option Shares at $1.65 per share, and the offering of the June 2nd Option Shares closed on June 10, 2020. The exercise of such over-allotment option resulted in additional gross proceeds, before deducting underwriting discounts and commissions and other estimated offering expenses, of $765,000, which the Company intends to use for general corporate purposes, including for compliance with certain Nasdaq continued listing requirements and continued investments in the Company’s commercialization efforts.

 

The underwriting agreement contained customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters. The Underwriters received discounts and commissions of seven percent (7%) of the gross cash proceeds received by the Company from the sale of the common shares in the June 2nd Offering. In addition, the Company agreed to pay the Underwriters “road show” expenses, diligence fees and the fees and expenses of the Underwriters’ legal counsel not to exceed $30,000. The net proceeds to the Company from the June 2nd Offering totaled $5,350,413, including the exercise of the underwriter’s overallotment option and after deducting underwriting discounts and commissions and estimated expenses payable by the Company.

 

On June 8, 2020, the Company entered into an underwriting agreement with Aegis Capital Corp., as the representative of the underwriters and sole book-running manager, pursuant to which the Company agreed to sell to the underwriters in a firm commitment underwritten public offering an aggregate of 2,325,581 shares of common stock at a public price of $2.15 per share (the “June 8th Offering”). The Company also granted the underwriters a forty-five (45)-day option to purchase up to an additional 213,953 shares of common stock to cover over-allotments, if any (the “June 8th Option Shares”).The June 8th Offering was registered and the common stock was issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-225227), which was initially filed with the SEC on May 25, 2018 and was declared effective on June 6, 2018.

 

On June 10, 2020, the Underwriters fully exercised their over-allotment option to acquire the June 8th Option Shares at $2.15 per share, and the offering of the June 8th Option Shares closed on June 10, 2020. The exercise of such over-allotment option resulted in additional gross proceeds, before deducting underwriting discounts and commissions and other estimated Offering expenses, of $460,000, which the Company intends to use for general corporate purposes, including for compliance with certain Nasdaq continued listing requirements and continued investments in the Company’s commercialization efforts.

 

The underwriting agreement contained customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters. The Underwriters received discounts and commissions of seven percent (7%) of the gross cash proceeds received by the Company from the sale of the common shares in the June 8th Offering. In addition, the Company agreed to pay the Underwriters “road show” expenses, diligence fees and the fees and expenses of the Underwriters’ legal counsel not to exceed $30,000. The net proceeds to the Company from the June 8th Offering totaled $4,976,692, including the exercise of the underwriter’s overallotment option and after deducting underwriting discounts and commissions and estimated expenses payable by the Company.

 

2020 Issuances of Restricted Common Stock.

 

On January 3, 2020, the board of directors approved the grant of 530,050 shares of restricted common stock to officers and employees of the Company. Such shares will generally vest one-half on January 2, 2021 and one half on January 2, 2022, provided that each grantee remains an officer or employee on such dates.

 

In April 17, 2020 the Compensation Committee of the Board of Directors of the Company determined that the cash portion of the annual base salaries of the Company’s President and Chief Executive Officer, and the Company’s Chief Financial Officer, Treasurer and Secretary, would be reduced to annual rates of $150,000 each for the balance of 2020 commencing May 1, 2020.

 

The Committee also decided that the reduction of the base annual salaries of Company’s President and Chief Executive Officer, and the Company’s Chief Financial Officer, Treasurer and Secretary, for 2020, which totaled $69,231 and $55,384, respectively, as of May 1, 2020 was paid through the issuance of shares of restricted stock under the 2018 Stock Option and Restricted Stock Plan with the Company paying the applicable federal and state taxes on such amounts. Accordingly, the Company issued the Company’s President and Chief Executive Officer, and the Company’s Chief Financial Officer, Treasurer and Secretary 75,250 shares and 60,200 shares, respectively, effective April 17, 2020 based on a closing price of $0.92 per share on such date.

v3.20.2
Net Loss Per Share
6 Months Ended
Jun. 30, 2020
Earnings Per Share [Abstract]  
Net Loss Per Share

NOTE 13. NET LOSS PER SHARE

 

The calculation of the weighted average number of shares outstanding and loss per share outstanding for the three and six months ended June 30, 2020 and 2019 are as follows:

 

   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
    2020     2019     2020     2019  
Numerator for basic and diluted income per share – Net loss   $ (497,894 )   $ (387,730 )   $ (2,832,004 )   $ (3,592,904 )
                                 
Denominator for basic loss per share – weighted average shares outstanding     18,976,724       11,305,248       16,430,214       11,124,222  
Dilutive effect of shares issuable under stock options and warrants outstanding                        
                                 
Denominator for diluted loss per share – adjusted weighted average shares outstanding     18,976,724       11,305,248       16,430,214       11,124,222  
                                 
Net loss per share:                                
Basic   $ (0.03 )   $ (0.03 )   $ (0.17 )   $ (0.32 )
Diluted   $ (0.03 )   $ (0.03 )   $ (0.17 )   $ (0.32 )

 

Basic loss per share is based upon the weighted average number of common shares outstanding during the period. For the three and six months ended June 30, 2020 and 2019, all shares issuable upon conversion of convertible debt and the exercise of outstanding stock options and warrants were antidilutive, and, therefore, not included in the computation of diluted income (loss) per share.

v3.20.2
Subsequent Events
6 Months Ended
Jun. 30, 2020
Subsequent Events [Abstract]  
Subsequent Events

NOTE 14. SUBSEQUENT EVENTS

 

Warehouse Building Acquisition. On July 13, 2020, the Company entered into a Commercial and Industrial Real Estate Sale Contract (the “Contract”) whereby it will purchase new warehouse space which will serve as the company’s warehouse and distribution location for its new branded temperature screening device ThermoVU™ and its Shield™ line of disinfectant/cleanser products. The terms of the Contract include a total purchase price of $420,000 with the closing expected to occur on or before August 21, 2020. The Company paid cash to close the purchase of the building on July 16, 2020.

 

Proceeds Investment Agreement Termination Agreement. - On July 20, 2020, the Company and BKI executed a Termination Agreement and Mutual Release (the “Termination Agreement”). Under the terms of the Termination Agreement the parties agreed to terminate the PIA and to release one another from any further liability under the PIA obligation. (See Note 4 — “Proceeds Investment Agreement Obligation”).

 

Under the terms of the Termination Agreement, upon payment of $1,250,000 by the Company to BKI both parties agreed to terminate the PIA and to release each other from any further liability thereunder. Such $1,250,000 payment was made on July 22, 2020. In addition to the $1,250,000 payment, the Company further agreed to pay BKI the following: (a) a contingent payment in the amount of $2,750,000 following the closing of an asset purchase, membership interest purchase, or similar transaction between the Company and a specified third-party (the “Purchase Transaction”) and (b) any and all future proceeds received from Watchguard and its successors and assigns by the Company for WatchGuard’s use of U.S. Patent Nos. 8,781,292 and 9,253,452. For clarity, the Company and BKI further agreed that the payment of the contingent payment would only be due and payable upon the closing of the specified Purchase Transaction and the relevant contingent payment portion of the Termination Agreement, and any obligations stemming therefrom, would automatically terminate if the specified Purchase Transaction is abandoned prior to its closing, including its failure to close within three years from the date of the Termination Agreement. The specified Purchase Transaction has not yet occurred and there is no binding agreement to complete such Purchase Transaction.

 

Shelf Registration Statement on Form S-3 On July 2, 2020 the SEC declared the Company’s shelf registration statement on Form S-3 (the “Shelf Registration Statement”) effective. The Shelf Registration Statement allows the Company to offer and sell, from time to time in one or more offerings, any combination of our common stock, debt securities, debt securities convertible into common stock or other securities in any combination thereof, rights to purchase shares of common stock or other securities in any combination thereof, warrants to purchase shares of common stock or other securities in any combination thereof or units consisting of common stock or other securities in any combination thereof having an aggregate initial offering price not exceeding $125,000,000.

v3.20.2
Nature of Business and Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations

Nature of Operations:

 

Digital Ally, Inc. its wholly-owned subsidiaries, Digital Ally International, Inc. and Shield Products, LLC (collectively, “Digital Ally,” “Digital,” the “Company”) produces digital video imaging, storage products and disinfectant and related safety products for use in law enforcement, security and commercial applications. The Company’s products include in-car digital video/audio recorders contained in a rear-view mirror for use in law enforcement and commercial fleets; a system that provides its law enforcement customers with audio/video surveillance from multiple vantage points and hands-free automatic activation of body-worn cameras and in-car video systems; a miniature digital video system designed to be worn on an individual’s body; and cloud storage solutions. The Company has recently added two new lines of branded products: (1) the ThermoVu™ line, which is a line of self-contained temperature monitoring stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2) the Shield™ disinfectant and cleanser line, which is for use against viruses and bacteria and which we began offering to the Company’s law enforcement and commercials customers beginning late in the second quarter of 2020. Both product lines are manufactured by third parties. In addition, the Company has active research and development programs to adapt its technologies to other applications. It can integrate electronic, radio, computer, mechanical, and multi-media technologies to create unique solutions to address needs in a variety of other industries and markets, including mass transit, school bus, taxicab and the military. The Company sells its products to law enforcement agencies, private security customers and organizations and consumer and commercial fleet operators through direct sales domestically and third-party distributors internationally.

 

The Company was originally incorporated in Nevada on December 13, 2000 as Vegas Petra, Inc. and had no operations until 2004. On November 30, 2004, Vegas Petra, Inc. entered into a Plan of Merger with Digital Ally, Inc., at which time the merged entity was renamed Digital Ally, Inc.

Basis of Presentation

Basis of Presentation:

 

The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month period ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

 

The balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements.

 

For further information, refer to the audited financial statements and footnotes included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 and the unaudited financial statements and footnotes included in the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2020.

COVID-19 Pandemic

COVID-19 pandemic:

 

The World Health Organization has declared the outbreak of COVID-19, or coronavirus, which began in December 2019, a pandemic and the U.S. federal government has declared it a national emergency. The COVID-19 pandemic had a negative impact on our revenues in the first and second quarters of 2020  and we expect it will adversely affect our business and operations during the remainder of 2020. While its full and continued impact cannot be determined at present, we do expect it will have a material adverse effect on our future business, financial condition, results of operations, and cash flows. The global spread of COVID-19 has already created significant volatility, uncertainty and economic disruption in the markets in which we operate. Governments, public institutions, and other organizations in countries and localities where cases of COVID-19 have been detected are taking certain emergency measures to mitigate its spread, including implementing travel restrictions and closing factories, schools, public buildings, and businesses. We are closely monitoring the spread of COVID-19 and continually assessing its potential effects on our business. In response to the impact that the COVID-19 pandemic and other future pandemics may have on the Company’s customers and legacy products, the Company has recently added two new lines of branded products: (1) the ThermoVu™ which is a line of self-contained temperature monitoring stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2) the Shield™ disinfectant and cleanser line which is for use against viruses and bacteria and which we began offering to the Company’s law enforcement and commercials customers beginning late in the second quarter of 2020.

 

The extent to which our future results are affected by COVID-19 will largely depend on future developments that cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy, our customers’ demand for our products and services, and our ability to provide our products and services, particularly as result of our employees working remotely and/or the closure of certain offices and facilities.

Management's Liquidity Plan and Going Concern

Management’s Liquidity Plan and Going Concern:

 

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred operating losses for the six months ended June 30, 2020 and for the year ended December 31, 2019 primarily due to reduced revenues and gross margins caused by a variety of factors, including the COVID-19 pandemic and its related effects on our customers and our supply chain, and by competitors’ introduction of newer products with more advanced features together with significant price cutting of their products. The Company incurred net losses of approximately $2.8 million during the six months ended June 30, 2020 and $10.0 million for the year ended December 31, 2019 and it had an accumulated deficit of $90.2 million as of June 30, 2020. During 2019, the Company settled one of its patent infringement cases and received a lump sum payment of $6.0 million, which was used to pay its obligations under its Proceeds Investment Agreement, as more fully described in Note 4 — “Proceeds Investment Agreement Obligation.”. In recent years the Company has accessed the public and private capital markets to raise funding through the issuance of debt and equity. In that regard, the Company raised $12.8 million in underwritten public offerings of its common stock, raised $5.2 million through the exercise of common stock purchase warrants and options, raised $1.6 million through the issuance of promissory notes through the Small Business Administration’s (“SBA”) Paycheck Protection Program (“PPP”) and the Economic Injury Disaster Loan (“EIDL”) programs, raised $1.5 million through the issuance of secured convertible notes and raised $419,000 in unsecured promissory notes and detachable warrants during the six months ended June 30, 2020. In addition, the Company raised $1,564,000 in the year ended December 31, 2019 from the exercise of warrants, the Company borrowed $300,000 pursuant to a short-term promissory note payable on December 23, 2019 with detachable warrants to purchase 107,000 shares of common stock and on August 5, 2019, it raised funds from the issuance of $2.78 million principal balance of secured convertible notes with detachable warrants to purchase 571,248 shares of common stock with the net proceeds being used for working capital purposes as more fully described in Note 3 – “Debt Obligations”. These debt and equity raises were utilized to fund its operations and management expects to continue this pattern until it achieves positive cash flows from operations, although it can offer no assurance in this regard.

 

The Company will have to restore positive operating cash flows and profitability over the next year and/or raise additional capital to fund its operational plans, meet its customary payment obligations and otherwise execute its business plan. There can be no assurance that it will be successful in restoring positive cash flows and profitability, or that it can raise additional financing when needed, and obtain it on terms acceptable or favorable to the Company.

 

The Company has increased its addressable market to non-law enforcement customers and obtained new non-law enforcement contracts in 2020 and 2019, which contracts include recurring revenue during the period 2020 to 2023. Further, it added two new product lines in response to the Covid-19 pandemic. The Company believes that its quality control and cost cutting initiatives, expansion to non-law enforcement sales channels and new product introductions will eventually restore positive operating cash flows and profitability, although it can offer no assurances in this regard. The extent to which its future operating results are affected by COVID-19 will largely depend on future developments which cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy, our customers’ demand for our products and services, and our ability to provide our products and services, particularly as result of our employees working remotely and/or the closure of certain offices and facilities. While degree of impact of these factors is uncertain, we believe that the COVID-19 pandemic or the perception of its effects will have a material adverse effect on our business, financial condition, results of operations, and cash flows.

 

Based on the uncertainties described above, the Company believes its business plan does not alleviate the existence of substantial doubt about its ability to continue as a going concern within one year from the date of the issuance of these unaudited condensed consolidated financial statements. The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Basis of Consolidation

Basis of Consolidation:

 

The accompanying financial statements include the consolidated accounts of Digital Ally and its wholly-owned subsidiaries, Digital Ally International, Inc. and Shield Products, LLC. All intercompany balances and transactions have been eliminated during consolidation.

 

The Company formed Digital Ally International, Inc. during August 2009 to facilitate the export sales of its products. The Company formed Shield Products, LLC in May 2020 to facilitate the sales of its Shield™ line of disinfectant/cleanser products and ThermoVu™ line of temperature monitoring equipment.

Revenue Recognition

Revenue Recognition:

 

The Company applies the provisions of Accounting Standards Codification (ASC) 606-10, Revenue from Contracts with Customers, and all related appropriate guidance. The Company recognizes revenue under the core principle to depict the transfer of control to its customers in an amount reflecting the consideration to which it expects to be entitled. In order to achieve that core principle, the Company applies the following five-step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.

 

The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with the customer. In situation where sales are to a distributor, the Company had concluded its contracts are with the distributor as the Company holds a contract bearing enforceable rights and obligations only with the distributor. As part of part of its consideration for the contract, the Company evaluates certain factors including the customers’ ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. As the Company’s standard payment terms are less than one year, it has elected the practical expedient under ASC 606-10-32-18 to not assess whether a contract has a significant financing component. The Company allocates the transaction price to each distinct product based on its relative standalone selling price. The product price as specified on the purchase order is considered the standalone selling price as it is an observable input which depicts the price as if sold to a similar customer in similar circumstances. Revenue is recognized when control of the product is transferred to the customer (i.e. when the Company’s performance obligations is satisfied), which typically occurs at shipment. Further in determining whether control has been transferred, the Company considers if there is a present right to payment and legal title, along with risks and rewards of ownership having transferred to the customer. Customers do not have a right to return the product other than for warranty reasons for which they would only receive repair services or replacement product. The Company has also elected the practical expedient under ASC 340-40-25-4 to expense commissions for product sales when incurred as the amortization period of the commission asset the Company would have otherwise recognized is less than one year.

 

The Company sells its products and services to law enforcement and commercial customers in the following manner:

 

  Sales to domestic customers are made direct to the end customer (typically a law enforcement agency or a commercial customer) through its sales force, which is composed of its employees. Revenue is recorded when the product is shipped to the end customer.
     
  Sales to international customers are made through independent distributors who purchase products from the Company at a wholesale price and sell to the end user (typically law enforcement agencies or a commercial customer) at a retail price. The distributor retains the margin as its compensation for its role in the transaction. The distributor generally maintains product inventory, customer receivables and all related risks and rewards of ownership. Accordingly, upon application of steps one through five above, revenue is recorded when the product is shipped to the distributor consistent with the terms of the distribution agreement.
     
  Repair parts and services for domestic and international customers are generally handled by its inside customer service employees. Revenue is recognized upon shipment of the repair parts and acceptance of the service or materials by the end customer.

 

Sales taxes collected on products sold are excluded from revenues and are reported as accrued expenses in the accompanying balance sheets until payments are remitted.

 

Service and other revenue is comprised of revenues from extended warranties, repair services, cloud revenue and software revenue. Revenue is recognized upon shipment of the product and acceptance of the service or materials by the end customer for repair services. Revenue for extended warranty, cloud service or other software-based products is over the term of the contract warranty or service period. A time-elapsed method is used to measure progress because the Company transfers control evenly over the contractual period. Accordingly, the fixed consideration related to these revenues is generally recognized on a straight-line basis over the contract term, as long as the other revenue recognition criteria have been met.

 

Contracts with some of the Company’s customers contain multiple performance obligations that are distinct and accounted for separately. The transaction price is allocated to the separate performance obligations on a relative standalone selling price (“SSP”). The Company determined SSP for all the performance obligations using observable inputs, such as standalone sales and historical pricing. SSP is consistent with the Company’s overall pricing objectives, taking into consideration the type of service being provided. SSP also reflects the amount the Company would charge for the performance obligation if it were sold separately in a standalone sale. Multiple performance obligations consist of product, software, cloud subscriptions and extended warranties.

 

The Company’s multiple performance obligations may include future in-car or body-worn camera devices to be delivered at defined points within a multi-year contract, and in those arrangements, the Company allocates total arrangement consideration over the life of the multi-year contract to future deliverables using management’s best estimate of selling price.

 

Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract and are reported separately as current liabilities and non-current liabilities in the Condensed Consolidated Balance Sheets. Such amounts consist of extended warranty contracts, prepaid cloud services and prepaid installation services and are generally recognized as the respective performance obligations are satisfied. Total contract liabilities consist of the following: Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract and are reported separately as current liabilities and non-current liabilities in the Condensed Consolidated Balance Sheets. Such amounts consist of extended warranty contracts, prepaid cloud services and prepaid installation services and are generally recognized as the respective performance obligations are satisfied.

Accounts Receivable

Accounts Receivable:

 

Accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a weekly basis. The Company determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded when received.

 

A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than thirty (30) days beyond terms. No interest is charged on overdue trade receivables.

Segments of Business

Segments of Business:

 

Management has determined that its operations comprise one reportable segment: the sale of digital audio and video recording and speed detection devices. For the three and six months ended June 30, 2020 and 2019, sales by geographic area were as follows:

 

    Three Months Ended June 30,     Six Months Ended June 30,  
    2020     2019     2020     2019  
Sales by geographic area:                                
United States of America   $ 1,726,119     $ 2,477,717     $ 4,097,815     $ 4,992,059  
Foreign     6,073       69,266       60,121       105,720  
                                 
Total   $ 1,732,192     $ 2,546,983     $ 4,157,936     $ 5,097,779  

 

Sales to customers outside of the United States are denominated in U.S. dollars. All Company assets are physically located within the United States.

Recent Accounting Pronouncements

Recent Accounting Pronouncements:

 

In February 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-02, Leases (“Topic 842”). The guidance requires lessees to put most leases on their balance sheets but recognize expenses on their income statements in a manner similar to today’s accounting. Lessees initially recognize a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The lease liability is measured at the present value of the lease payments over the lease term. The right-of-use asset is measured at the lease liability amount, adjusted for lease prepayments, lease incentives received and the lessee’s initial direct costs. The standard is effective for public business entities for annual reporting periods beginning after December 15, 2018, and interim periods within that reporting period, which was the first quarter of 2019 for the Company.

 

The Company adopted the new guidance on January 1, 2019 using the optional transitional method and elected to use the package of three practical expedients which allows the Company not to reassess whether contracts are or contain leases, lease classification and whether initial direct costs qualify for capitalization. The Company has completed its assessment of the impact of the standard and determined that the only lease that the Company held was an operating lease for its office and warehouse space. Upon adoption of the standard, the Company recorded Right of Use (ROU) assets of approximately $501,000 and lease liabilities of approximately $582,000 related to it office and warehouse space operating leases. The Company also removed deferred rent of approximately $81,000 when adopting the new guidance.

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission (the “SEC”) to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation will not be required until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

 

In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. Furthermore, an entity is permitted to early adopt any removed or modified disclosures upon issuance of the update and delay adoption of the additional disclosures until their effective date. The Company implemented the revised disclosure requirements upon adoption of ASU 2018-13.

 

In August 2018, the FASB issued ASU No. 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40), or ASU 2018-15. ASU 2018-15 updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes - simplifying the accounting for income taxes (Topic 740), which is meant to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, Income Taxes. The amendment also improves consistent application and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

v3.20.2
Nature of Business and Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Sales by Geographic Area

Management has determined that its operations comprise one reportable segment: the sale of digital audio and video recording and speed detection devices. For the three and six months ended June 30, 2020 and 2019, sales by geographic area were as follows:

 

    Three Months Ended June 30,     Six Months Ended June 30,  
    2020     2019     2020     2019  
Sales by geographic area:                                
United States of America   $ 1,726,119     $ 2,477,717     $ 4,097,815     $ 4,992,059  
Foreign     6,073       69,266       60,121       105,720  
                                 
    $ 1,732,192     $ 2,546,983     $ 4,157,936     $ 5,097,779  
v3.20.2
Inventories (Tables)
6 Months Ended
Jun. 30, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventories

Inventories consisted of the following at June 30, 2020 and December 31, 2019:

 

    June 30, 2020     December 31, 2019  
Raw material and component parts   $ 2,575,710     $ 4,481,611  
Work-in-process     30,679       35,858  
Finished goods     4,146,308       4,906,956  
                 
Subtotal     6,752,697       9,424,425  
Reserve for excess and obsolete inventory     (2,000,412 )     (4,144,013 )
                 
Total   $ 4,752,285     $ 5,280,412  
v3.20.2
Debt Obligations (Tables)
6 Months Ended
Jun. 30, 2020
Summary of Secured Convertible Debentures and Proceeds Investment Agreement

Debt obligations is comprised of the following:

 

    June 30, 2020     December 31, 2019  
Payroll protection program loan (PPP)   $ 1,418,900     $  
Economic injury disaster loan (EIDL)     150,000        
2019 Secured convertible notes, at fair value           1,593,809  
Unsecured promissory notes payable, less unamortized discount of $-0- and $66,061 at June 30, 2020 and December 31, 2019, respectively           233,939  
                 
Debt obligations     1,568,900       1,827,748  
Less: current maturities of debt obligations     552,258       1,827,748  
Debt obligations, long-term   $ 1,016,642     $  
Schedule of Maturity of Debt Obligations

Debt obligations mature as follows as of June 30, 2020:

 

    June 30, 2020  
2020 (July 1, 2020 to December 31, 2020)   $ 68,241  
2021     948,391  
2022     401,321  
2023     3,166  
2024     3,286  
2025 and thereafter     144,495  
         
Total   $ 1,568,900  
2019 Secured Convertible Notes [Member]  
Schedule of Fair Value of Embedded Derivatives and Warrants

The following represents the resulting fair value as determined on August 5, 2019, the date of origination:

 

Secured convertible notes   $ 1,845,512  
Common stock issued as Commitment Shares     118,749  
Common stock purchase warrants     535,739  
         
Gross cash proceeds   $ 2,500,000  
Summary of Fair Value and Adjusted Carrying Value of Secured Convertible Notes

Following is an analysis of the activity in the secured convertible notes during the six months ended June 30, 2020:

 

    Amount  
Balance at December 31, 2019   $ 1,593,809  
Principal repaid during the period by issuance of common stock     (1,259,074 )
Principal repaid during the period by payment of cash     (747,180 )
Change in fair value of secured convertible note during the period     412,445  
         
Balance at June 30, 2020   $  
Schedule of Certain Estimates and Assumptions of Fair Value of Secured Convertible Notes

Following is a range of certain estimates and assumptions utilized as of December 31, 2019 to determine the fair value of secured convertible notes:

 

    December 31, 2019  
    Assumptions  
Volatility – range     115 %
Risk-free rate     1.60 %
Contractual term     0.6 years  
Calibrated stock price   $ 1.06  
Debt yield     123.6 %
2020 Secured Convertible Notes [Member]  
Schedule of Fair Value of Embedded Derivatives and Warrants

The following represents the resulting fair value as determined on April 17, 2020, the date of origination:

 

Secured convertible notes   $ 778,859  
Common stock purchase warrants     721,141  
         
Gross cash proceeds   $ 1,500,000  

Summary of Fair Value and Adjusted Carrying Value of Secured Convertible Notes

Following is an analysis of the activity in the secured convertible notes during the six months ended June 30, 2020:

 

    Amount  
Balance at December 31, 2019   $  
Issuance of 2020 convertible notes at fair value     778,859  
Principal repaid during the period by issuance of common stock     (1,665,666 )
Principal repaid during the period by payment of cash     (1,000 )
Change in fair value of secured convertible note during the period     887,807  
         
Balance at June 30, 2020   $  
Schedule of Certain Estimates and Assumptions of Fair Value of Secured Convertible Notes

Following is a range of certain estimates and assumptions utilized as of the April 17, 2020 issuance date to determine the fair value of secured convertible notes:

 

    April 17, 2020  
    Assumptions  
Volatility – range     90 %
Risk-free rate     0.36 %
Contractual term     1.0 years  
Stock price   $ 0.92  
Debt yield     132.2 %
v3.20.2
Proceeds Investment Agreement Obligation (Tables)
6 Months Ended
Jun. 30, 2020
Proceeds Investment Agreement Obligation  
Schedule of Proceeds Investment Obligation

The proceeds investment agreement obligations is comprised of the following:

 

    June 30, 2020     December 31, 2019  
Proceeds investment agreement, at fair value   $ 3,615,000     $ 6,500,000  
Less: Current portion     (3,615,000 )      
                 
Proceeds investment agreement, at fair value - Long-term   $     $ 6,500,000  
Schedule of Fair Value of PIA

The Company elected to account for the PIA on the fair value basis. Therefore, the Company determined the fair value of the PIA and PIA Warrants which yielded estimated fair values of the PIA including their embedded derivatives and the detachable PIA Warrants as follows:

 

Proceeds investment agreement   $ 9,067,513  
Common stock purchase warrants     932,487  
         
Gross cash proceeds   $ 10,000,000  
Schedule of Certain Estimates and Assumptions of Weighted Patent Asset

Following is a range of certain estimates and assumptions utilized as of June 30, 2020 and December 31, 2019 to probability weighted present value of expected patent asset proceeds for the litigation involving both Axon and WatchGuard:

 

    June 30, 2020     December 31, 2019  
Discount rate     15.13% -15.18%       3.0% -16.6%  
Expected term to patent asset proceeds payment     0.33 years – 3.75 .06 - .29 years       0.58 years - 4 years  
Probability of success     90.0 %     5.9% -38.5%  
Estimated minimum return payable to BKI     $ 4 million       $ 21 million  
Negotiation discount     0.0 %     43.3 %
Schedule of Proceeds Investment Agreement Activity

The following represents activity in the PIA during the six months ended June 30, 2020:

 

Beginning balance as of December 31, 2019   $ 6,500,000  
Repayment of obligation      
Change in the fair value during the period     (2,885,000 )
Ending balance as of June 30, 2020   $ 3,615,000  
v3.20.2
Fair Value Measurement (Tables)
6 Months Ended
Jun. 30, 2020
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table represents the Company’s hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2020 and December 31, 2019:

 

    June 30, 2020  
    Level 1     Level 2     Level 3     Total  
Liabilities:                                
Secured convertible notes   $     $     $     $  
Proceeds investment agreement obligation                 3,615,000       3,615,000  
    $     $     $ 3,615,000     $ 3,615,000  

 

    December 31, 2019  
    Level 1     Level 2     Level 3     Total  
Liabilities:                                
Secured convertible notes   $     $     $ 1,593,809     $ 1,593,809  
Proceeds investment agreement obligation                 6,500,000       6,500,000  
    $     $     $ 8,093,809     $ 8,093,809  
Fair Value Measurements Change in Level 3 Inputs

The following table represents the change in Level 3 tier value measurements:

 

    2019     2020              
    Secured     Secured     Proceeds        
    Convertible     Convertible     Investment        
    Notes     Notes     Agreement     Total  
                         
Balance, December 31, 2019   $ 1,593,809     $     $ 6,500,000     $ 8,093,809  
                                 
Issuance of secured convertible debt           778,859             778,859  
                                 
Conversion of secured convertible debentures     (1,259,074 )     (1,665,666 )           (2,924,740 )
                                 
Repayment of secured convertible notes     (747,180 )     (1,000 )           (748,180 )
Change in fair value of secured convertible debentures and proceeds investment agreement     412,445       887,807       (2,885,000 )     (1,548,748 )
                                 
Balance, June 30, 2020   $     $     $ 3,615,000     $ 3,615,000  
v3.20.2
Accrued Expenses (Tables)
6 Months Ended
Jun. 30, 2020
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses comprised of the following at June 30, 2020 and December 31, 2019:

 

    June 30, 2020     December 31, 2019  
Accrued warranty expense   $ 30,711     $ 17,838  
Accrued litigation costs     250,000       295,000  
Accrued sales commissions     25,772       28,480  
Accrued payroll and related fringes     181,970       233,254  
Accrued insurance     60,894       78,579  
Accrued sales returns and allowances     10,267       18,258  
Accrued sales taxes     43,900       50,136  
Other     235,233       124,336  
                 
    $ 838,747     $ 845,881  
Schedule of Accrued Warranty Expense

Accrued warranty expense comprised of the following for the six months ended June 30, 2020:

 

Beginning balance   $ 17,838  
Provision for warranty expense     52,796  
Charges applied to warranty reserve     (39,923 )
         
Ending balance   $ 30,711  
v3.20.2
Operating Leases (Tables)
6 Months Ended
Jun. 30, 2020
Leases [Abstract]  
Schedule of Operating Leases Right of Use Assets and Liabilities

The following sets forth the operating lease right of use assets and liabilities as of June 30, 2020:

 

Assets:        
Operating lease right of use assets   $ 769,635  
         
Liabilities:        
Operating lease obligations-Long-term portion   $ 731,334  
Operating lease obligations-Current portion   $ 44,308  
Total operating lease obligations   $ 775,642  
Schedule of Components of Lease Expenses

The components of lease expense were as follows for the six months ended June 30, 2020:

 

Selling, general and administrative expenses   $ 252,290  

Schedule of Future Minimum Lease Payments

Following are the minimum lease payments for each year and in total.

 

Year ending December 31:      
2020 (July 1, to December 31, 2020)   $ 21,986  
2021     169,691  
2022     172,666  
2023     172,542  
2024     159,703  
Thereafter     310,259  
Total undiscounted minimum future lease payments     1,006,847  
Imputed interest     (231,205 )
Total operating lease liability   $ 775,642  
v3.20.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2020
Share-based Payment Arrangement [Abstract]  
Summary of Stock Options Outstanding

Activity in the various Plans during the six months ended June 30, 2020:

 

Options  

Number of

Shares

   

Weighted

Average

Exercise Price

 
Outstanding at December 31, 2019     589,125     $ 3.74  
Granted            
Exercised     (1,875 )     4.16  
Forfeited     (3,937 )     (12.14 )
Outstanding at June 30, 2020     583,313     $ 3.69  
Exercisable at June 30, 2020     583,313     $ 3.69  
Shares Authorized Under Stock Option Plans by Exercise Price Range

The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable options under the Company’s option plans as of June 30, 2020:

 

      Outstanding options   Exercisable options  

Exercise price

range

   

Number of

options

   

Weighted average

remaining

contractual life

 

Number of

options

   

Weighted average

remaining

contractual life

 
                         
$ 0.01 to $3.49       470,313     7.9 years     470,313       7.9 years  
$ 3.50 to $4.99       64,000     3.8 years     64,000       3.8 years  
$ 5.00 to $6.49           — years           — years  
$ 6.50 to $7.99       7,250     1.3 years     7,250       1.3 years  
$ 8.00 to $9.99       2,500     0.9 years     2,500       0.9 years  
$ 10.00 to $19.99       39,250     0.5 years     39,250       0.5 years  
                                 
          583,313     6.8 years     583,313       6.8 years  
Summary of Restricted Stock Activity

A summary of all restricted stock activity under the equity compensation plans for the six months ended June 30, 2020 is as follows:

 

   

Number of

Restricted

shares

   

Weighted

average

grant date

fair

value

 
Nonvested balance, January 1, 2020     514,875     $ 2.97  
Granted     665,500       1.05  
Vested     (410,375 )     (2.14 )
Forfeited     (35,250 )     (1.84 )
Nonvested balance, June 30, 2020     734,750     $ 1.75  
Schedule of Non-vested Balance of Restricted Stock

The nonvested balance of restricted stock vests as follows:

 

Years ended  

Number of

shares

 
       
2020 (April 1, 2020 through December 31, 2020)     13,125  
2021     480,250  
2022     241,375  
v3.20.2
Common Stock Purchase Warrants (Tables)
6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Summary of Warrant Activity

The following table summarizes information about shares issuable under warrants outstanding during the six months ended June 30, 2020:

 

    Warrants    

Weighted

average

exercise

price

 
Vested Balance, January 1, 2020     4,824,573     $ 5.15  
Granted     1,273,374       1.31  
Exercised     (2,704,583 )     (1.95 )
Cancelled            
Vested Balance, June 30, 2020     3,393,364     $ 6.26  
Summary of Range of Exercise Prices and Weighted Average Remaining Contractual Life of Warrants

The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable warrants to purchase common shares as of June 30, 2020:

 

      Outstanding and exercisable warrants  
Exercise price     Number of warrants    

Weighted average

remaining

contractual life

 
$ 2.60       465,712       3.1 years  
$ 3.00       316,800       2.8 years  
$ 3.36       166,667       1.7 years  
$ 3.36       566,666       2.7 years  
$ 3.65       167,000       2.0 years  
$ 3.75       25,753       2.1 years  
$ 5.00       800,000       1.5 years  
$ 13.43       879,766       0.6 years  
$ 16.50       5,000       0.1 years  
                     
          3,393,364       1.8 years  
v3.20.2
Net Loss Per Share (Tables)
6 Months Ended
Jun. 30, 2020
Earnings Per Share [Abstract]  
Calculation of Weighted Average Number of Shares Outstanding and Loss Per Share Outstanding

The calculation of the weighted average number of shares outstanding and loss per share outstanding for the three and six months ended June 30, 2020 and 2019 are as follows:

 

   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
    2020     2019     2020     2019  
Numerator for basic and diluted income per share – Net loss   $ (497,894 )   $ (387,730 )   $ (2,832,004 )   $ (3,592,904 )
                                 
Denominator for basic loss per share – weighted average shares outstanding     18,976,724       11,305,248       16,430,214       11,124,222  
Dilutive effect of shares issuable under stock options and warrants outstanding                        
                                 
Denominator for diluted loss per share – adjusted weighted average shares outstanding     18,976,724       11,305,248       16,430,214       11,124,222  
                                 
Net loss per share:                                
Basic   $ (0.03 )   $ (0.03 )   $ (0.17 )   $ (0.32 )
Diluted   $ (0.03 )   $ (0.03 )   $ (0.17 )   $ (0.32 )
v3.20.2
Nature of Business and Summary of Significant Accounting Policies (Details Narrative)
3 Months Ended 6 Months Ended 12 Months Ended
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2020
USD ($)
shares
Mar. 31, 2020
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2020
USD ($)
Integer
shares
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 23, 2019
USD ($)
shares
Jan. 02, 2019
USD ($)
Net losses   $ (497,894) $ (2,334,110) $ (387,730) $ (3,205,174) $ (2,832,004) $ (3,592,904) $ 10,000,000    
Accumulated deficit   $ (90,220,623)       (90,220,623)   (87,388,619)    
Lump sum payment received               6,000,000    
Proceeds from sale of common stock in underwritten public offering           12,829,241      
Proceeds from issuance of common stock upon exercise of warrants and options           5,203,122 1,564,000      
Issuenace of promissory note           1,568,900      
Proceeds from issuance of secured convertible notes payable           1,500,000      
Proceeds from exercise of warrants               1,564,000    
Unsecured promissory notes and detachable warrants           $ 419,000        
Short-term promissory note payable                 $ 300,000  
Warrants to purchase common stock | shares 571,248 2,686,582       2,686,582     107,000  
Proceeds from convertible debentures $ 2,780,000                  
Number of reportable segments | Integer           1        
Operating lease right of use assets   $ 769,635       $ 769,635   $ 122,459    
Operating lease obligations   $ 775,642       $ 775,642        
ASU 2016-02 Leases [Member]                    
Operating lease right of use assets                   $ 501,000
Operating lease obligations                   582,000
Deferred rent                   $ 81,000
v3.20.2
Nature of Business and Summary of Significant Accounting Policies - Summary of Sales by Geographic Area (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Sales by geographic area $ 1,732,192 $ 2,546,983 $ 4,157,936 $ 5,097,779
United States of America [Member]        
Sales by geographic area 1,726,119 2,477,717 4,097,815 4,992,059
Foreign [Member]        
Sales by geographic area $ 6,073 $ 69,266 $ 60,121 $ 105,720
v3.20.2
Inventories (Details Narrative) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Finished goods inventory $ 140,158 $ 80,711
v3.20.2
Inventories - Schedule of Inventories (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Raw material and component parts $ 2,575,710 $ 4,481,611
Work-in-process 30,679 35,858
Finished goods 4,146,308 4,906,956
Subtotal 6,752,697 9,424,425
Reserve for excess and obsolete inventory (2,000,412) (4,144,013)
Total $ 4,752,285 $ 5,280,412
v3.20.2
Debt Obligations (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
May 12, 2020
Apr. 30, 2020
Apr. 17, 2020
Jan. 17, 2020
Dec. 23, 2019
Aug. 05, 2019
Feb. 29, 2020
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2020
Jun. 30, 2019
Mar. 03, 2020
Warrant to purchase of common stock shares         107,000 571,248   2,686,582   2,686,582    
Common stock for aggregate purchase price of notes               $ 5,350,413 $ 2,502,136      
Proceeds from warrants                   $ 5,203,122    
Amortization of debt discount                   86,867  
Private, Third-party Lenders [Member]                        
Debt instrument interest rate         8.00%              
Debt maturity date         Mar. 31, 2020              
Warrant to purchase of common stock shares         107,000              
Warrant exercise price         $ 1.40              
Unsecured notes payable         $ 300,000              
Warrant exercisable date         Dec. 23, 2024              
Proceeds from warrants         $ 71,869              
Amortization of debt discount                   66,061    
Securities Purchase Agreement [Member] | Investors [Member]                        
Warrant term     5 years     5 years            
Warrant to purchase of common stock shares     1,237,624     571,428            
Warrant exercise price     $ 1.31     $ 1.8125            
Common stock percentage           5.00%            
Common stock for aggregate purchase price of notes     $ 1,500,000     $ 125,000            
Aggregate purchase price of notes           2,500,000            
Paycheck Protection Program [Member] | 2020 Small Business Administration Notes [Member]                        
Loan amount     $ 1,418,900                  
Debt instrument term     2 years                  
Debt instrument interest rate     1.00%                  
Monthly principal payments     $ 79,851                  
2020 Small Business Administration Notes [Member]                        
Debt instrument interest rate 3.75%                      
Monthly principal payments $ 731                      
Proceeds from loans 150,000                      
Debt instrument face amount $ 150,000                      
8% Senior Secured Convertible Promissory Notes [Member] | Securities Purchase Agreement [Member] | Investors [Member]                        
Debt instrument face amount     $ 1,666,666     $ 2,777,778            
Debt maturity date     Apr. 16, 2021     Aug. 04, 2020            
Debt converted into shares     1,650,164     1,984,126            
Conversion price, per share     $ 1.01     $ 1.40            
Agreement description     As a result of such conversion or exercise, such holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company's common stock outstanding immediately after giving effect to such exercise. However, the investors may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to the Company.     As a result of such conversion or exercise, such holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company's common stock outstanding immediately after giving effect to such exercise. However, the investors may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to the Company.            
2019 Convertible Notes [Member] | Securities Purchase Agreement [Member]                        
Monthly principal payments               172,839   172,839    
Debt instrument face amount               1,259,074   1,259,074    
Prepay in cash the remaining outstanding principal                       $ 574,341
2020 Convertible Notes [Member]                        
Debt instrument term     11 months 1 day                  
2020 Convertible Notes [Member] | Securities Purchase Agreement [Member]                        
Debt instrument face amount               1,665,666   1,665,666    
Prepay in cash the remaining outstanding principal               $ 1,000   1,000    
Unsecured Promissory Note Payable [Member]                        
Debt instrument interest rate   6.00%         6.00%          
Debt maturity date   May 28, 2020         May 28, 2020          
Unsecured notes payable   $ 319,000         $ 319,000          
Total interest accrued                   5,236    
Unsecured Promissory Note Payable [Member] | Private, Third-party Lenders [Member]                        
Debt instrument interest rate       8.00%                
Debt maturity date       Apr. 17, 2020                
Warrant to purchase of common stock shares       35,750                
Warrant exercise price       $ 1.40                
Unsecured notes payable       $ 100,000                
Warrant exercisable date       Jan. 17, 2025                
Proceeds from warrants       $ 20,806                
Amortization of debt discount                   $ 20,806    
v3.20.2
Debt Obligations - Summary of Secured Convertible Debentures and Proceeds Investment Agreement (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Debt obligations $ 552,258 $ 1,827,748
Less: current maturities of debt obligations 552,258 1,827,748
Debt obligations, long-term 1,016,642
Paycheck Protection Program [Member]    
Debt obligations 1,418,900
Economic Injury Disaster Loan [Member]    
Debt obligations 150,000
2019 Secured Convertible Notes [Member]    
Debt obligations 1,593,809
Unsecured Promissory Note Payable [Member]    
Debt obligations $ 233,939
v3.20.2
Debt Obligations - Summary of Secured Convertible Debentures and Proceeds Investment Agreement (Details) (Parenthetical) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
Less unamortized discount $ 0 $ 66,061
v3.20.2
Debt Obligations - Schedule of Maturity of Debt Obligations (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
2020 (July 1, 2020 to December 31, 2020) $ 68,241  
2021 948,391  
2022 401,321  
2023 3,166  
2024 3,286  
2025 and thereafter 144,495  
Total $ 1,016,642
v3.20.2
Debt Obligations - Schedule of Fair Value of Embedded Derivatives and Warrants (Details) - USD ($)
6 Months Ended
Apr. 17, 2020
Aug. 05, 2019
Jun. 30, 2020
Jun. 30, 2019
Gross cash proceeds     $ 1,500,000
2020 Secured Convertible Notes [Member]        
Gross cash proceeds $ 1,500,000      
Secured Convertible Notes [Member] | 2020 Secured Convertible Notes [Member]        
Gross cash proceeds 778,859      
Common Stock Purchase Warrants [Member] | 2020 Secured Convertible Notes [Member]        
Gross cash proceeds $ 721,141      
2019 Secured Convertible Notes [Member]        
Gross cash proceeds   $ 2,500,000    
2019 Secured Convertible Notes [Member] | Secured Convertible Notes [Member]        
Gross cash proceeds   1,845,512    
2019 Secured Convertible Notes [Member] | Common Stock Issued as Commitment Shares [Member]        
Gross cash proceeds   118,749    
2019 Secured Convertible Notes [Member] | Common Stock Purchase Warrants [Member]        
Gross cash proceeds   $ 535,739    
v3.20.2
Debt Obligations - Summary of Fair Value and Adjusted Carrying Value of Secured Convertible Notes (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Secured convertible notes, beginning balance     $ 1,593,809  
Change in fair value of secured convertible note during the period $ 887,807 1,300,252
Secured convertible notes, ending balance    
2019 Secured Convertible Notes [Member]        
Secured convertible notes, beginning balance     1,593,809  
Principal repaid during the period by issuance of common stock     (1,259,074)  
Principal repaid during the period by payment of cash     (747,180)  
Change in fair value of secured convertible note during the period     412,445  
Secured convertible notes, ending balance    
2020 Convertible Notes [Member]        
Secured convertible notes, beginning balance      
Issuance of 2020 convertible notes at fair value     778,859  
Principal repaid during the period by issuance of common stock     (1,665,666)  
Principal repaid during the period by payment of cash     (1,000)  
Change in fair value of secured convertible note during the period     887,807  
Secured convertible notes, ending balance    
v3.20.2
Debt Obligations - Schedule of Certain Estimates and Assumptions of Fair Value of Secured Convertible Notes (Details) - Integer
12 Months Ended
Apr. 17, 2020
Dec. 31, 2019
2019 Secured Convertible Notes [Member]    
Contractual term   7 months 6 days
2019 Secured Convertible Notes [Member] | Volatility [Member]    
Debt instrument, measurement input   115
2019 Secured Convertible Notes [Member] | Risk Free Interest Rate [Member]    
Debt instrument, measurement input   1.60
2019 Secured Convertible Notes [Member] | Calibrated Stock Price [Member]    
Debt instrument, measurement input   1.06
2019 Secured Convertible Notes [Member] | Debt Yield [Member]    
Debt instrument, measurement input   123.6
2020 Convertible Notes [Member]    
Contractual term 11 months 1 day  
2020 Convertible Notes [Member] | Volatility [Member]    
Debt instrument, measurement input 90  
2020 Convertible Notes [Member] | Risk Free Interest Rate [Member]    
Debt instrument, measurement input 0.36  
2020 Convertible Notes [Member] | Calibrated Stock Price [Member]    
Debt instrument, measurement input 0.92  
2020 Convertible Notes [Member] | Debt Yield [Member]    
Debt instrument, measurement input 132.2  
v3.20.2
Proceeds Investment Agreement Obligation (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Aug. 21, 2018
Jul. 31, 2018
May 31, 2019
Dec. 31, 2019
Jun. 30, 2020
Common stock, par value       $ 0.001 $ 0.001
Lump sum payment received       $ 6,000,000  
2018 Proceeds Investment Agreement [Member] | Brickell Key Investments LP [Member]          
Funded amount   $ 10,000,000      
Investment agreement description   The Company agreed to assign to BKI (i) 100% of all gross, pre-tax monetary recoveries paid by any defendant(s) to the Company or its affiliates agreed to in a settlement or awarded in judgment in connection with the patent assets, plus any interest paid in connection therewith by such defendant(s) (the "Patent Assets Proceeds"), up to the minimum return (as defined in the Agreement) and (ii) if BKI has not received its minimum return by the earlier of a liquidity event (as defined in the Agreement) and July 31, 2020, then the Company agreed to assign to BKI 100% of the Patent Asset Proceeds until BKI has received an amount equal to the minimum return on $4.0 million.      
Payments of minimum return   $ 4,000,000      
Indebtedness   $ 500,000      
Common stock, par value   $ 0.001      
Description of warrants reflecting agreement        
Warrant to purchase shares of common stock   465,712      
Warrant Exercise Price Per Share   $ 2.60      
Lump sum payment received     $ 6,000,000    
Minimum return payment obligations     $ 6,000,000    
2018 Proceeds Investment Agreement [Member] | Brickell Key Investments LP [Member] | First Tranche [Member]          
Funded amount   $ 500,000      
2018 Proceeds Investment Agreement [Member] | Brickell Key Investments LP [Member] | Second Tranche [Member]          
Funded amount $ 10,000,000 $ 9,500,000      
Number of option exercised 9,500,000        
v3.20.2
Proceeds Investment Agreement Obligation - Schedule of Proceeds Investment Obligation (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Proceeds Investment Agreement Obligation    
Proceeds investment agreement, at fair value $ 3,615,000
Less: Current portion (3,615,000)
Proceeds investment agreement, at fair value - Long-term $ 6,500,000
v3.20.2
Proceeds Investment Agreement Obligation - Schedule of Fair Value Proceeds Investment Obligation (Details)
6 Months Ended
Jun. 30, 2020
USD ($)
Gross cash proceeds $ 10,000,000
Proceeds Investment Agreement [Member]  
Gross cash proceeds 9,067,513
Common Stock Purchase Warrants [Member]  
Gross cash proceeds $ 932,487
v3.20.2
Proceeds Investment Agreement Obligation - Schedule of Certain Estimates and Assumptions of Weighted Patent Asset (Details) - Patent Asset [Member] - Axon and WatchGuard [Member] - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2020
Dec. 31, 2019
Dec. 30, 2019
Probability of success 90.00%    
Estimated minimum return payable to BKI $ 4,000,000   $ 21,000,000
Negotiation discount 0.00%   43.30%
Minimum [Member]      
Discount rate 15.13% 3.00%  
Expected term to patent asset proceeds payment 3 months 29 days 6 months 29 days  
Probability of success   5.90%  
Maximum [Member]      
Discount rate 15.18%   400.00%
Expected term to patent asset proceeds payment 3 years 9 months   4 years
Probability of success     38.50%
v3.20.2
Proceeds Investment Agreement Obligation - Schedule of Proceeds Investment Agreement Activity (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Proceeds Investment Agreement Obligation        
Beginning balance as of December 31, 2019      
Repayment of obligation      
Change in the fair value during the period $ (2,578,000) $ 2,961,000 (2,885,000) $ 3,098,000
Ending balance as of June 30, 2020 $ 3,615,000   $ 3,615,000  
v3.20.2
Fair Value Measurement - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Secured convertible notes $ 1,593,809
Proceeds investment agreement obligation 3,615,000 6,500,000
Liabilities, fair value 3,615,000 8,093,809
Level 1 [Member]    
Secured convertible notes
Proceeds investment agreement obligation
Liabilities, fair value
Level 2 [Member]    
Secured convertible notes
Proceeds investment agreement obligation
Liabilities, fair value
Level 3 [Member]    
Secured convertible notes 1,593,809
Proceeds investment agreement obligation 3,615,000 6,500,000
Liabilities, fair value $ 3,615,000 $ 8,093,809
v3.20.2
Fair Value Measurement - Fair Value Measurements Change in Level 3 Inputs (Details)
6 Months Ended
Jun. 30, 2020
USD ($)
Fair value measurement, beginning balance $ 8,093,809
Issuance of secured convertible debt 778,859
Conversion of secured convertible debentures (2,924,740)
Repayment of 2019 secured convertible notes (748,180)
Change in fair value of secured convertible debentures and proceeds investment agreement (1,548,748)
Fair value measurement, ending balance 3,615,000
2019 Secured Convertible Notes [Member]  
Fair value measurement, beginning balance 1,593,809
Issuance of secured convertible debt
Conversion of secured convertible debentures (1,259,074)
Repayment of 2019 secured convertible notes (747,180)
Change in fair value of secured convertible debentures and proceeds investment agreement 412,445
Fair value measurement, ending balance
2020 Convertible Notes [Member]  
Fair value measurement, beginning balance
Issuance of secured convertible debt 778,859
Conversion of secured convertible debentures (1,665,666)
Repayment of 2019 secured convertible notes (1,000)
Change in fair value of secured convertible debentures and proceeds investment agreement 887,807
Fair value measurement, ending balance
Proceeds Investment Agreement [Member]  
Fair value measurement, beginning balance 6,500,000
Issuance of secured convertible debt
Conversion of secured convertible debentures
Change in fair value of secured convertible debentures and proceeds investment agreement (2,885,000)
Fair value measurement, ending balance $ 3,615,000
v3.20.2
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Payables and Accruals [Abstract]    
Accrued warranty expense $ 30,711 $ 17,838
Accrued litigation costs 250,000 295,000
Accrued sales commissions 25,772 28,480
Accrued payroll and related fringes 181,970 233,254
Accrued insurance 60,894 78,579
Accrued sales returns and allowances 10,267 18,258
Accrued sales taxes 43,900 50,136
Other 235,233 124,336
Total accrued expenses $ 838,747 $ 845,881
v3.20.2
Accrued Expenses - Schedule of Accrued Warranty Expense (Details)
6 Months Ended
Jun. 30, 2020
USD ($)
Payables and Accruals [Abstract]  
Beginning balance $ 17,838
Provision for warranty expense 52,796
Charges applied to warranty reserve (39,923)
Ending balance $ 30,711
v3.20.2
Income Taxes (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Effective tax rate expected statutory valuation allowance on net deferred tax assets 100.00% 100.00%
Net operating loss carry-forwards $ 67,000,000  
Research And Development [Member]    
Tax credit carryforwards $ 1,795,000  
v3.20.2
Operating Leases (Details Narrative)
6 Months Ended
Jun. 30, 2020
USD ($)
Warehouse And Office Space [Member]  
Weighted average remaining lease term 79 months
Warehouse And Office Space [Member] | Minimum [Member]  
Operating lease monthly payments $ 12,398
Warehouse And Office Space [Member] | Maximum [Member]  
Operating lease monthly payments 13,693
October 2019 for Copiers [Member]  
Operating lease monthly payments $ 1,598
Weighted average remaining lease term 43 months
Operating lease maturity date Oct. 31, 2023
Office Space and Copier [Member]  
Operating lease expense $ 252,290
Weighted average discount rate 8.00%
v3.20.2
Operating Leases - Schedule of Operating Leases Right of Use Assets and Liabilities (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Leases [Abstract]    
Operating lease right of use assets $ 769,635 $ 122,459
Operating lease obligations-Long-term portion 731,334 44,460
Operating lease obligations-Current portion 44,308 $ 159,160
Total operating lease obligations $ 775,642  
v3.20.2
Operating Leases - Schedule of Components of Lease Expenses (Details)
6 Months Ended
Jun. 30, 2020
USD ($)
Selling, General and Administrative Expenses [Member]  
Selling, general and administrative expenses $ 252,290
v3.20.2
Operating Leases - Schedule of Future Minimum Lease Payments (Details)
Jun. 30, 2020
USD ($)
Leases [Abstract]  
2020 (July 1, to December 31, 2020) $ 21,986
2021 169,691
2022 172,666
2023 172,542
2024 159,703
Thereafter 310,259
Total undiscounted minimum future lease payments 1,006,847
Imputed interest (231,205)
Total operating lease liability $ 775,642
v3.20.2
Commitments and Contingencies (Details Narrative) - USD ($)
Jun. 04, 2020
Apr. 22, 2020
Jan. 13, 2020
Jan. 08, 2020
Jul. 11, 2019
May 13, 2019
Market Value Listed Securities [Member]            
Description on terms of Nasdaq listing On June 4, 2020 and June 10, 2020, we consummated underwritten public offerings, pursuant to underwriting agreements and raised aggregate gross proceeds of approximately $11.3 million, before underwriting discounts and commissions and other estimated expenses of such offerings. As a result of such offerings, we achieved compliance with Rule 5550(b)(1) and on June 18, 2020 we received written notice from the Staff stating that we had regained compliance with such rule and the matter is now closed. On April 22, 2020, we received a written notification from the Nasdaq Stock Market LLC indicating that we were not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price for our Common Stock was below $1.00 per share for the last thirty (30) consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we were granted a 180-calendar day compliance period to regain compliance with the minimum bid price requirement. Subsequently, the 180-day grace period to regain compliance with such minimum bid price requirement under applicable Nasdaq Stock Market LLC rules was extended due to the global market impact caused by COVID-19. More specifically, the Nasdaq Stock Market LLC has stated that the compliance periods for any company previously notified about non-compliance will be suspended effective April 16, 2020, through June 30, 2020. On July 1, 2020, companies not in compliance would receive the balance of any pending compliance period exception to come back into compliance with such minimum bid price requirement. As a result of this extension, we had until December 28, 2020, to regain compliance with such minimum bid price requirement. During the compliance period, our Common Stock would still continue to be listed and traded on Nasdaq. To regain compliance, the closing bid price of the Common Stock had to have met or exceeded $1.00 per share for at least ten (10) consecutive business days by December 28, 2020. On June 11, 2020, our Common Stock met such minimum bid price requirement, as the closing sale price of our Common Stock had equaled or exceeded $1.00 per share on Nasdaq at the close of each trading day since May 29, 2020, and we received written notice from the Staff stating that the Company regained compliance with such requirement and the matter is now closed. On January 13, 2020, we requested a hearing before the Nasdaq Hearings Panel to appeal the Letter and a hearing was held on February 20, 2020, when we appeared before the Panel to discuss our plan to regain compliance, including, but not limited to, complying with Nasdaq Listing Rule 5550(b)(1), which is the minimum stockholders’ equity standard for continued listing, which requires that companies listed on Nasdaq maintain a minimum of $2,500,000 in stockholders’ equity (“Rule 5550(b)(1)”). On March 6, 2020, we received written notice from the Panel indicating that, based on the plan of compliance that we had presented at such hearing, the Panel granted our request for the continued listing of our Common Stock on Nasdaq, subject to, among other things, us keeping the Staff updated on the progress of our compliance plan and ultimately being able to evidence shareholder equity in an amount greater than or equal to $2,500,000 in accordance with Rule 5550(b)(1) no later than June 30, 2020. During this time, our Common Stock remained listed and trading on Nasdaq. On January 8, 2020, we received a determination letter from the staff of The Nasdaq Stock Market LLC stating that we had not regained compliance with the MVLS Standard, since our Common Stock was below the $35 million minimum MVLS requirement for continued listing on Nasdaq under the MLVS Rule and had not been at least $35 million for a minimum of 10 consecutive business days at any time during the 180-day grace period granted to us. Pursuant to the Letter, unless we requested a hearing to appeal this determination by January 15, 2020, our Common Stock would have been delisted from Nasdaq, trading of our Common Stock would have been suspended at the opening of business on January 17, 2020, and a Form 25-NSE would have been filed with the SEC, which would have removed our Common Stock from listing and registration on Nasdaq. On July 11, 2019, we were officially notified by The Nasdaq Stock Market LLC that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (the “MVLS”) for our Common Stock was below the $35 million minimum MVLS requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we had 180 calendar days, or until January 7, 2020, to regain compliance with the MVLS Rule, or in the alternative, the minimum stockholders’ equity requirement of $2,500,000. To regain compliance with the MVLS Rule, the minimum MVLS for our Common Stock must have been at least $35 million for a minimum of 10 consecutive business days at any time during this 180-day period. If we failed to regain compliance with either the MVLS Rule or the minimum stockholders’ equity requirement by January 7, 2020, we could have been delisted from Nasdaq.  
WatchGuard [Member]            
One-time settlement payment           $ 6,000,000
v3.20.2
Stock-Based Compensation (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Sep. 09, 2020
Stock based compensation $ 376,738 $ 585,195 $ 688,415 $ 1,310,393  
Number of common stock authorized to grant 4,175,000   4,175,000    
Number of shares, available for grant 1,437   1,437    
Fair value of stock options issued     $ 0    
Stock options granted        
Aggregate intrinsic value of options outstanding $ 187,800   $ 187,800    
Intrinsic value of options exercisable 187,800   187,800    
Intrinsic value of options exercised        
Unrecognized stock compensation expense 0   0    
Non Vested Restricted Stock Grants [Member]          
Unrecognized stock compensation expense $ 505,271   $ 505,271    
2005 Stock Option Plan [Member] | During 2015 [Member]          
Number of common stock shares reserved for awards which unavailable for issuance 19,678   19,678    
Unexercised and outstanding stock options 7,563   7,563    
2006 Stock Option Plan [Member] | During 2016 [Member]          
Number of common stock shares reserved for awards which unavailable for issuance 25,849   25,849    
Unexercised and outstanding stock options 39,750   39,750    
2007 Stock Option Plan [Member] | During 2017 [Member]          
Number of common stock shares reserved for awards which unavailable for issuance 89,651   89,651    
Unexercised and outstanding stock options 5,000   5,000    
2008 Plan [Member] | During 2018 [Member]          
Number of common stock shares reserved for awards which unavailable for issuance 9,249   9,249    
Unexercised and outstanding stock options 312,50.   312,50.    
2020 Stock Option Plan [Member]          
Number of common stock shares reserved for awards which unavailable for issuance 1,500,000   1,500,000    
2020 Stock Option Plan [Member] | Subsequent Event [Member] | Annual Meeting [Member]          
Number of common stock authorized to grant         1,500,000
Number of common stock shares reserved for awards which unavailable for issuance         1,500,000
v3.20.2
Stock-Based Compensation - Summary of Stock Options Outstanding (Details)
6 Months Ended
Jun. 30, 2020
$ / shares
shares
Options Granted
Stock Options [Member]  
Options Outstanding, Beginning balance 589,125
Options Granted
Options Exercised (1,875)
Options Forfeited 3,937
Options Outstanding, Ending balance 583,313
Options Exercisable, Ending balance 583,313
Weighted Average Exercise Price, Outstanding, Beginning balance | $ / shares $ 3.74
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares 4.16
Weighted Average Exercise Price, Forfeited | $ / shares (12.14)
Weighted Average Exercise Price, Outstanding, Ending balance | $ / shares 3.69
Weighted Average Exercise Price, Exercisable, Ending balance | $ / shares $ 3.69
v3.20.2
Stock-Based Compensation - Shares Authorized Under Stock Option Plans by Exercise Price Range (Details)
6 Months Ended
Jun. 30, 2020
$ / shares
shares
Number of options, outstanding 583,313
Weighted average remaining contractual life, outstanding options 6 years 9 months 18 days
Number of options, exercisable 583,313
Weighted average remaining contractual life, exercisable options 6 years 9 months 18 days
Exercise Price Range One [Member]  
Exercise price range, lower limit | $ / shares $ 0.01
Exercise price range, upper limit | $ / shares $ 3.49
Number of options, outstanding 470,313
Weighted average remaining contractual life, outstanding options 7 years 10 months 25 days
Number of options, exercisable 470,313
Weighted average remaining contractual life, exercisable options 7 years 10 months 25 days
Exercise Price Range Two [Member]  
Exercise price range, lower limit | $ / shares $ 3.50
Exercise price range, upper limit | $ / shares $ 4.99
Number of options, outstanding 64,000
Weighted average remaining contractual life, outstanding options 3 years 9 months 18 days
Number of options, exercisable 64,000
Weighted average remaining contractual life, exercisable options 3 years 9 months 18 days
Exercise Price Range Three [Member]  
Exercise price range, lower limit | $ / shares $ 5.00
Exercise price range, upper limit | $ / shares $ 6.49
Number of options, outstanding
Weighted average remaining contractual life, outstanding options 0 years
Number of options, exercisable
Weighted average remaining contractual life, exercisable options 0 years
Exercise Price Range Four [Member]  
Exercise price range, lower limit | $ / shares $ 6.50
Exercise price range, upper limit | $ / shares $ 7.99
Number of options, outstanding 7,250
Weighted average remaining contractual life, outstanding options 1 year 3 months 19 days
Number of options, exercisable 7,250
Weighted average remaining contractual life, exercisable options 1 year 3 months 19 days
Exercise Price Range Five [Member]  
Exercise price range, lower limit | $ / shares $ 8.00
Exercise price range, upper limit | $ / shares $ 9.99
Number of options, outstanding 2,500
Weighted average remaining contractual life, outstanding options 10 months 25 days
Number of options, exercisable 2,500
Weighted average remaining contractual life, exercisable options 10 months 25 days
Exercise Price Range Six [Member]  
Exercise price range, lower limit | $ / shares $ 10.00
Exercise price range, upper limit | $ / shares $ 19.99
Number of options, outstanding 39,250
Weighted average remaining contractual life, outstanding options 6 months
Number of options, exercisable 39,250
Weighted average remaining contractual life, exercisable options 6 months
v3.20.2
Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock [Member]
6 Months Ended
Jun. 30, 2020
$ / shares
shares
Number of Restricted shares, Non-vested Beginning Balance | shares 514,875
Number of Restricted shares, Granted | shares 665,500
Number of Restricted shares, Vested | shares (410,375)
Number of Restricted shares, Forfeited | shares (35,250)
Number of Restricted shares, Non-vested Ending Balance | shares 747,500
Weighted average grant date fair value, Non-vested Beginning Balance | $ / shares $ 2.97
Weighted average grant date fair value, Granted | $ / shares 1.05
Weighted average grant date fair value, Vested | $ / shares (2.74)
Weighted average grant date fair value, Forfeited | $ / shares (1.84)
Weighted average grant date fair value, Non-vested Ending Balance | $ / shares $ 1.75
v3.20.2
Stock-Based Compensation - Schedule of Non-vested Balance of Restricted Stock (Details) - Restricted Stock [Member]
Jun. 30, 2020
shares
Non-vested balance, 2020 (April 1, 2020 through December 31, 2020) 13,125
Non-vested balance, 2021 480,250
Non-vested balance, 2022 241,375
v3.20.2
Common Stock Purchase Warrants (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2020
Dec. 23, 2019
Aug. 05, 2019
Warrants to purchase common stock 2,686,582 107,000 571,248
Cash proceeds from warrants $ 5,203,122    
Warrants to purchase common shares were exercised on a cashless basis 18,000    
Forfeiture of common shares 10,715    
Common Stock Purchase Warrants [Member]      
Warrant expiration term, description July 15, 2020 through January 17, 2025    
Common Stock Purchase Warrants [Member] | Minimum [Member]      
Warrant, exercise per share $ 1.40    
Common Stock Purchase Warrants [Member] | Maximum [Member]      
Warrants to purchase common stock 3,393,364    
Warrant, exercise per share $ 16.50    
Warrants [Member]      
Intrinsic value of all outstanding warrants $ 295,836    
Warrants, weighted average remaining term 21 years 9 months 18 days    
v3.20.2
Common Stock Purchase Warrants - Summary of Warrant Activity (Details) - Warrants [Member]
6 Months Ended
Jun. 30, 2020
$ / shares
shares
Warrants, Vested, Beginning balance | shares 4,824,573
Warrants, Granted | shares 1,273,374
Warrants, Exercised | shares (2,704,583)
Warrants, Cancelled | shares
Warrants, Vested, Ending balance | shares 3,393,364
Weighted average exercise price, Vested, Beginning balance | $ / shares $ 5.15
Weighted average exercise price, Granted | $ / shares 1.31
Weighted average exercise price, Exercised | $ / shares (1.95)
Weighted average exercise price, Cancelled | $ / shares
Weighted average exercise price, Vested, Ending balance | $ / shares $ 6.26
v3.20.2
Common Stock Purchase Warrants - Summary of Range of Exercise Prices and Weighted Average Remaining Contractual Life of Warrants (Details) - Warrants [Member]
6 Months Ended
Jun. 30, 2020
$ / shares
shares
Outstanding and exercisable warrants, Number of warrants 3,393,364
Outstanding and exercisable warrants, Weighted average remaining contractual life 1 year 9 months 18 days
Exercise Price Range One [Member]  
Outstanding and exercisable warrants, Exercise price | $ / shares $ 2.60
Outstanding and exercisable warrants, Number of warrants 465,712
Outstanding and exercisable warrants, Weighted average remaining contractual life 3 years 1 month 6 days
Exercise Price Range Two [Member]  
Outstanding and exercisable warrants, Exercise price | $ / shares $ 3.00
Outstanding and exercisable warrants, Number of warrants 316,800
Outstanding and exercisable warrants, Weighted average remaining contractual life 2 years 9 months 18 days
Exercise Price Range Three [Member]  
Outstanding and exercisable warrants, Exercise price | $ / shares $ 3.36
Outstanding and exercisable warrants, Number of warrants 166,667
Outstanding and exercisable warrants, Weighted average remaining contractual life 1 year 8 months 12 days
Exercise Price Range Four [Member]  
Outstanding and exercisable warrants, Exercise price | $ / shares $ 3.36
Outstanding and exercisable warrants, Number of warrants 566,666
Outstanding and exercisable warrants, Weighted average remaining contractual life 2 years 8 months 12 days
Exercise Price Range Five [Member]  
Outstanding and exercisable warrants, Exercise price | $ / shares $ 3.65
Outstanding and exercisable warrants, Number of warrants 167,000
Outstanding and exercisable warrants, Weighted average remaining contractual life 2 years
Exercise Price Range Six [Member]  
Outstanding and exercisable warrants, Exercise price | $ / shares $ 3.75
Outstanding and exercisable warrants, Number of warrants 25,753
Outstanding and exercisable warrants, Weighted average remaining contractual life 2 years 1 month 6 days
Exercise Price Range Seven [Member]  
Outstanding and exercisable warrants, Exercise price | $ / shares $ 5.00
Outstanding and exercisable warrants, Number of warrants 800,000
Outstanding and exercisable warrants, Weighted average remaining contractual life 1 year 6 months
Exercise Price Range Eight [Member]  
Outstanding and exercisable warrants, Exercise price | $ / shares $ 13.43
Outstanding and exercisable warrants, Number of warrants 879,766
Outstanding and exercisable warrants, Weighted average remaining contractual life 7 months 6 days
Exercise Price Range Nine [Member]  
Outstanding and exercisable warrants, Exercise price | $ / shares $ 16.43
Outstanding and exercisable warrants, Number of warrants 5,000
Outstanding and exercisable warrants, Weighted average remaining contractual life 1 month 6 days
v3.20.2
Stockholders' Equity (Deficit) (Details Narrative) - USD ($)
6 Months Ended
Jun. 10, 2020
Jun. 08, 2020
Jun. 02, 2020
Apr. 17, 2020
Mar. 03, 2020
Jan. 03, 2020
Jun. 30, 2020
Jun. 30, 2019
May 01, 2020
Mar. 31, 2020
Purchase of additional granted common stock                  
Gross proceeds from offering             $ 12,829,241    
President and Chief Executive Officer [Member] | 2020 Issuance of Restricted Common Stock [Member]                    
Reduction in annual salaries       $ 150,000            
President and Chief Executive Officer [Member] | 2018 Stock Option and Restricted Stock Plan [Member]                    
Number of common stock issued       60,200            
Annual salaries                 $ 69,231  
Chief Financial Officer, Treasurer and Secretary [Member] | 2020 Issuance of Restricted Common Stock [Member]                    
Reduction in annual salaries       $ 150,000            
Chief Financial Officer, Treasurer and Secretary [Member] | 2018 Stock Option and Restricted Stock Plan [Member]                    
Number of common stock issued       75,250            
Annual salaries                 $ 55,384  
Public Offering [Member]                    
Stock issued price per shares             $ 1.65     $ 1.15
Underwriting Agreement [Member] | Officers and Employees [Member] | 2020 Issuance of Restricted Common Stock [Member]                    
Restricted stock granted           530,050        
Restricted common stock description           Shares will generally vest one-half on January 2, 2021 and one half on January 2, 2022, provided that each grantee remains an officer or employee on such dates.        
Underwriting Agreement [Member] | Public Offering [Member]                    
Underwriter's legal counsel expense, description The Underwriters received discounts and commissions of seven percent (7%) of the gross cash proceeds received by the Company from the sale of the common shares in the June 8th Offering. In addition, the Company agreed to pay the Underwriters “road show” expenses, diligence fees and the fees and expenses of the Underwriters’ legal counsel not to exceed $30,000.   The Underwriters received discounts and commissions of seven percent (7%) of the gross cash proceeds received by the Company from the sale of the common shares in the June 2nd Offering. In addition, the Company agreed to pay the Underwriters “road show” expenses, diligence fees and the fees and expenses of the Underwriters’ legal counsel not to exceed $30,000.   The Underwriters received discounts and commissions of seven percent (7%) of the gross cash proceeds received by the Company from the sale of the common stock in the Offering. In addition, the Company agreed to pay the Underwriters (a) a non-accountable expense reimbursement of 1% of the gross proceeds received and (b) “road show” expenses, diligence fees and the fees and expenses of the Underwriters’ legal counsel not to exceed $50,000.          
Underwriter's legal counsel expense $ 30,000   $ 30,000   $ 50,000          
Gross proceeds from offering 4,976,692   5,350,413   $ 2,502,136          
Estimated offering expenses                
Underwriting Agreement [Member] | Roth Capital Partners, LLC [Member] | Public Offering [Member]                    
Number of common stock issued         2,521,740          
Stock issued price per shares         $ 1.15          
Purchase of additional granted common stock         378,261          
Underwriting Agreement [Member] | Aegis Capital Corp [Member] | Public Offering [Member]                    
Number of common stock issued   2,325,581 3,090,909              
Stock issued price per shares   $ 2.15 $ 1.65              
Purchase of additional granted common stock   213,953 463,636              
v3.20.2
Net Loss Per Share - Calculation of Weighted Average Number of Shares Outstanding and Loss Per Share Outstanding (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Earnings Per Share [Abstract]              
Numerator for basic and diluted income per share - Net loss $ (497,894) $ (2,334,110) $ (387,730) $ (3,205,174) $ (2,832,004) $ (3,592,904) $ 10,000,000
Denominator for basic loss per share - weighted average shares outstanding 18,976,724   11,305,248   16,430,214 11,124,222  
Dilutive effect of shares issuable upon conversion of convertible debt and the exercise of stock options and warrants outstanding      
Denominator for diluted loss per share - adjusted weighted average shares outstanding 18,976,724   11,305,248   16,430,214 11,124,222  
Net loss per share: Basic $ (0.03)   $ (0.03)   $ (0.17) $ (0.32)  
Net loss per share: Diluted $ (0.03)   $ (0.03)   $ (0.17) $ (0.32)  
v3.20.2
Subsequent Events (Details Narrative) - USD ($)
Jul. 22, 2020
Jul. 13, 2020
Jul. 02, 2020
Commercial and Industrial Real Estate Sale Contract [Member]      
Total purchase price   $ 420,000  
Termination Agreement [Member] | Subsequent Event [Member] | Brickell Key Investments LP [Member]      
Payment for contract termination $ 1,250,000    
Contingent payment $ 2,750,000    
Contract termination description Under the terms of the Termination Agreement, upon payment of $1,250,000 by the Company to BKI both parties agreed to terminate the PIA and to release each other from any further liability thereunder. Such $1,250,000 payment was made on July 22, 2020. In addition to the $1,250,000 payment, the Company further agreed to pay BKI the following: (a) a contingent payment in the amount of $2,750,000 following the closing of an asset purchase, membership interest purchase, or similar transaction between the Company and a specified third-party (the “Purchase Transaction”) and (b) any and all future proceeds received from Watchguard and its successors and assigns by the Company for WatchGuard’s use of U.S. Patent Nos. 8,781,292 and 9,253,452. For clarity, the Company and BKI further agreed that the payment of the contingent payment would only be due and payable upon the closing of the specified Purchase Transaction and the relevant contingent payment portion of the Termination Agreement, and any obligations stemming therefrom, would automatically terminate if the specified Purchase Transaction is abandoned prior to its closing, including its failure to close within three years from the date of the Termination Agreement. The specified Purchase Transaction has not yet occurred and there is no binding agreement to complete such Purchase Transaction.    
Shelf Registration Statement [Member] | Subsequent Event [Member] | IPO [Member]      
Aggregate initial offering price     125,000,000